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Abstract 
Efficient transcription of the human immunodeficiency virus type 1 (HIV-1) requires the 
interaction of the viral protein Tat with the trans-activation response (TAR) stem-loop of 
the long-terminal repeat (LTR) portion of nascent viral RNA. The production of viable 
transcripts is enhanced dramatically by the interaction of HIV-1 Tat with the host protein 
human Cyclin T1. Interaction with hCycT1 remodels Tat protein contributing a single 
cysteine residue that is critical to the formation of the second of two zinc fingers (Zn2). 
Here we suggest that it is the presence of this critical cysteine residue and not the 
presence of arginine residues from human Cyclin T1 that imparts high affinity and 
specificity to the interaction with HIV-1 TAR RNA. Crucial structural features of this 
interaction remain unresolved by NMR or existing crystal structures. Specifically, the 
structure of the Tat activation domain (AD), and Tat interaction with hCycT1 while 
bound to HIV-1 TAR RNA remain elusive. Much of the difficulty in obtaining structural 
data is a result of the notoriously difficult expression of native HIV-1 Tat caused in large 
part by the high cysteine count, and poor solubility of the Tat protein. This work presents 
a protocol for the expression and purification of a high affinity recombinant chimeric 
protein which includes the full 101 amino acid Tat protein fused to an essential minimal 
portion of  CycT1m) necessary for TAR binding in sufficient purity and concentration for 
structural study by nuclear magnetic resonance (NMR).The elucidation of this critical 
region has the potential for profound impact in the structural based drug design of HIV-1 
therapeutics. 
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Introduction 
The focus of this work is the recombinant expression, purification, and characterization 
of a difficult to express non-membrane chimeric protein comprised of the HIV-1 Tat 
regulatory protein fused to an integral portion of its in vivo host binding partner the 
human protein Cyclin T1. The first portion of this work will focus on the rationale behind 
the importance, design, and potential applications of this particular chimera, as well as 
the cloning experiments involved in producing the chimera, the conditions found 
necessary to achieve adequate yield, and the methods required for purification. The latter 
portion of this work will focus primarily on characterizing binding interaction through the 
use of binding assays involving the in vivo TAR HIV-1 nucleic acid binding partner of 
the proteins, and the expression and purification protocol modifications necessary to 
obtain highly concentrated labeled protein for structural experiments. The ultimate goal 
of this work is to provide data that will aid in the process of drug discovery for the 
efficacious treatment of HIV-1 by improving our structural understanding of an, as yet, 
unexploited drug target the HIV-1 Tat regulatory protein. 
 
All of the presently employed HIV therapeutics that target viral proteins target the Env 
and Pol proteins that are expressed late in the viral infection cycle (1,2). Regulatory 
proteins Tat and Rev are expressed early in the infection cycle, as is the accessory protein 
Nef (3). Inhibitors that target proteins early in viral infection cycle have the potential to 
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be significantly more effective in reducing viral load (2), and may also be less prone to 
the development of resistant strains.  
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Chapter 1 The Tat-TAR Interaction 
 
The HIV-1 regulatory protein Trans-Activator of Transcription (Tat), at its full length, is 
a 101 amino acid, two zinc finger protein that interacts with the TAR stem-loop located 
within the 5’ Long Terminal Repeat (LTR) region of nascent viral RNA. After synthesis, 
a nuclear localization signal facilitates transport of Tat into the nucleus (4) where, in 
concert with other host proteins, Tat facilitates the production of a large number of full 
length viral RNA transcripts (Figure 1-1). In the absence of Tat the nascent viral RNA 
transcript is prematurely terminated and the production of viable viral RNA is 
substantially reduced (5). The potential impact of the interruption of this essential 
interaction on viral load makes the Tat-TAR interaction an attractive target for drug 
discovery (6). As of this writing however, there are no FDA approved drugs targeting the 
inhibition of this important interaction. 
 
1.1. Tat Domains 
The Tat protein consists of two exons, and five domain regions (Figure 1-2) (7). The first 
three domains, from amino acids 1-48, form the Activation Domain (AD) that interacts 
with the host protein human cyclin T1 comprised of a highly ordered and acidic minimal 
activation region rich in proline (1-20), a cysteine rich zinc finger region (containing 
seven highly conserved cysteine residues) (20-40), and a highly conserved core region 
(40-48). A basic RNA Binding Domain (RBD) region (49-57) (including six arginine and 
two lysine residues) (Frankel et al. 1988), and a Glutamine rich region (57-72) interact 
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with HIV TAR RNA (7,8). Exon 2 of the Tat protein (73-101) contains a splicing silencer 
(ESS) that inhibits splicing of viral mRNA at an upstream 3’ splice site (9), and does not 
play a primary role in transcription (8). 
 
1.2. Tat-P-TEFb Interaction  
 In vivo Tat interacts with the human host Positive Transcription Elongation Factor b (P-
TEFb), which regulates transcription by RNA polymerase II (RNAP II) (10). The P-TEFb 
is comprised of a Cyclin dependent kinase CDK9, and the cell cycle regulatory protein 
Cyclin T1 (11,12). The Cyclin T1 protein is a 726 amino acid catalytic subunit of P-TEFb 
(Figure 1-3), and contains a purported Tat/TAR-recognition motif (TRM) at amino acids 
250-272 (13). However, more recently other researchers have described the TRM as 
being located between residues 250 and 263 of Cyclin T1 (14). Since it is not yet clear 
which of these regions is the more accurate the larger region is displayed in Figure 1-3. 
Cyclin T1 protein binds at the cysteine rich Activation Domain (AD) (1-48) of the Tat 
regulatory protein (14).  
 
An intramolecular CHCC zinc finger (ZnF1) of Tat is formed by amino acids Cys22, 
His33, Cys34, and Cys37 (Figure 1-4). A second intermolecular CCCC zinc finger 
(ZnF2) is formed by Cys261 of Cyclin T1 in concert with three additional cysteine 
residues Cys25, Cys27, and Cys30 of Tat (Figure 1-5) (15). Both of the Tat zinc fingers 
are structurally dissimilar to other known zinc fingers and metalloproteins (7,8). 
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1.3. Recruiting P-TEFb 
Acetylation of Tat Lys28 by the transcriptional coactivator p300/CREB-binding protein 
Associated Factor (PCAF) facilitates the recruitment of P-TEFb (16) bringing the CDK9 
catalytic subunit in close proximity for hyperphosphorylation of the C terminal domain of 
RNA Polymerase II (Figure 1-6) (14,15). A large number of intermolecular hydrogen 
bonds between Tat and the P-TEFb alter Tat folding on contact with the complex (8). 
This interaction remodels the AD of Tat into an extended conformation with an unusually 
large area of interface with Cyclin T1 (7,8).  
 
Both Tat and Cyclin T1 bind the TAR RNA stem-loop, purportedly, at a nucleotide bulge 
formed by a base triple in the stem, and at the apical portion of the stem-loop respectively 
(15,17). Tat binds the nucleotide bulge thorough an arginine-rich motif (ARM) at 
residues 49-57 (18). Such arginine-rich binding motifs are also found to regulate RNA 
binding in several other viral regulatory proteins lending to increased conservation in this 
region, and a high affinity and specific interaction (19). Binding of the P-TEFb-Tat 
complex to TAR is enhanced by the interaction between Cyclin T1 and Tat in the 
bridging of ZnF2 (8) with the contribution of Cyclin T1 C261 (Figure 1-5) (7,15). 
 
1.4. Tat-TAR Structural Study 
Much of what we know about the Tat-P-TEFb interaction can be attributed to the 
mutational and binding assays of Garber et al. 1998 who first suspected the formation of 
a zinc bridge between Tat and human Cyclin T1. Since then the crystal structure of HIV-
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1 Tat complexed with P-TEFb reported by Tahirov et al. 2010 appears to confirm these 
early conclusions. Though ground breaking work, the Tahirov et al. 2010 structure is 
reported in the absence of TAR and the conformation of the Tat AD and the Tat-TAR 
complex remain obscure (8). In the Tahirov structure residues 50-86 of the arginine rich 
Tat RNA-binding domain are undefined, and the conformation of ZnF2 remains elusive 
in the absence of residues 252-260 of Cyclin T1 (Figure 1-7) (7,8).  
 
The first NMR structures of the TAR-arginine complex reported by Puglisi et al. 1992, 
TAR as reported by Aboul-ela et al. 1995, and a 24 residue Tat peptide bound to TAR as 
reported by Long et al. 1999 provided much of the original insight into this interaction 
and remain our primary sources of structural detail from NMR. Yet in these as well, 
crucial structural features remain unclear, specifically that of the Tat Activation Domain 
and its interaction with Cyclin T1 in the binding of TAR RNA. Elucidation of these 
critical regions, as might be accomplished by additional NMR or X-ray crystallography 
work, that includes detailed conformations of both zinc fingers has the potential for 
profound impact on structure-based drug design. 
 
1.5. TAR -The UCU Bulge 
In 1992 Puglisi et al. published the NMR structure of a 31 nucleotide portion of the HIV-
1 Transactivation-Response Region (TAR) RNA in complex with the arginine analog 
argininamide (20). The structure revealed a UCU nucleotide bulge at the Tat protein 
binding site, and a flexible six nucleotide apical loop. The highly conserved cis-acting 
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RNA regulatory element TAR binds to the Tat protein at a U23-A27-U38 base triple 
(Figure 1-8) (20,21). Functional groups of the pyrimidine bulge and the phosphate 
backbone are repositioned during binding resulting in a conformational change that is an 
essential feature of specific recognition (22). This dynamic interaction has been described 
as a “ligand-induced conformational rearrangement” that occurs on a micro- to 
millisecond timescale (23). The base triple itself undergoes conjugated pi bond 
stabilization by interaction with the guanidinium groups of arginines within the arginine 
rich basic RNA binding domain of Tat (20). 
 
 In the unbound state the helical structure of TAR is distorted by the nucleotides of the 
bulge that stack within the stem. In the bound form the nucleotides of the bulge loop 
outward, and allow the bases above and below the bulge to stack coaxially (21). Work 
with conformationally restricted peptide mimics of Tat indicates that looping out of U23 
and C24 on Tat binding induces the formation of a binding pocket that places the 
guanidinium group of arginine in proximity for hydrogen bonding to functional groups of 
G26 and U23 (22). Supporting this, mutation of critical nucleotides G26 or U23 has been 
shown to eliminate Tat binding and recognition (20,24). 
 
1.6. TAR - The Apical Loop 
The apical region of TAR is a six nucleotide loop that, due to high flexibility, does not 
lend itself readily to NMR spectroscopy. Dethoff et al. 2008 used mutational analysis, 
molecular dynamics, and NMR data to conclude that the binding at the bulge and at the 
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apical loop are largely independent dynamic events with the possibility of some long 
range interaction between them (25). The CUGGGA nucleotide sequence of the apical 
loop binds Cyclin T1 of P-TEFb producing additional conformational changes (17). 
However, much of the finer detail of this interaction remains unclear (20).  
 
We do know from mutational analysis that nucleotides G32, which loops outward, and 
G34 of the apical loop are essential for Cyclin T1 binding, and that elimination, but not 
substitution, of A35 diminishes binding substantially (11,26). From NMR data it is 
apparent that Cyclin T1 interacts directly with U31 of the apical loop (25). Nucleotides 
A35 and G34 displace one another in alternation between looped in and looped out 
conformations (25). To date however, considerably more work has focused on 
characterizing the dynamics of the UCU bulge than on the dynamics of the apical region 
of TAR (25). Toward the goal of improving rational drug design, much remains to be 
gained from additional characterization of the apical loop and the recognition of its 
contribution to the structurally dynamic interaction between TAR RNA, and the Cyclin 
T1 and Tat proteins.  
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Figure 1-1 The HIV infection cycle. 
The HIV infection cycle is comprised of nine principal events: binding, membrane 
fusion, entry, reverse transcription, integration, transcription, assembly, budding, and 
maturation. After synthesis, a nuclear localization signal facilitates transport of Tat into 
the nucleus (4) where, in concert with other host proteins, Tat facilitates the production of 
a large number of full length viral RNA transcripts. 
Accessed online at: http://www.bioafrica.net/proteomics/HIVproteome.html 
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MEPVDPNLEP WKHPGSQPRT ACNNCYCKKC CFHCYACFTR KGLGISYGRK 
KRRQRRRAPQ DSQTHQASLS KQPASQSRGD PTGPTESKKK VERETETDPF D 
 
Figure 1-2 The Five Domains of the HIV-1 Protein Tat. 
The HIV-1 Tat protein consists of two exons, and five domain regions (A) above. The 
first three domains of Tat, from amino acids 1-48, form the Activation Domain (AD) that 
interacts with the cellular protein human cyclin T1, increases specificity for TAR (27), 
and is comprised of a highly ordered and acidic minimal activation region rich in proline 
(1-20), a cysteine rich zinc finger region (20-40), and a highly conserved core region (40-
48). A basic RNA Binding Domain (RBD) region (49-57), and a Glutamine rich region 
(57-72) interact with HIV TAR RNA. Exon 2 of the Tat protein (73-101) contains a 
splicing silencer (ESS) that inhibits splicing of viral mRNA at an upstream 3’ splice site 
(9), and does not play a primary role in transcription (8). The amino acid sequence of Tat 
that corresponds to each of these domains appears in B above. 
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Figure 1-3 Cyclin T1. 
The Cyclin T1 protein is a 726 amino acid catalytic subunit of P-TEFb, and contains a 
Tat/TAR-recognition motif (TRM) at amino acids 250-272. The Cyclin T1 protein binds 
HIV-1 Tat through the cysteine rich Activation Domain (1-48) (14). Reprinted from: 
Retrovirology, vol. 5 Page 63, Copyright 2008 (13), with permission from J. Jadlowsky.  
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Figure 1-4 An intramolecular CHCC zinc finger (ZnF1) 
An intramolecular CHCC zinc finger (ZnF1) is formed by residues Cys22, His33, Cys34, 
and Cys37 of the HIV-1 regulatory protein Tat. Protein Data Bank File: 3MI9 (7) Crystal 
structure of HIV-1 Tat complexed with human P-TEFb. Image rendered by C. Fischer 
from Protein Data Bank File: 3M19 using Insight II molecular modeling software. 
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Figure 1-5 A CCCC intermolecular zinc finger (ZnF2) 
A CCCC intermolecular zinc finger (ZnF2) is formed by the cysteine 261 of Cyclin T1 in 
concert with three additional cysteine residues 25, 27, and 30 from the HIV-1 regulatory 
protein Tat. Protein Data Bank File:3MI9 (7) Crystal structure of HIV-1 Tat complexed 
with human P-TEFb. Image rendered by C. Fischer from Protein Data Bank File: 3M19 
using Insight II molecular modeling software. 
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Figure 1-6 HIV-1 Tat recruits P-TEFb by binding Cyclin T1. 
The HIV-1 Tat protein and a portion of Cyclin T1, the Tat/TAR-recognition motif (TRM), purportedly bind 
the trinucleotide bulge as well as the apical portion, respectively, of the HIV-1 TAR RNA stem-loop. The 
CDK9 catalytic subunit of P-TEFb is then brought into close proximity to RNA Polymerase II facilitating 
hyperphosphorylation of the RNA Polymerase II C-terminal domain (CTD). This interaction results in the 
production of a high number of full length viable transcripts, and thus is an attractive target for therapeutic 
intervention (14,15). The terms hCycT1, mCycT1, and hCycT1(249-280)-Tat refer to full length 726 amino 
acid human Cyclin T1, murine Cyclin T1 (724 amino acids) which does not support Tat transactivation, 
and the minimal chimera of residues 249-280 of human Cyclin T1 fused to 101 amino acid Tat respectively 
with the latter being the experimental construct as developed by Koh Fujinaga(28). The hCycT1(249-280)-
Tat construct is able to activate HIV-1 transcription in murine cells which do not normally transcribe HIV-
1 presumably due to the absence of cysteine 261 in murine Cyclin T1 where residue 261 is tyrosine (28). 
Reprinted from: Journal of Virology, vol. 76(24), Pages 12934-9. Copyright 2002 (28) with permission 
from Koh Fujinaga. 
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Figure 1-7 Tahirov et al. 2010 Crystal structure of HIV-1 Tat with human P-TEFb. 
Tahirov et al. 2010 Crystal structure of HIV-1 Tat complexed with human P-TEFb. 
RCSB Protein Data Bank: 3MI9 (7)HIV Tat protein (86 aa) in orange, Cyclin T1 (266 aa) 
in pink CDK9 in green (351 aa). 
 
The Tahirov et al. 2010 structure is reported in the absence of TAR. The conformation of 
the Tat Activation Domain and the Tat-TAR complex remain obscure (8). Residues 50-
86 of the arginine rich Tat RNA-binding domain are undefined, and the conformation of 
ZnF2 remains elusive in the absence of residues 252-260 of Cyclin T1 (in red) (7,8).  
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Figure 1-8 Wild type HIV-1 TAR stem loop. 
A U23-C24-U25 trinucleotide bulge is present in the stem of the HIV-1 TAR RNA (at 
left).The TAR RNA binds HIV-1 Tat protein at a U23-A27-U38 base triple (20,21). 
Functional groups of the pyrimidine bulge and the phosphate backbone are repositioned 
during binding, and result in a conformational change that is an essential feature of 
specific recognition (22).  
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Chapter 2 Targeting the Tat-P-TEFb-TAR Interaction 
 
The interaction between HIV Tat, human P-TEFb, and HIV TAR RNA is a highly 
attractive target for the development of new HIV therapies that may potentially be less 
prone to the development of drug resistance because of their potential to inhibit the 
essential activity of Tat early in the infection cycle. The Tat-TAR interaction is critical 
not only during the exponential phase of virus reproduction, when it substantially 
enhances processive elongation of the full length HIV-1 mRNA, but also during the 
activation of the integrated provirus that leads to mutation and drug resistant strains (29).  
 
Current therapeutics inhibiting viral entry and formation of the provirus are not effective 
at eliminating viral proteins produced early in the infection cycle from provirus already 
integrated in the host genome. The neurodegenerative effects of HIV-1 are experienced in 
some 50-70% of patients, and begin soon after infection as viral reservoirs are established 
in the glial cells of the brain. This neurocognitive impairment persists despite effective 
control of viral load (30). The viral protein Tat has been demonstrated to be a potent 
neurotoxin and may play a role in this HIV-1 associated neurocognitive disease (HAND) 
(30,31). Inhibitors of Tat-TAR interaction have the potential to substantially reduce viral 
replication, as well as to improve neurocognitive prognosis.  
 
Attempts to inhibit the Tat-TAR interaction have generally engaged one of three angles 
of approach: anti-TAR, anti-Tat, and anti-Tat-P-TEFb. To date, compounds found to 
inhibit these interactions have failed to demonstrate sufficient specificity, cell-
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penetration, or stability to be effectively employed as therapeutics for the treatment of 
HIV (32). 
 
2.1. Anti-TAR Agents 
The bulk of research on the inhibition of the Tat-P-TEFb-TAR interaction has focused on 
anti-TAR agents, and specifically on inhibition of Tat binding at the pyrimidine bulge in 
the TAR RNA stem. Agents found to disrupt the interaction can be categorized into three 
classes: peptide-based, oligonucleotide-based, and small molecule inhibitors. In the 
category of peptide-based inhibitors: Tat-derived natural peptides, and Tat-mimetics such 
as peptoids, and D and β peptides have demonstrated some ability to inhibit the Tat-TAR 
interaction with the peptide mimetics demonstrating superior resistance to enzymatic 
degradation (32). Oligonucleotide inhibitors include TAR decoys such as: antisense 
oligonucleotides, aptamers, and RNA interference (RNAi), and have demonstrated only 
moderate efficacy in the inhibition of HIV-1 replication (32). Small molecule inhibitors 
such as: arginine derivatives, quinolones, and others have also displayed some ability to 
inhibit the Tat-TAR interaction, but as yet no small molecule has demonstrated the 
sufficiency to warrant further consideration as a drug candidate (32,33). 
 
2.2. Anti-Tat Agents 
Small molecules, biopolymers, and antibodies have all demonstrated inhibition of HIV 
replication by binding directly to Tat but, here also, with insufficient efficacy to produce 
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viable drugs (32). Recently, a synthetic form of didehydro-Cortistatin A isolated from the 
marine sponge Corticium simplex has shown promise in the early phases of research as an 
anti-Tat drug, and has been described as a potent suppressor of viral transcription at 
subnanomolar concentrations (34). 
 
2.3. Anti-Tat-P-TEFb Agents 
Targeting the Tat-P-TEFb complex is complicated by the unintended consequence of 
inhibiting basal cellular transcription that ordinarily requires P-TEFb (32). Selective 
disruption of the Cyclin T1 subunit of P-TEFb, while highly desirable, is therefore 
difficult to achieve without unwanted side-effects. Small molecules, antibodies, protein 
chimeras, intracellular inhibitors, and inhibitors of Tat co-activators of the Tat-P-TEFb 
interaction have, as yet, all failed to produce feasible drug candidates (32).   
 
2.4. Aptamers as Diagnostic Tools: A Novel Approach to TAR Interaction 
Elucidation of the structural features of the TAR-Tat-P-TEFb interaction could offer a 
great deal toward the facilitation of rational structure based drug design. In the absence of 
structural detail however, a high-throughput approach could be used to identify drug 
candidates. Our laboratory utilizes oligonucleotide aptamers in a high-throughput 
approach toward identification of promising small molecule drug candidates that disrupt 
interactions between ligands and nucleic acid targets. Figure 2-1 illustrates an aptamer 
diagnostic tool, here called an “AlloSwitch”, in which a chimeric RNA-DNA molecule 
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comprised of a “probe” strand and a “cover” strand is tethered together by a fixed 
nucleotide duplex that does not change as the rest of the switch changes its conformation 
(35-37). 
 
In the absence of the target the equilibrium between the two forms of the switch favors 
the Hidden (H) form at the left of the figure, where the target’s binding site is hidden by 
base-pairs. The equilibrium shifts toward the right as target is added and binds the probe 
segment in the Open (O) form. 
 
The RNA probe strand is generally designed with a high degree of sequence and 
structural similarity to the in vivo RNA target (or to an aptamer that binds to the same 
region of the target), while the DNA cover strand is mostly complementary to the probe 
strand. When the concentration of target is low, the probe and cover are annealed in the 
extended “on” form, where a 5’ fluorophore is distant from, and therefore not quenched 
by, a strategically placed downstream quencher. At high concentrations of target, the 
open-probe form is favored and the fluorescence is efficiently quenched in this “off” 
state. If a competitive inhibitor is present, the conformation of the switch molecule 
reverts to the on-state indicating the presence of a potential drug candidate. Other switch 
formats are being investigated in our lab (35-39). 
 
The sensitivity of an AlloSwitch is related to the three equilibria for high-throughput 
screening of drug candidates (Figure 2-2). The K1-equilibrium is controlled by the degree 
of complementarity between the RNA probe strand, and the DNA cover strand. The 
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greater the complementarity between the probe and cover the more the molecule becomes 
“locked” in the on form, so less of the switch molecule can be turned off by target 
binding (K2-equilibrium). The right combination of K1 and K2 usually gives about 90% 
of the maximum possible decrease in fluorescence on binding the target. This diagnostic 
tool is then able to detect and rank the affinity of drug candidates via the K3-equilibium. 
 
2.5. Building and Testing the AlloSwitches 
Designing and construction of the nucleic acid AlloSwitch requires the careful 
consideration of thermodynamic, and structural factors, as well as the consideration of the 
mechanics of oligonucleotide synthesis. Testing the switch requires an experimental 
ligand that accurately simulates the interaction between the in vivo ligand and its nucleic 
acid target. In the case of the Tat-P-TEFb-TAR interaction, a 33 nucleotide stem-loop 
portion of TAR complete with pyrimidine bulge can be easily secured from available 
commercial sources. Recreating the essential features of the Tat-P-TEFb interaction then 
becomes the challenge that has been the focus of this work. Important consideration must 
be given to the conformation that unbound Tat adopts (7,8) as well as to the fact that, un-
remodeled by interaction with Cyclin T1 and the completion of ZnF2, unbound Tat alone 
cannot effectively mimic in vivo interaction with TAR. Hence, mimicking this interaction 
in a manner that is structurally accurate requires essential features of both Cyclin T1 and 
Tat to be present in the experimental target. 
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Figure 2-1 An indicator for Tat-TAR Binding 
(a) A Tat-TAR indicator,T1, shown in the H conformation where most of the Tat-binding 
UCU bulge is hidden by base pairs, and (b) in the O-form, where the bulge is open for 
binding Tat. The critical binding elements for Tat (40) are circled. RNA monomers are 
shown in dark italics, DNA in regular font. The Probe and Cover strands are tethered by a 
fixed duplex, F (see text). Strands are numbered 53 and do not include the F-
sequences. The fluorophore =  and quencher = Q are marked. A second version of the 
switch has modifications in lower-case letters that include a “balancing” stem extension, 
ATCG:cgat in the O-form, which increases the stability of the double hairpin O-form. 
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Figure 2-2 High-throughput screen assay format for Tat-TAR blockers.  
Indicators have two stable states: H and O. Interesting competitors, X, will block 
formation of the LO complex (here, L = Tat). 
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Chapter 3 A Tat-Cyclin T1 Chimera 
 
Embarking on the recombinant expression of a protein frequently presents biochemical 
challenges that are unique to the specific characteristics of the protein of interest and, the 
expression strain being used, and which require optimization by what can be a lengthy 
empirical process. The existing literature on the expression and purification of HIV-1 Tat 
protein demonstrates that Tat expression in E. coli is notoriously difficult to achieve at 
appreciable yield, solubility, and in native form. This observation is often attributed to the 
high cysteine content of the Tat activation domain (41). The presence of several atypical 
codons in the corresponding DNA can compound this problem by stalling expression in 
E. coli (42). Accommodation must be made for the atypical codons either by codon 
optimization, or by providing the appropriate supplemental tRNA. The presence and 
maintenance of the two zinc fingers of the Tat protein, and the corresponding secondary 
structure they induce, present additional considerations for expression and purification 
which appear to have hindered other work (43).  
 
3.1. Recombinant Tat Expression  
Much of the recombinant expression of Tat has been performed in mammalian cells. 
Where Tat has been expressed in E. coli, it is most commonly extracted from inclusion 
bodies by denaturation and refolding, and is often still hindered by problems with 
insolubility, precipitation, and aggregation (43,44). Unfortunately, the process of 
denaturing and refolding is a cumbersome one that, if accomplished successfully, will 
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then necessitate additional assays in order to confirm the biological activity of the target 
(41). A high yield of soluble protein from denaturing and refolding protocols is rare (45). 
Hence, a recombinant expression protocol for adequate yield of the soluble protein in its 
native form is highly desirable.  
 
In order to facilitate the expression and purification of Tat, researchers frequently opt to 
express only the first exon of the Tat protein (42,46). The second exon, which is high in 
basic lysine residues, is not known to play a primary role in viral transcription (8,47,48). 
Still, difficulty with oxidation, misfolding, insolubility, precipitation, aggregation, or low 
yield persist even in the expression of truncated Tat in E. coli (42,43,49-52). Oxidation of 
recombinant Tat has been found to produce disulfide bond formation at C27-C30, and is 
suspected at C31-C34, and C22-C25 (53,54). In some cases, while working with Tat, 
oxidation was of such great concern that purification and refolding were performed in an 
anaerobic chamber (43). Even with the use of the anaerobic chamber protein dimers were 
observed. This can perhaps be explained, however, by the absence of the Cys261 residue 
contributed by CycT1 rather than by oxidation. 
 
3.2. Human Cyclin T1 
The work of Garber et al. 1998 suggested that Tat binding to TAR is mediated by Tat 
interaction with human Cyclin T1 and specifically by the completion of an intermolecular 
zinc finger by Cys261 of Cyclin T1(15). From an experiment mutating all cysteine and 
histidine residues of Cyclin T1, with the exception of Cys261, Fujinaga et al. 2002 
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concluded that Cyclin T1 binds Tat in a Zn2+ dependent manner at Cys261, and that no 
other cysteine or histidine residue of Cyclin T1 between amino acids 1 to 280 was 
required. This conclusion was largely based on the fact that Tat transactivation was not 
supported in mutants lacking Cys261(28). However, since the structure of HIV-1 Tat 
bound to HIV-1 TAR has not yet been solved, many questions remain including whether 
Cys261 of Cyclin T1 is mediating the interaction of Cyclin T1 with Tat or whether it is in 
fact directly responsible for binding to TAR. It is also possible that Cys261 could be 
influential in both interaction between Cyclin T1 and Tat and between the Tat-P-TEFb 
complex and TAR. Interestingly, it has also been suggested that TAR nucleates and 
enhances the interaction between Tat and Cyclin T1 (55) perhaps involving Cys261. 
 
Complicating an already rather nebulous image of the interaction, Richter et al. 2002 
concluded that residues 252-260 of Cyclin T1 were essential for TAR interaction with 
one side of the TAR RNA stem-loop and that these same residues enhanced the 
interaction of Tat residue K50 with the opposite side of the stem-loop (11). Unfortunately 
the 252-260 residues of Cyclin T1 are missing from the Tahirov crystal structure (Figure 
1-7) (7,8). Das et al 2004 however, performed mutagenesis experiments that strongly 
support a metal binding role for cysteine 261 in the formation of a ternary complex with 
HIV-1 TAR (27). Also of interest are the basic residues R251 and R254 which have been 
implicated by some as potential stabilizers of the Tat-P-TEFb-TAR interaction (15). That 
there is, as yet, little consensus about this interaction is perhaps the only certainty. 
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Because of the role zinc finger proteins are now known to play in gene transcription, it 
would seem intuitive that this interaction could be highly influential in binding and 
recognition between Cyclin T1-Tat and TAR and that the zinc fingers are likely to play 
an important role in specificity and transactivation. Much of the existing research, 
however, focuses on the importance of the arginine-rich region of Tat binding to the 
nucleotide bulge of TAR, and also on arginine residues 251 and 254 of Cyclin T1 as the 
modulators of TAR interaction rather than on Zn1 and Zn2. Since the original suggestion 
of the importance of the two zinc fingers in this interaction by Garber et al. 1998 little has 
been done to assess the effective contribution of the zinc fingers alone. A minimal 
construct of Cyclin T1 eliminating or mutating R251 and R254 of Cyclin T1 and 
reducing the contribution of Cyclin T1 (as much as possible) to that solely provided by 
completion of Zn2 could offer important insight toward this end. Moreover, the mutation 
or elimination of arginine residues in the arginine-rich region of Tat purported to bind the 
TAR stem-loop bulge could also yield valuable insight. 
 
Of the 726 residues of Cyclin T1 the first 272, encompassing the entire Cyclin domain, 
were originally found sufficient to bind Tat (15,28,56). However, interaction between the 
N-terminal and C-terminal region of Cyclin T1 has an autoinhibitory effect on TAR 
binding that is removed in vivo by Cyclin T1 C-terminal interaction with Tat-SF1 (57). 
The size and complexity of the dynamic interaction between P-TEFb-Tat-TAR suggests 
that structural study of the complex would be difficult to accomplish (28), and that a 
minimal construct could provide much needed structural information. With the intention 
 - 28 - 
of identifying such a minimal construct, Fujinaga et al. 2002 produced a series of 
minimal chimeras of N-terminally truncated Cyclin T1 fused to the full length (101 
amino acid) Tat. 
 
Working with N-terminally GST tagged chimeras of amino acids 1 through 280 of human 
Cyclin T1 fused to the 101 amino acid Tat in NIH 3T3 cells, Fujinaga et al. 2002 
measured transactivation of viral RNA for a series of Cyclin T1 N-terminally truncated 
variants of the construct. Predictably, the 1-280 amino acid Cyclin T1-Tat chimera was 
able to produce the highest level of transactivation at greater than 250 fold increase over 
baseline transactivation. However, a minimal construct of amino acids 249-281 of Cyclin 
T1 fused to the full 101 amino acid Tat produced an efficient 125 fold increase in 
transactivation. 
 
Working with a minimal chimera presents the possibility of acquiring important 
structural data from a construct of an appropriate length for 600-800 MHz NMR 
structural determination, and so was chosen as the chimera construct for this work. 
Subsequent to the work of Fujinaga, circular dichroism experiments performed on a 
human Cyclin T1 construct of amino acids 1-272 demonstrated that the 20 amino acids at 
the C-terminus of the construct were conformationally flexible or disordered (27). 
Similarly, and as mentioned previously (Figure 1-7), residues 252-260 of Cyclin T1 were 
absent from the Tahirov crystal structure (7,8), perhaps due to the flexibility and/or 
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disorder observed by Das et al. 2004. Thus an even shorter construct omitting non-
essential and flexible or disordered residues of Cyclin T1 could yield the important 
advantage of reducing this intractable region, while providing insight into questions about 
the importance of the completion of Zn2 by cysteine 261, as well as insight into the role 
of residues R251 and R254 in high affinity TAR binding. 
 
Since the Tat protein is notoriously difficult to express, purportedly due to insolubility 
and a high number of cysteine residues (43), work on the recombinant production of the 
chimera began by using the 249-280 hCyclin T1-Tat chimera published by Fujinaga et al. 
2002 in an attempt to assess the yield obtainable from this construct.  
 
3.3. pGEX 2TK Plasmid 249-280 hCyclin T1-Tat Chimera 
The pGEX 2TK plasmid of the 249-280 human Cyclin T1-Tat chimera was generously 
provided by Koh Fujinaga from Case Western University. While the details and yield 
were not published, Fujinaga (personal communication) indicated that the construct had 
been expressed in E. coli BL21 cells (28). Sequencing of the plasmid by Upstate Medial 
University DNA Core Facility confirmed that the open reading frame of the plasmid 
coded for the correct portion of human Cyclin T1followed by a 25 amino acid linker 
(within which a myc tag has been placed for antibody assay), and finally the full length 
(101 amino acid) Tat protein (Figure 1-2). The molecular weight of the GST-hCycT1-Tat 
construct is ~ 33.5 kDa, with an extinction coefficient (without disulfide bonds) at 280 
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nm of ~41250, and pI = 8.1 (Appendix 1). The Tat 101 aa portion of the sequence is 
identical with the Tat 101 aa protein sequence of accession number AAB59879.1 (101 aa 
Tat HIV-1 Group M Subtype B isolate ARV2/SF2) by Blast and was confirmed by 
ClustalX2 alignment. 
 
3.4. Expression of the pGEX 2TK GST hCycT1-Tat Chimera in E. coli 
The pGEX 2TK (~ 5.0 kb) chimera plasmid utilizes a tac promoter which is a hybrid of 
the lacUV5 and trp promoters. The tac promoter produces a tightly controlled, high-yield 
expression of recombinant protein. In general, the tac promoter necessitates the use of 
BL21 (non-DE3) (non-pLys) expression strain for optimal expression. The BL21(DE3) 
(pLys) strain designed for use with a T7 promoter would unnecessarily tax the cells with 
the production of the T7 polymerase, and reduce the yield of the target protein expression 
(Novagen conversations). While some researchers suggest it is possible to use DE3 
strains with plasmids utilizing a tac promoter, Figure 5-1 demonstrates clearly that yield 
of recombinant protein was considerably lower when using a DE3 strain to express the 
protease TEV from a pRK793 plasmid with a tac promoter. 
 
Unfortunately, many trials of recombinant expression of the pGEX 2TK plasmid, even 
when using the appropriate BL21 (non-DE3) (non-pLys) expression strain and following 
in close accordance with the protocol conditions generously provided by Koh Fujinaga 
(personal correspondence), produced a lower than anticipated yield (Figure 3-2) that was 
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insufficient for structural work with NMR. Estimates of crude and soluble protein yield 
were made using gel electrophoresis since the full length GST protein (already well 
below approximately 10 mg/L) was unstable when UV absorbing surfactants were 
removed. Concentration of the target after removal of the GST tag was too low for 
accurate determination by NanoDrop. A great deal of time and effort was spent varying 
expression conditions such as: culture temperature, IPTG concentration, media and media 
additives, among many others, and in the hopes of improving yield, but these efforts were 
to no avail. A variety of cell lysis techniques including sonication, microfluidizer 
processing, and freeze thaw cycling also failed to provide any observable improvement in 
the yield. 
Investigation into the potential causes of the low expression yield observed in the BL21 
(non-DE3) (non-pLys) expression strain revealed a number of significant factors. 
Analysis of the DNA sequences of the Cyclin T1 and Tat portions of the chimera alone 
(not including the adjoining sequence) showed that 15 of the chimera codons are atypical 
in E. coli (discussed in Chapter 7, see Table 7-1), and can therefore stall expression when 
corresponding tRNA are either unavailable or are in low abundance. However, 
transformation of the plasmid into the Rosetta 2 E. coli expression strain (Novagen 
Madison, WI), which contains an additional plasmid that codes for the production of 
several rare tRNA, increased basal protein expression while making only modest 
improvements in the expression of the target (Figure 3-4).  
Solubility also appeared to be a limiting factor early in the expression as much of the 
expressed protein remained in the insoluble fraction after cell lysis. This was somewhat 
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surprising in view of the presence of the GST tag. Moreover, cleavage of the GST tag 
using thrombin was highly non-specific and resulted in a further reduction in yield of the 
cleaved protein after FPLC purification (Figure 3-3). The diminished yield was observed 
when using a second benzamidine column to remove thrombin after cleavage, and was 
worse still when using a heparin sepharose column for thrombin removal, as in an 
unfortunate coincidence heparin bound Tat as well. In all trials with the pGEX 2TK 
plasmid the yield of the Tat chimera was far too low for structural work with NMR with 
the total yield of the full length chimera (with GST tag attached) at approximately 14 
mg/L. Yield of the target after removal of the tag was predictably lower still, and the final 
sample was substantially contaminated by co-purified proteins. 
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                       249–280 human Cyclin T1-----------------------     
        PN RLKRIWNWRA CEAAKKTKAD DRGTDEKTSE  
Spacer------myc------Spacer------- 
QTMPEQKLIS EEDLAMEFLE IDPVD 
HIV-1 Tat (1-101) --------------------------------------------------- 
MEPVDPNLEP WKHPGSQPRT ACNNCYCKKC CFHCYACFTR KGLGISYGRK 
         Proline rich domain                           Cysteine rich domain                                     Arginine-rich- 
------------------------------------------------------------------- 
KRRQRRRAPQ DSQTHQASLS KQPASQSRGD PTGPTESKKK VERETETDPF DLX 
(basic) domain                                         RGD containing C-terminal domain 
 
Figure 3-1 Sequence of the pGEX 2TK GST Chimera 
The sequence of the pGEX 2TK GST Chimera: shown in green for amino acids 249-280 
of human cyclin T1, in cyan for a myc antibody recognition sequence (which, together 
with 12 surrounding residues shown in black, constitute a spacer between the cyclin T1 
domain and Tat) , and in magenta for the 101 amino acid full length HIV-1 Tat protein; 
key residues are underlined. Blocks of residues are aligned in groups of ten according to 
the numbering schemes for cyclin T1 and Tat. A residual leucine remains at the C-
terminal of the Tat sequence as an artifact of the cloning process and X indicates the stop 
codon that terminates translation. The three features are recombinantly expressed as a 
single GST tagged construct The presence of the myc tag permits recognition of the 
chimera by anti-myc antibodies. The spacer portion of the contruct lends sufficient 
flexibility for the chimera to form a high-affinity complex with TAR RNA. The GST tag 
coding region upstream from the cloned insert and positioned at the N-terminus of the 
recombinant protein. The GE pGEX-2TK GST plasmid contains the GST tag sequence in 
the generic form prior to cloning. The GST sequence is not shown.  
 - 34 - 
7
L UN IN SE IE
  
 
Figure 3-2 Expression of the pGEX 2TK GST  hCycT1-Tat chimera  
 The expression of the pGEX 2TK GST hCycT1-Tat chimera in BL21 (non-DE3) (non-
pLys) in LB media. Red arrow indicates the full ~33.5 kDa GST tagged chimera. From 
left to right:  
(L) ladder (UN) uninduced 
(IN) induced with 1 mM IPTG at 0.6 OD600 and harvested after 6 hours  
(SE) soluble extract  (IE) insoluble extract 
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Figure 3-3 Cleavage of full purified GST- hCycT1-Tat chimera 
 Cleavage of the full purified GST hCycT1-Tat chimera after three hours of incubation 
with thrombin at room temperature (RT) from left to right:  
6 U Thrombin/mg 12 U Thrombin/mg Tat 
18 U Thrombin/mg Tat Full GST tagged Chimera  
Red arrow indicates location of cleaved chimera. The thrombin protease 37,000 kDa was 
present at concentrations too low for visible detection on the gel stained with GelCode 
Blue coomasie protein stain (this section of the gel omitted). 
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Figure 3-4 Expression of pGEX 2TK GST-hCycT1-Tat in Rosetta 2 cells 
Expression of pGEX 2TK  GST-hCycT1-Tat full chimera 
 in Rosetta 2 cells (Novagen Madison, WI). From left to right:  
ladder uninduced induced 
soluble insoluble FPLC purified fraction 
 
Note that the full length chimera and the tag-free chimera (not shown) run at a higher 
molecular weight than predicted. This artifact was observed consistently throughout all 
gel electrophoresis experiments, and is likely due to preferential SDS loading and the 
high number of cysteine residues present in the Tat chimera. 
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Chapter 4 Re-engineering the hCycT1-Tat Chimera Plasmid 
 
When re-engineering the chimera plasmid the first task was to increase the expression 
yield and to improve the solubility of the native hCycT1-Tat chimera. To this end a 
multitude of plasmid attributes were considered for their potential to impact the final 
yield of the active purified protein. For example, in some cases the expression yield can 
be improved by an alternate inducible promoter, which provides more tightly regulated 
expression while mitigating the buildup of toxic recombinant proteins in the cell. Once an 
adequate expression level is achieved, the final yield can be improved by increasing the 
solubility of the target protein. One approach to improving solubility is the addition of 
“solubility enhancing” tags or fusion proteins encoded by the plasmid, and expressed at 
either the N-terminus or the C-terminus of the recombinant protein.  
For many downstream applications the fusion tag may remain on the protein of interest 
without confounding the assay. With respect to the binding assays and structural work 
that the purified chimera is intended for, the frequently cumbersome fusion tag must 
often be removed. As a general rule, each step added to the purification process has the 
unintended effect of reducing yield. With this in mind, optimizing the cleavage sequence, 
and employing a highly specific protease enzyme to cleave solubility enhancing tags can 
contribute substantially to recombinant protein yield by cleaving as much of the tag from 
the target as possible while minimizing non-specific cleavage. 
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The second important task in re-engineering the chimera plasmid was to truncate the 
human Cyclin T1 portion of the chimera. By omitting the flexible region of Cyclin T1 
and removing the arginine residues suspected of influencing the affinity of TAR binding 
the contribution of Cyclin T1 Cys261 may be assessed. Specifically, the role of Cyclin T1 
in the binding of such a truncated construct is likely to be solely attributable to Cys261 of 
Zn2. By including only residues 257-280 of human Cyclin T1, the arginine residues R251 
and R254 could be removed while still allowing a few additional residues following 
Cys261 to afford conformational stability and flexibility. 
  
4.1. Selection of an Appropriate Vector 
When selecting a vector the size of the insert, copy number, promoter, selection marker, 
cloning sites, and other additional attributes of the vector must be thoroughly considered 
with respect to downstream applications (58). Commercially available plasmids can 
accommodate inserts approaching 15 kb in size. The chimera DNA insert is 
comparatively small, at less than 500 base pairs, and can be readily accommodated by 
most commercially available plasmids. Since the recombinant protein being expressed is 
considered  toxic to E. coli in high concentrations, a low copy number plasmid, rather 
than a high, is a prudent choice (59,60).  
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4.2. Solubility Enhancing Tags 
The initial expression of the glutathione S-transferase (GST) tagged chimera produced a 
low yield with a high proportion of the target protein in the insoluble fraction. Hence, the 
primary objective in re-engineering the chimera was to exchange this fusion protein, in 
the hopes of improving both expression and solubility of the chimera. Oddly, while the 
GST tag (24 kDa) is often characterized as solubility enhancing, improved solubility as a 
direct result of the inclusion of the GST tag is rarely observed (61-63). In fact, GST 
tagged proteins are frequently expressed at even lower levels, and in less soluble form 
than their untagged counterparts (63). A comparison by Braun and LaBaer 2003 reports 
the solubility achieved with GST in their own work, and the work of two other research 
groups, Hammarstrom et al. 2002, and Shih et al. 2002, at 50%, 48%, and 38% solubility, 
respectively (64,65). Thus, the true advantage of including the GST tag may lie in the 
ability to purify the protein by affinity chromatography, rather than in any predictable 
effect on solubility.  
 
Some of the more commonly employed solubility enhancing tags are: maltose-binding 
protein (MBP) (43 kDa), thioredoxin (Trx) (11 kDa), calmodulin-binding protein (CBP) 
(4 kDa), cellulose-associated protein (CAP) (17 kDa), NusA (54 kDa), and SUMO (11.5 
kDa) (64,66,67). However, little is known about the mechanism by which solubility is 
achieved with the use of these fusion proteins (68). 
Selecting an optimal solubility enhancing tag remains an empirical process that, using 
traditional methods, can be prohibitively time consuming. Recent advances in high-
throughput technology have facilitated parallel cloning, and rapid screening techniques 
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that expedite this process. As a general rule, larger solubility enhancing tags tend to 
produce higher expression yields of more soluble proteins, to improve folding, and also 
to reduced proteolysis of the target (66,69). However, larger tags tend to complicate 
structure determination necessitating their removal, and reducing yield as an inevitable 
and undesirable consequence. Folding, function, crystallization, and NMR experiments 
can all be hindered by the presence of solubility enhancing tags. Thus, keeping the fusion 
tag at a low molecular weight, and/or removing the tag entirely after purification are part 
of a repertoire of conventional strategies that can be used to deliberately design target 
proteins to facilitate downstream applications. 
 
4.3. Gateway® Cloning of hCycT1-Tat into pDEST HisMBP 
The fusion protein MBP has demonstrated exceptional efficiency at enhancing both the 
total expression and the solubility of many target proteins (68). Hammarstrom et al. 2002, 
Shih et al. 2002, and Braun and LaBaer 2003 reported solubility of target proteins fused 
to MBP at 70%, 60%, and 90% respectively, far better than these researchers observed 
with the same targets tagged by GST. In some cases MBP has specifically exhibited the 
ability to influence proper folding of the target by acting as a molecular chaperone (68). 
These observations suggested that the MBP fusion protein was an attractive candidate for 
improving the overall expression yield of the Tat chimera.  
 
One potential drawback to the use of MBP is problematic affinity purification where 
MBP often does not bind well to amylose resin, or where the target protein interferes with 
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MBP binding (70-72). The difficulties of MBP affinity purification can be circumvented 
by the use of a double-affinity fusion system such as that developed by Pryor and Leiting 
(1997). Addition of a 6 histidine (His6) tag to the C-terminus of MBP permits metal 
chelating affinity purification, and by employing both tags simultaneously solubility and 
purification are enhanced beyond what would be achieved by employing either of the 
tags independently. Building on the work of Pryor and Leiting (1997), the David Waugh 
Lab designed a similar pDEST-His6MBP plasmid for use in the Gateway Cloning 
method. In this construct the His6 tag is placed at the N-terminus of MBP. We chose this 
route for production of the MBP tagged hCycT1-Tat chimera. The pDEST HisMBP 
plasmid (#11085) was deposited with, and secured from, Addgene for the construction of 
the hCycT1-Tat pDEST His-MBP. A tac promoter in the pDEST His-MBP plasmid 
generates a low copy number, and is well-suited to expression of the (possibly) toxic 
chimera. 
 
4.4. Gateway® Cloning Technology 
Gateway® Technology exploits the recombination properties of the bacteriophage lambda 
by introducing att recombination sites flanking the sequence of interest. In the presence 
of the proprietary Clonase™ enzyme the desired sequence, with flanking att sequences, is 
recombined into a donor plasmid containing the appropriately complementary att 
recombination sequences. On recombination the desired sequence is inserted into the 
donor plasmid in a directional manner replacing the ominous control of cell death (ccd) 
gene and providing stringent selection. Subsequently, and in the presence of the 
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proprietary enzymes, the insert may be transferred by recombination into a number of 
commercially available destination plasmids with a variety of attributes that can be 
tailored to alternate downstream applications. The entire protocol may be accomplished 
in a few hours with the insert remaining in frame, and appropriately oriented, and without 
the need for a ligation step (73). 
 
4.5.Cloning Protocol 
A nine step procedure was followed for the production of the pDEST His-MBP hCycT1-
Tat vector: 
1. Introduce AfeI Blunt-end Restriction Sites into the pGEX 2TK hCycT1-Tat 
plasmid by Site Directed Mutagenesis  
2. Cleave pGEX 2TK hCycT1-Tat plasmid  
3. Isolate insert from agarose gel 
4. PCR amplify insert with N1 and C primer  
5. Purify insert with N1 and C attachments from agarose gel 
6. PCR amplify N1 C insert with N2 and C primers 
7. Purify insert with N1, N2, and C by agarose gel 
8. BP reaction to pDONR221 entry vector (Appendix 7) 
9. LR reaction to pDEST HisMBP vector (Appendix 7) 
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4.6. Introduction of AfeI Blunt-end Restriction Sites  
Prior to cloning the DNA fragment into the pDEST HisMBP plasmid (Figure 4-1), and 
beginning with the Cyclin T1 residue 257, the insert was excised from the pGEX-2TK 
(GE Healthcare Biosciences Pittsburg, PA) plasmid leaving blunt end restriction sites 
necessary for Gateway® cloning. Two flanking AfeI restriction sites were introduced to 
the chimeric sequence by site directed mutagenesis (Stratagene La Jolla, CA) (Figure 
4-2) (Appendix 6). Primer X online software was used to design the mutagenic primers 
(Figures 4-3, 4-4). The AfeI restriction site AGC/GCT (serine/alanine) cleaves between 
the cytosine and guanine residues of the DNA. As an artifact of this procedure the 
chimeric sequence will have an alanine added to the N-terminus and a residual serine 
added to the C-terminus of the protein. After site directed mutagenesis the inserts were 
analyzed by agarose gel electrophoresis (Figure 4-5), excised, purified, and sequenced. 
The correct placement of the mutations was confirmed by sequencing from the Upstate 
Medical University DNA Core Facility, and analyzed with Serial Cloner software. 
 
4.7. Addition of the att and TEV sites by PCR  
After excising the insert the att recombination sites must be added by polymerase chain 
reaction (PCR) at each end in order to facilitate recombination into the entry vector. At 
this point a tobacco etch virus (TEV) protease cleavage site was introduced 3’ of the 5’ 
att recombination site (Figure 4-6). The TEV protease is a highly specific protease that 
provides efficient cleavage of the MBP fusion tag (74). Introduction of the TEV cleavage 
site will facilitate MBP removal from the chimera at the amino acid sequence 
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ENLYFQ/G with a single residual glycine amino acid artifact that when added to the 
alanine artifact produced by the introduction of the AfeI restriction sites will leave 2 
residual amino acids at the N-terminus. Following the 101 amino acid Tat sequence, a 
single additional serine residue will follow a residual leucine that remains at the C-
terminus as an artifact of the cloning process (Figure 4-11). 
Following the work of Austin et al. 2009 for the construction of a pDEST HisMBP 
plasmid with a TEV cleavage site, three primers were employed to produce the insert: 
primer N1, primer C, and primer N2 in a two sequential PCR reactions. In the first 
reaction the forward primer N1 contains a 5’ region coding for the restriction sequence of 
TEV (Figures 4-6) followed by 20 nucleotides of the coding passenger DNA. The reverse 
primer, Primer C, has a 5’ region encoding the attB2 recombination site followed by 21 
nucleotides of the 3’ coding region of the passenger DNA (Figure 4-7). Here an 
excessively long forward primer is obviated by a second PCR reaction in which the first 
PCR amplicon becomes the primer for the second PCR amplicon N2 (Figure 4-6) (75). 
Primer C, the reverse primer, is used in both reactions. Primer N2, the forward primer for 
the second PCR reaction, encodes the attB1 recombination site followed by 19 
nucleotides of the coding TEV protease site. The three primers can be employed in a 
single PCR reaction to obtain a final insert with flanking attB1 and attB2 recombination 
sites, and a TEV protease site, or the reaction can be done in series amplifying first with 
Primer N1 and C, purifying the PCR product, and then amplifying a second time with 
Primer N2 and C.  
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The reaction was performed in both single step (not shown), and two step reactions with 
only the later successfully producing the appropriate insert. Concentrations of the primers 
were consistent with those used by Austin et al. 2009 (Table 1). The PCR thermal cycler 
settings were as follows: initial melt 5 min at 95°C; 35 cycles of 95°C for 30 s, 55°C for 
30 s, and 72°C for 60 s then hold at 4°C. After agarose gel electrophoresis (Figures 4-7, 
4-8) PCR products excised, and then purified with the Pure Link™ PCR clean-up kit 
(Invitrogen, Carlsbad CA). 
 
4.8. Gateway® Cloning Donor Vector  
After PCR the inserts were purified, and introduced by recombination into the donor 
vector pDONR221 (Invitrogen Carlsbad, CA). The hCycT1-Tat gene was transferred 
from the attB flanked PCR product into the attP flanking donor vector by recombination 
in what is called a “Gateway® BP reaction” (referring to the joining of the attB and attP 
sites) (Figure 4-9) by incubating equimolar amounts of attB-PCR product and donor 
vector with BP Clonase overnight at 25°C (Invitrogen Carlsbad, CA) in TE buffer at pH 
8.0. At the end of the BP reaction Proteinase K solution was added and the reaction was 
incubated for 10 minutes at 37ºC. The pDONR221 vector was then transformed into 
OmniMAX™ 2-TIR chemically competent E. coli. The negative selection gene ccdB of 
the pDONR221 plasmid was replaced by recombination of the attB flanked PCR product 
and only successful recombinants survived on LB plates with 50 ug/ml kanamycin (73).  
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4.9. Gateway® Cloning Destination Vector  
Once the hCycT1-Tat gene was transferred into the pDONR221 donor vector the target 
gene was then transferred by LR recombination reaction into the expression or 
“destination” vector (more details of the recombination reactions will be described in 
connection with Fig. 6-10). The attP recombination sites of the pDONR221 vector 
recombined with the attB sites of the PCR insert to form attL sites that recombine into the 
attR sites of the destination vector during the LR reaction. The pDONR221 plasmid DNA 
(150 ng/ul in TE, pH 8.0) was incubated with 150 ng/ul of pDEST HisMBP in TE, pH 
8.0 overnight at 25ºC. At the end of the LR reaction Proteinase K solution was added and 
the reaction was incubated for 10 minutes at 37ºC (73). The pDEST His-MBP hCycT1-
Tat vector was then transformed into chemically competent Rosetta Gami B (Novagen 
Madison, WI) E. coli (Figure 4-8). The pDEST HisMBP hCycT1-Tat plasmid was 
sequenced at Upstate Medical DNA Core Facility, and the correct sequence and the 
reading frame of the insert were confirmed (Figures 4-10 and 4-11). 
 
 - 47 - 
 
 
Figure 4-1 pDEST-HisMBP Plasmid. 
Addgene#:11085. Deposited by The David Waugh Lab. 
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Figure 4-2 Introduction of AfeI restriction sites by site directed mutagenesis. 
The location for introduction, by site directed mutagenesis, of two AfeI blunt-end 
restriction sites to the pGEX 2TK plasmid flanking the hCycT1-Tat chimera DNA 
sequence. The AfeI sites were placed such that the 5’ site cleaved the insert prior to the 
codon corresponding to residue 257 of the 249-280 portion of Cyclin T1 and the 3’ 
restriction site was placed after the codon corresponding to a single residual leucine 
residue past the 101 amino acid Tat sequence that remains as an artifact of the cloning 
process.  
 
pGEX 2TK hCycT1 249-280 Tat 101@1@2 with AfeI 
mutations 
1351 bp 
Bam HI (803) 
Cla I (966) 
Eco RI (953) Hin dIII (1176) 
Nco I (948) 
Ava I (959) Ava I (1209) 
Afe I (829) 
Afe I (1288) 
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 Primer pair 1 
                                  ***** 
    Forward: 5' CCAACAGGCTCAAACGCAGCGCTAATTGGAGGGCATGCGAG 3' 
    Reverse: 5' CTCGCATGCCCTCCAATTAGCGCTGCGTTTGAGCCTGTTGG 3' 
                                  ***** 
     GC content: 58.54%           Location: 754-794 
     Melting temp: 77.2°C         Mismatched bases: 5 
     Length: 41 bp                     Mutation: Substitution 
     5' flanking region: 18 bp    Forward primer MW: 12678.36 Da 
     3' flanking region: 18 bp    Reverse primer MW: 12535.25 Da 
 
Figure 4-3 Two PCR primers for the introduction of the 5’ restriction sites. 
Using PrimerX software two primers were designed  
to add the same AGC/GCT blunt end restriction site to the 5’ end of the insert (Serial 
Cloner) 
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Primer pair 1 
                                   ****** 
    Forward: 5' 
GACAGATCCGTTCGATTTGAGCGCTGTCGAGAGAGCGGCCGCATC 3' 
    Reverse: 5' 
GATGCGGCCGCTCTCTCGACAGCGCTCAAATCGAACGGATCTGTC 3' 
                                    ****** 
     GC content: 60.00%           Location: 1211-1255 
     Melting temp: 78.1°C         Mismatched bases: 6 
     Length: 45 bp                Mutation: Substitution 
     5' flanking region: 19 bp    Forward primer MW: 13903.14 Da 
     3' flanking region: 20 bp    Reverse primer MW: 13783.08 Da 
 
Figure 4-4 Two PCR primers for the introduction of the 3’ restriction sites. 
Using PrimerX software two primers were designed to add the same AGC/GCT blunt end 
restriction site to the 3’ end of the insert (Serial Cloner) 
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Figure 4-5 Agarose gel electrophoresis of the PCR products for AfeI sites  
Agarose gel electrophoresis analysis of the PCR products for the addition of AfeI blunt-
end restriction sites by site directed mutagenesis at sites 5’ and 3’ of the hCycT1-Tat 
insert. Gel electrophoresis at 0.7% agarose 140 V. From top to bottom:  
1 – forward primer for 3’ mutation 2 – reverse primer for 3’ mutation,  
3, 4, 5 – pGEX 2TK plasmid with 5’ AfeI sites,  
6,7,8 – pGEX 2TK plasmid with both 5’ and 3’AfeI sites. 
1 
2 
3 
4 
5 
6 
7 
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Figure 4-6 Diagram of the sequential PCR reaction for the att flanked insert. 
Diagram of the sequential PCR reactions for the production of the HisMBP hCycT1-Tat 
chimera insert with flanking att, and internal TEV protease sites. 
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Set-up of the sequential PCR reactions for primers N1, N2, and C for the production of 
the HisMBP hCycT1-Tat chimera insert. 
 
 
 
  
Table 1 Set-up of the PCR reactions for primers N1, N2, and C 
 - 54 - 
Primer N1 – 5’ - GAG AAC CTG TAC TTC CAG GGT GCT AAT TGG AGG GCA 
TGC GA – 3’ 
Primer C  - 5’ - GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT ATT AGC 
TCA AAT CGA ACG GAT CTG T – 3’ 
Primer N2 – 5’ - GGG GAC AAG TTT GTA CAA AAA AGC AGG CTC GGA GAA 
CCT GTA CTT CCA G – 3’ 
 
Figure 4-7 Nucleotide Sequences of N1, C, and N2 primers 
Sequences of N1, C, and N2 primers for addition of the TEV protease site, and the attB1, 
and attB2 flanking recombination sequences for Gateway® cloning. For the N1 and N2 
primers sequences in blue include the sequence for addition of the TEV protease site. For 
primer N1 the sequence in black complements the antisense strand of the Tat chimera 
insert after cleavage by AfeI. For primer C the sequence in green includes the sequence 
for the addition of the attB2 site, and the portion in black complements the sense strand. 
The primer N2 sequence in red includes the sequence for addition of the attB1 site, while 
the sequence in blue is the same as the TEV protease sequence in N1 (with the exception 
of the final three nucleotides), and complementary to the antisense strand after the first 
PCR reaction with N1 and C.  
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Figure 4-8 Agarose gel electrophoresis of PCR products for the N1 and C primers 
An agarose gel electrophoresis analysis of the PCR products for the N1 and C primers 
adding the TEV protease site and the flanking att B2 recombination site to the hCycT1-
Tat chimera DNA insert. Gel electrophoresis 0.7% agarose 0.5 X TBE 140 Volts. From 
top to bottom:  
 1 – ladder 1 kb                 2 - negative control primers only (no template DNA)  
 3 – positive control (kit template DNA and primers)                        4 – empty  
 5 – primer N1, primer C, and Tat chimera insert reaction (20 ul). 
 
 
  
1 
2 
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4 
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Figure 4-9 Agarose gel electrophoresis of PCR products for the N2 and C primers 
 An agarose gel electrophoresis analysis of the PCR products for the second round of 
PCR with the N2 and C primers adding the attB1 and attB2 sites, respectively to the Tat 
chimera DNA insert after the first round of PCR with N1 and C primers. Gel 
electrophoresis 0.7% agarose 0.5 X TBE 140 Volts. From top to bottom:  
 1 – ladder 1 kb                   2 – negative control primers only (no template DNA)  
 3 – positive control (kit template DNA and primers)                            4 – empty  
 5 and 6 – primer N1, primer C, and Tat chimera insert reaction (20 µl) 
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Figure 4-10 Gateway cloning BP and LR reaction 
Gateway cloning BP and LR reactions for the production of the pDEST HisMBP (257-
280) hCycT1-Tat (101) chimera expression plasmid. In the BP reaction (top) the att 
flanked insert is recombined into the pDONR221 entry vector. In the LR reaction 
(bottom) att sites of the donor vector recombine with att sites on the pDEST-HisMBP 
expression plasmid.  
* According to Life Technologies Corporation the letters B, P, L, and R refer to bacterial, phage, left, and right respectively. 
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Figure 4-11 Diagram of the pDEST-HisMBP hCycT1-Tat chimera. 
Schematic diagram of the pDEST-HisMBP hCycT1-Tat chimera plasmid. The chimera 
insert is flanked by attR sites compatible with the Gateway® Cloning recombination 
system. The tightly regulated tac promoter is upstream from the dual HisMBP tag which 
facilitates purification, and enhances solubility of the Tat chimera. The straight portions 
between the Tat (orange), myc (yellow), and hCycT1 (red), are linker regions that 
provide the chimera with the flexibility to adopt secondary structure. 
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Figure 4-12 pDEST HisMBP 257-280 hCycT1-myc-Tat Protein Sequence 
The final translated protein sequence of the HisMBP 257-280 hCycT1-Tat chimera 
confirmed with DNA sequencing by the Upstate Medical University DNA Core Facility 
and translated by Serial Cloner software. The sequence begins with glycine and alanine 
(artifact residues of the cloning process) at the N-terminus of the protein. The 257-280 
portion of Cyclin T1 appears underlined in green, followed by a spacer region which 
contains the myc tag (underlined in blue). The 101 amino acid Tat sequence is followed 
by residual amino acids leucine and serine which remain (as artifacts of the cloning 
process) at the C-terminus.  
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Chapter 5 A Preliminary Cyclin T1-Tat Chimera 
 
Once the construction of the pDEST HisMBP hCycT1-Tat chimera was complete, a 
suitable expression strain was selected. Choosing an appropriate strain for the production 
of a heterologous protein is essential to achieving high yield, adequate solubility, and 
proper folding. Due to rapid growth rate, low cost, and the extensive amount of genetic 
information available E. coli strains are regularly chosen for the production of 
recombinant proteins. In order to achieve the high yield required for structural study of 
the hCycT1-Tat chimera the chosen strain would first be required to accommodate the 
tightly controlled tac promoter of the pDEST-HisMBP plasmid.  
 
5.1. The tac Promoter 
When expressing recombinant proteins from plasmids with tac promoters it is generally 
best to select a non-DE3 non-pLysS expression strain (Novagen conversation). 
Researchers often propose that a DE3 strain can be used with plasmids utilizing tac 
promoters (42,76). However, here we show that the expression of the pRK793 plasmid 
(Appendix 8) for production of the TEV protease enzyme (HisMBP-TEV[S219V]) (74) in 
Rosetta Gami B (Novagen, Madison, WI) (Figure 5-1), a non-DE3 strain of E. coli, provides 
a substantial increase in target expression, as well as a moderate increase in basal expression, 
over the Rosetta Gami B DE3 strain. This observation can likely be attributed to the fact that 
the DE3 prophage expresses T7 RNA polymerase which, when utilizing a tac promoter, 
unnecessarily taxes the cells and should be avoided as tac expression systems employ the 
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native E. coli RNA polymerase. It is also important to note that the pLysS plasmid often 
provided with DE3 strains produces T7 lysozyme which regulates T7 RNA polymerase 
reducing basal expression, but is also unnecessarily taxing in, and obviated by, the use of 
plasmids with tac promoters. 
 
5.2. Codon Usage 
The next important consideration in the recombinant expression of the chimera is the 
presence of codons that are atypical in E. coli. Using the UCLA Rare Codon Calculator 
(http://nihserver.mbi.ucla.edu/RACC/) it was estimated, prior to sequencing, that the 
cleaved chimera sequence contains at least 15 rare codons that are known to hinder 
expression in E. coli by the stalling and premature termination of translation, 
incorporation of incorrect amino acids, and by frameshifts that contribute to low 
expression yield (77) (Table 7-1). Of the rare codons known to be present, 11 are rare 
arginine codons. There are also two occurrences of a rare leucine codon, and two 
occurrences of a rare proline codon. 
 
The presence of rare codons in recombinant expression can be addressed by codon 
optimization, where an equivalent E. coli codon is substituted for the atypical codon, or 
by the use of expression strains that contain additional plasmids coding for the atypical 
tRNAs such as Rosetta Gami B (Novagen, Madison, WI). 
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5.3. Disulfide Bonds 
In E. coli the formation of disulfide bonds is compartmentalized in the periplasm. 
Subsequently, the reduction of disulfide bonds is accomplished through the thioredoxin, 
and glutathione/glutaredoxin pathways in the cytoplasm. Mutation of the thioredoxin 
reductase (trxB), and glutathione reductase (gor) genes allow disulfide bond formation in 
heterologous protein to take place in the cytoplasm of E. coli by destabilization of the 
reduction mechanism (78). Substantial increases in active protein yield have been 
observed in expression strains with both the trxB and gor mutations with the result being 
attributed to improved folding where disulfide bond formation in the cytoplasm is 
facilitated (79). Strains possessing the dual mutation are commercially available. 
 
The high number of cysteine residues in the Tat chimera and the presence of two zinc 
fingers alone suggest that an environment favorable to disulfide bond formation during 
expression could potentially augment expression yield. In support of the potential 
importance of disulfide bond formation, dramatically inhibited Tat activity has been 
observed in the presence of strong reducing agents leading to speculation about the 
presence of disulfide bonds in the active protein (44,80,81). Though no such disulfide 
bonds were reported by Tahirov et al. 2010 in the published structure of Tat complexed 
with P-TEFb, the conformation of the active site of Tat remains unknown, as does the 
conformation of Tat when bound to TAR. Moreover, a number of zinc finger proteins 
have been shown to demonstrate redox sensitivity (82) as well as behavior consistent 
with that of redox sensory proteins that may alternate conformation between zinc bound 
states and disulfide bond formation between cysteine residues.  
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5.4. Outer Membrane and Lon Proteases in E. coli  
The outer membrane protease T (OmpT) of E. coli is a member of the omptin family of 
integral membrane peptidases implicated in the pathogenicity of several gram-negative 
bacteria. This highly specific endopeptidase cleaves between two basic amino acids, and 
demonstrates resistance to extreme denaturing conditions (83). In E. coli OmpT has been 
implicated in protein degradation (84). Expression strains containing an OmpT mutation 
inactivating this endopeptidase have demonstrated higher yields of heterologous proteins.  
 
The Lon protease of E. coli is a highly conserved ATP dependent protease that degrades 
misfolded, or mutant proteins, and a few specific regulatory proteins (85). In the 
expression of recombinant proteins it is desirable to choose an expression strain with the 
Lon protease inactivated by mutation in an effort to prevent possible degradation of the 
target protein.  
 
5.5. Lactose Permease 
In E. coli lactose is utilized under the control of the lac operon system where lacY 
facilitates the transport of lactose into the cell, and lacZ cleaves lactose (86). In E. coli 
protein expression strains containing the lacZY deletion mutation, protein expression 
levels may be adjusted (called “tuning”) throughout all cells in a culture by regulating 
IPTG concentration at induction. Proteins with solubility issues occasionally exhibit 
improved solubility with reduced concentrations of IPTG that theoretically allow the 
protein more time to fold properly. Therefore, in difficult to express proteins it may be 
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advantageous to employ this mutation. However, when using such strains auto-induction 
media may not be used as strains with the lacZY mutation do not produce the required 
allolactose. 
 
5.6. Rosetta Gami B Strain (Novagen, Madison WI) 
The commercially available Rosetta Gami B Strain of competent cells (Novagen, 
Madison, WI) provides a combination of attributes that are well suited to the expression 
of the recombinant Tat chimera. Rosetta Gami B cells carry an additional plasmid 
accommodating the expression of six rare codons. This strain, bearing the trxB and gor 
mutations, may also improve protein folding and the yield of soluble protein in proteins 
containing disulfide bonds. Both the OmpT and the Lon proteases have been removed by 
mutation from the Rosetta Gami B expression strain. Finally, this strain has a “tunable” 
expression feature, as a result of the lacZY mutation, presenting another potential 
mechanism for improved folding and solubility.  
 
During the initial expression attempts with the GST tagged chimera virtually no 
expression was observed in either BL21 DE3 pLysS or BL21 non-DE3 non-pLysS, and 
very low expression was achieved with the Rosetta 2 (Novagen, Madison, WI) cells that 
contain a plasmid accommodating expression of atypical codons. After carefully 
considering the combination of attributes afforded by the strain, the characteristics of the 
recombinant protein being expressed, and the initial observations during expression of the 
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GST tagged chimera, the Rosetta Gami B cells were selected for the first attempts at 
expression of the HisMBP-hCycT1-Tat chimera. 
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Position Codon Amino Acid 
5 AGC Arginine 
18 CGA Arginine 
59 CTA Leucine 
61 CCC Proline 
70 AGG Arginine 
91 AGA Arginine 
100 AGG Arginine 
104 AGA Arginine 
106 CGA Arginine 
107 CGA Arginine 
108 AGA Arginine 
120 CTA Leucine 
124 CCC Proline 
129 CGA Arginine 
135 CCC Proline 
144 AGA Arginine 
 
Table 2 Rare codons and their position in the hCycT1-Tat chimera. 
Rare codons in red and green are not accommodated by the Rosetta Gami B strain. 
This fact will not prevent expression entirely as these rare tRNA are present in E. coli 
albeit in lower amounts. 
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Figure 5-1 Expression of the HisMBP TEV pRK793 plasmid 
The expression of the HisMBP TEV pRK793 plasmid (Appendix 8) (for recombinant 
expression of the Tobacco Etch Virus protease S219V mutant) in Rosetta Gami B DE3 
versus non-DE3 strains. From left to right: 
 1 – ladder                                                        2 – Rosetta Gami B DE3 uninduced  
 3 – Rosetta Gami B non-DE3 uninduced   4 – Rosetta Gami B DE3 induced 
 5 - Rosetta Gami B non-DE3 Induced 
 
 
           1               2               3      4       5 
10 
15 
20 
25 
37 
50 
75 
100 
150 
250 
 - 68 - 
Chapter 6 Optimizing Protein Expression Yield 
 
Optimizing the yield of recombinant protein expression is an empirical process that 
requires a dual pronged approach. First the overall crude protein expression yield must be 
optimized, and second the fraction of the expressed protein available in soluble form 
must be maximized. Care must be taken to avoid aggregation and precipitation after 
cleaving solubility enhancing tags, and when the target protein is present in solutions at 
both low and high concentrations. With an eye toward downstream applications, buffer 
compatibility with purification and assay requirements and long-term storage conditions 
must be optimized.  
 
Control over the final soluble expression yield may be exerted at many points throughout 
the expression, purification, and storage of the protein. The choices of expression strain, 
growth media, and growth conditions, as well as a long list of potentially helpful 
techniques and additives that can be employed along the way results in a daunting 
number of possible combinations of varying efficacy. Predicting which of these 
techniques will be most effective for a particular protein is rarely possible, and empirical 
determination can be extremely costly and time-consuming. Hence, wherever possible 
high-throughput methods of assessing the efficacy of yield and/or solubility enhancing 
techniques are highly desirable. 
 
While the subject of choosing an expression strain has been discussed previously, it is 
worth noting here that even within a specific transformed strain target protein expression 
 - 69 - 
levels of some colonies may surpass that of others. Thus, it is often advantageous to 
screen multiple colonies of the same transformed strain for the purpose of comparing 
expression yields. In an assay called a Double Colony Selection (DCS) several colonies 
from a single transformation are assessed for recombinant target expression yield. The 
colony with the highest yield is then cultured overnight, plated, and in a second round of 
selection several colonies are again compared by yield of the target protein. In some 
cases this procedure can substantially increase the yield of recombinant expressions. 
Periodically re-transforming, and screening the expression strain to be sure that the 
plasmid is not lost is also an important step in maintaining high yields of protein 
expressions. 
 
Once the transformed strain has been optimized, the next step is to optimize the growth 
conditions by providing appropriate nutrients in the form of growth media, and additives 
where necessary, and by controlling the growth conditions of temperature, aeration, and 
pH of the growth environment. Many different media formulations are available with a 
variety of nutrients and additives that may improve both the yield, and the efficiency of 
the expression protocol. 
 
6.1. Growth Media 
The appropriate selection of growth media is necessary for achieving maximal growth 
rate and cell yield. While E. coli are able to synthesize many of the nutrients they require, 
the production of soluble, stable, and functional recombinant proteins is best achieved 
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with the addition of trace metals, minerals, and vitamins to the growth medium (87). The 
basic components of E. coli growth media include water, an amino acid nitrogen source 
such as tryptone, a carbon source in the form of a fermentable sugar (such as glucose), 
yeast extract (an additional nitrogen source), sodium chloride to regulate the osmotic 
environment, and phosphate to provide a source of phosphate for growth and also to 
buffer the growth media. Where a specific strain is growing aerobically at a fixed 
temperature, both growth rate and yield of cells are dependent on the carbon source (88). 
Supplementation of the E. coli medium with appropriate nutrients increases the quantity 
of E. coli cells. Both plasmid and recombinant protein yield are directly proportional to 
the quantity of E. coli cells. 
 
Another important condition in the optimal growth of E. coli is the maintenance of near 
neutral pH. While sensitivity to low pH is somewhat lower than sensitivity to high pH, 
which can cause cell death, the optimal pH range for E. coli growth is 5.5 to 8.5 (87). 
Without proper aeration E. coli produce acetic acid which lowers the pH of the culture, 
and inhibits cell growth. Agitation of the culture during cell growth increases aeration of 
the culture, as does the use of a baffle bottom flask. In addition, many media formulations 
employ buffers such as potassium phosphate to maintain an optimal pH range during cell 
growth.  
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6.2. LB Media 
Lysogenic Broth (LB) also known as Luria-Bertani is a commonly used media formula 
for the growth of E. coli cell cultures. Originally, the formula was supplemented with the 
addition of 1 mg/ml glucose, but such supplementation is no longer common in 
contemporary LB formulas. Sezonov et al. 2007 found that steady-state growth of E. coli 
ended when the culture reached an OD600 of 0.3, and that the growth of the cell culture 
was limited by availability of carbon sources which E. coli catabolized, not from sugars, 
but from available amino acids (89). The use of LB media is generally an appropriate 
choice for recombinant expression of a protein of interest, and tends to produce low basal 
expression of other E. coli cellular proteins. 
 
6.3. Rich Media 
Achieving high cell yield and cost effective and efficient recombinant protein production 
can be enhanced in some expression systems with the use of rich media. Accumulation of 
acetic acid, a byproduct of glucose metabolism that inhibits cell growth, can be reduced 
with the use of alternative carbon sources such as glycerol, and also by media with 
buffering capacity. Many recipes for rich media contain trace metals, trace minerals, and 
vitamins, as well as proprietary ingredients in commercial formulations which often have 
animal sources (87). As with most other aspects of recombinant protein expression 
protocols, the usefulness of any particular media formulation must be determined 
empirically. One of the potential disadvantages of the use of rich media is an increase in 
basal expression which can hinder purification.  
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6.4. Turbo Broth™ 
One proprietary media formulation, Turbo BrothTM (AthenaES Baltimore, MD), claims to 
achieve 4 to 5 times higher E. coli cell yields than that achieved in LB media alone. This 
rich media substitutes glycerol for glucose as a carbon source, and is supplemented with 
trace minerals, vitamins, inorganic compounds, and amino acids. The addition of 
potassium phosphate maintains the culture pH at 7.2 ± 0.2. Although not quantitatively 
compared, by visual comparison the induced protein yield of the HisMBP-hCycT1-Tat 
chimera appears considerably higher with the use of Turbo BrothTM when compared to 
LB media (Figure 6-1). Predictably however, the basal expression of other E. coli cellular 
proteins also appears to have been considerably increased. 
 
6.5. Auto-induction Media 
Auto-induction media contains the carbohydrates lactose, and glucose. Initially E. coli 
use the limited amount of glucose available in the formula as an energy substrate 
typically until mid or late log phase. When the glucose has been depleted the E. coli then 
use lactose converting it to allolactose with the enzyme β-galactosidase. The lac repressor 
is released from the DNA by allolactose initiating the expression of the recombinant 
protein. The advantages of using this formula are that it is not necessary to monitor the 
culture to determine the induction point, increased cell mass is generally observed, and 
that optimal initiation of expression tends to increase protein yield (90). However, 
because of the lacZY mutation the Rosetta Gami B cells will not produce allolactose, and 
therefore this strain cannot be used for protein expression in auto-induction media. 
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6.6. Minimal Media 
For structural study of proteins using nuclear magnetic resonance (NMR) isotopically 
labeled proteins must be expressed in E. coli. In particular, heteronuclear single quantum 
coherence (HSQC) requires the protein of interest to be 15N labeled. Isotopic labeling of 
the protein with 15N is typically achieved by growing E. coli in M9 media (Appendix 9) 
containing 15NH4Cl as the sole nitrogen source. The M9 media is supplemented with 
glucose, trace metals, vitamins, and other minerals, but in general E. coli incorporating 
15N tend to grow more slowly in minimal media. Some proteins can be expressed 
sufficiently with little effort in minimal media, while other less tractable targets can prove 
problematic. A multitude of minimal media formulas have been developed to improve 
labeled protein yields in minimal media, and a number of commercial and proprietary 
formulas are marketed for use in exceptionally difficult expressions. Commercial 
formulas such as BioExpress® (Cambridge Isotope Laboratories, Inc. Andover, MA), 
however, can be quite costly (at present in excess of $700 per liter) depending upon the 
number of isotopes incorporated. 
 
6.7. Growth Phases of E. coli 
The growth of E. coli can be described in four phases: lag phase, log phase, stationary 
phase, and death phase. When the optical density at 600 nm of a solution of E. coli in 
growth media is plotted as a function of time each of these four phases can be seen to 
occur in succession. When the culture is first inoculated the rate of growth is typically 
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during the initial lag phase as the E. coli acclimate to fresh media and antibiotics. During 
the second phase, the logarithmic phase or “log” phase, E. coli reproduce exponentially.  
 
It is at the mid-point of this log phase that induction of recombinant protein expression 
will generally produce optimal yield. During the log phase the E. coli are said to be 
“healthy” as the medium is not yet depleted of nutrients, nor yet full of the toxic 
byproducts of E. coli metabolism. Recombinant protein expression is a process which is 
heavily taxing to the cell, and which sequesters many cellular resources. Moreover, many 
recombinant proteins are toxic to E. coli. Thus, the induction of expression when the E. 
coli are most fit and reproducing rapidly will generally produce the highest yield. As 
nutrients are depleted, byproducts contaminate the medium, and crowding occurs. At this 
point cells enter the stationary phase. In the stationary phase cell density is maintained at 
a steady state. During the final “death phase” the effects of the nutrient depleted medium 
and the buildup of the toxic waste byproducts of metabolism combine causing cell death 
observable as a decrease in culture density.  
 
6.8. Growth Curves for the Tat Chimera in Various Media 
Figures 6-2, 6-3, and 6-4, show the growth curves for the pDEST HisMBP hCycT1-Tat 
chimera in Rosetta Gami B cells (RBG) in LB, Turbo, and BioExpress® media. Figure 6-
5 shows the growth curve for the double colony selection mutant (DCS) in BioExpress® 
media. In each of the growth curves below we see that optimal induction should occur 
between OD600 of 0.6 to 0.8.The mid-point of the mid-log phase for the growth curves of 
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the Rosetta Gami B (RGB) in LB, Turbo Broth™, and BioExpress®, and for the double 
colony selection (DCS) was approximately OD600 0.7.  
 
When Tat chimera expression by RGB transformed with pDEST HisMBP-hCycT1-Tat 
was compared in LB, Turbo Broth™, and BioExpress® media, as anticipated, the highest 
recombinant protein expression was found in the Turbo Broth™ rich media (Figure 6-7).  
Tat chimera expression by DCS in BioExpress® media was compared to expression by 
RGB in BioExpress® media. The specifically selected DCS mutant demonstrated higher 
expression than RGB in samples taken four hours after induction (Figure 6-7), but lower 
levels of expression than RGB in samples taken after 18 hours. This could be due to 
protein degradation which is commonly observed in lengthy expression protocols, and 
which for some reason the DCS mutant may be more susceptible to. The yield achieved 
for both RGB and DCS in the BioExpress® media was comparable to that achieved in 
LB (Figure 6-7), a promising result when considering the low levels of recombinant 
expression typical of minimal media when compared to nutrient rich media. 
 
6.9. Comparison of Construct, Strain, and Media Changes 
There was no consistent observable overexpression of the GST-hCycT1-Tat chimera in 
BL21 with either the DE3 pLysS, or non-DE3 non-pLysS strains. This observation is 
most likely due to the approximately 14% atypical codons which would not be 
accommodated by these strains. When the GST chimera was expressed in Rosetta 2 
(Novagen) cells a low level of expression was observed in 1 L of LB induced at OD600 
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=0.7 with 1.0 mM IPTG and after 6 hours of growth at 28º C (Figure 6-8 A). By visual 
comparison of the samples in SDS PAGE, expression of the HisMBP chimera construct 
in Rosetta Gami B in 1 L of Turbo Broth™ was clearly and substantially increased over 
that of the original GST construct and protocol (Figure 6-8 B) 
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Figure 6-1xpression of the HisMBP Tat Chimera in LB and Turbo Broth 
A. Expression of the HisMBP-hCycT1-Tat chimera in LB media 
 : 1 – Ladder 2 – Uninduced 3 – Induced. 
 B. Expression of the HisMBP-hCycT1-Tat chimera in Turbo BrothTM  
: 1 – Ladder 2 – Uninduced 3 – Induced  
Both samples from one liter cultures induced at OD600 0.7 and grown at 28°C for 7 hours. 
 
A 
B 
250 
150 
100 
75 
50 
37 
250 
150
00 
100 
75 
50 
37 
 - 78 - 
 
Figure 6-2 Growth Curve of Rosetta Gami B in LB Media 
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells in LB media 
at 37°C. 
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Figure 6-3 Growth Curve of Rosetta Gami B in Turbo Media 
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells in Turbo 
media at 37°C. 
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Figure 6-4 Growth Curve of Rosetta Gami B in BioExpress® Media 
The Growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B Cells in 
BioExpress® Media at 37°C. 
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Figure 6-5 Growth Curve of Double Colony Selection in LB Media 
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells Double 
Selection Mutant in LB media at 37°C. 
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Figure 6-6 Growth Curve of Double Colony Selection in BioExpress® media. 
The growth curve of pDEST HisMBP hCycT1-Tat in Rosetta Gami B cells Double 
Selection Mutant in BioExpress® media at 37°C. 
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Figure 6-7 Small Scale Media and Strain Comparison in Various Media 
Small scale (6 ml) media and strain comparison in various media with induction at OD600 
=0.7. From left to right:  
 1 – ladder                                          2 – uninduced Rosetta Gami B (RGB) in LB  
 3 – induced RGB in LB after 4 hours         4 – induced RGB in LB after 18 hours 
 5 – uninduced RGB in Turbo BrothTM       
 6 – induced RGB in Turbo BrothTM  after 4 hours  
 7 – induced RGB in Turbo BrothTM after 18 hours 
 8 – uninduced RGB in BioExpress® minimal media  
 9 – induced RGB in BioExpress® minimal media after 4 hours 
 10 – induced RGB in BioExpress® minimal media after 18 hours  
 11 – uninduced double colony selection (DCS) in BioExpress® minimal media 
 12 – induced DCS in BioExpress® minimal media after 4 hours  
 13 – induced DCS in BioExpress® minimal media after 18 hours 
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A             B  
 
Figure 6-8 Comparison of GST Chimera and HisMBP Chimera Constructs 
Comparison of protein expression with the original GST chimera construct and protocol 
and in the re-engineered HisMBP construct with revised expression strain and protocol. 
A. Original GST-hCycT1-Tat chimera in Rosetta 2 cells expressed in LB induced at 
OD600=0.7 with 1.0 mM IPTG after 6 hours at 28°C (as per original protocol from 
K. Fujinaga (Appendix 10)). 
B. HisMBP-hCycT1-Tat chimera in Rosetta Gami B cells expressed in Turbo 
Broth™ induced at OD600 =0.7 with 1.0 mM IPTG after 6 hours at 28°C. 
Samples from 1 ml of 1 L induced culture resuspended in 100 ul 1 X SDS. 
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Chapter 7 Optimizing Recombinant Protein Solubility 
 
Once a high rate of recombinant protein expression is achieved the next set of challenges 
entail avoiding proteolytic degradation of the nascent target protein, achieving a 
sufficient yield of soluble and active protein, and removing the solubility enhancing tag 
in preparation for downstream applications. While proteolytic degradation can generally 
be mitigated substantially by the introduction of protease inhibitors to the working 
solutions, solubility can be considerably less tractable.  
 
The majority of published work addressing techniques shown to improve the solubility of 
recombinant proteins focuses on the notoriously difficult expression of membrane 
proteins. Receiving considerably less attention, however, are the 80% of non-membrane 
proteins which are poor subjects for structural assays primarily due to insolubility (91). 
Mammalian and other proteins are frequently poorly expressed in bacteria where the 
absence of post-translational modification and differences in the folding environment 
introduce formidable challenges to recombinant expression (92). In eukaryotic proteins 
multiple domains, and the requirement of cofactors, and protein partners tend to hinder 
recombinant expression efforts (93). In fact, the production of many of the recombinant 
proteins that would make attractive subjects for research is often abandoned because of 
the time and expense involved in their pursuit. The introduction of high-throughput 
protein expression and purification methods is a valuable addition to the field, with the 
advantage of permitting the screening of a multitude of variable expression, purification, 
 - 86 - 
and storage conditions simultaneously. Unfortunately, this equipment is not yet widely 
available, and most laboratories still rely on more traditional empirical methods. 
 
7.1. Denaturing and Refolding Recombinant Proteins 
In many cases high expression levels of the recombinant protein are observed in the crude 
extract, but the protein can present in misfolded and inactive forms that aggregate in 
insoluble inclusion bodies. Rescuing the active form of the protein from insoluble 
inclusion bodies may or may not be possible, and can involve complicated denaturing 
protocols utilizing chaotropic agents or acids, followed by difficult refolding procedures 
into what the researcher hopes will be suitable buffers. Many problematic proteins do not 
readily refold into active conformations by known in vitro folding techniques (94), and 
high yields of soluble recombinant protein from denaturing and refolding protocols are 
rarely observed (45). Where refolding is possible, confirming that the form achieved is 
the proper native and active form of the protein generally requires additional assays that 
can also be challenging. Moreover, confirming the proper conformation may be 
complicated by a lack of available structural information for the protein of interest.  Thus, 
wherever possible obviating such complicated denaturing and refolding techniques is 
highly desirable. 
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7.2. Increasing Recombinant Protein Solubility 
Yield of the purified soluble and active protein may potentially be improved by a plethora 
of measures, among them: changes in expression conditions such as post-induction 
temperature, and IPTG concentration, as well as the strategic addition of a variety of 
potentially solubility enhancing compounds to the growth media. It is also possible to 
introduce a number of techniques during cell lysis, purification, concentration, and 
storage procedures that can further enhance solubility, and ultimately improve the final 
yield of the active protein. Commonly, a multitude of techniques are evaluated 
empirically, and combined in a single protocol in order to achieve adequate yield of the 
protein of interest. 
 
7.3. Reducing the Expression Rate 
One simple approach to improving the soluble yield of the target protein is to reduce the 
expression rate in order to allow additional time for proper folding of the native and 
thermodynamically favored state. Reducing the concentration of the inducing agent 
(IPTG in this case), and/or decreasing the temperature of the culture post-induction 
reduces the expression rate of the recombinant protein and frequently results in an 
increase in the yield of the soluble protein. A range of concentrations of the inducing 
agent, and temperatures post-induction should be evaluated to determine the optimal 
conditions for enhanced solubility. Weaker promoters and lower copy number plasmids 
can also be employed to reduce the expression rate of the recombinant proteins.  
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7.4. Increasing the Expression of Chaperone Proteins 
In vivo protein folding can occur over a timescale ranging from milliseconds to days. 
During the folding process protein folding intermediates often have exposed hydrophobic 
surfaces that promote self-association and the formation of aggregates that lead to 
insoluble inclusion bodies and precipitation (95). Proteins known as chaperone proteins 
assist in the process of folding nascent proteins and in refolding improperly folded 
proteins. 
 
 In overexpression systems the high concentration of newly formed protein can 
exacerbate self-association leading to the increased formation of insoluble proteins and 
inclusion bodies. Moreover, the limited availability of chaperone proteins to assist in the 
folding and refolding of the newly synthesized proteins will also result in a higher 
fraction of insoluble protein in the form of inclusion bodies (45,94). Whenever possible, 
expression of these chaperone proteins should be increased concomitant with 
overexpression of the target protein in order to accommodate the increased folding 
requirements of the highly concentrated nascent protein.  
 
In the cytoplasm of E. coli Trigger Factor, and the DnaK and GroES complexes are 
chaperone proteins that assist in the folding, refolding, and the prevention of aggregation 
in newly synthesized proteins (45). However, which chaperone protein is capable of 
enhancing the solubility of a particular recombinant protein of interest may differ 
depending upon characteristics of the target that are usually unknown at the time when 
optimization begins (94). Once again the empirical determination of optimal expression 
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conditions by multiple trials with a variety of chaperone proteins, and solubility 
enhancing media additives remains a necessary and time consuming process.  
 
7.5. Ethanol 
When employed as a media additive, ethanol mimics the heat-shock response in E. coli 
and has demonstrated efficacy in increasing the expression of heat-shock proteins that 
function as molecular chaperones in E. coli (92,94-96). Media supplemented with as little 
as 1% ethanol demonstrated enhanced heterologous protein expression in E. coli (96-98). 
Georgiou and Valax 1996 reported that 3 % ethanol added to the growth medium 
increased the heat-shock response and the production of chaperone proteins GroES/EL 
and DnaK/J and demonstrated a synergistic effect on protein expression. Interestingly, 
the enhancing effect of  the addition of ethanol on solubility was prominent at the post-
induction temperature of 30ºC, but was markedly reduced at 37 ºC and at 42 ºC (95).  
 
During expression of the HisMBP-hCycT1-Tat chimera the addition of 1% ethanol to the 
growth medium approximately 30 minutes prior to induction, and the reduction in culture 
temperature from 37ºC to 28ºC for 7 hours of expression produced a substantial increase 
in solubility of the recombinant chimera (Figure 7-1). Here the introduction of ethanol 
prior to the induction of expression allows some time for the accumulation of chaperone 
proteins prior to expression of the target, and appeared to have little detrimental effect on 
the growth rate of the culture (data not shown).  
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However, other work indicates a high yield of soluble protein can also be achieved with 
the introduction of ethanol prior to inoculation. Barroso et al. 2003 attributes the 
observed high target solubility in the presence of ethanol to the accumulation of 
stoichiometric intracellular concentrations of chaperone proteins prior to induction, and 
the expression of most rather than only some chaperone proteins though the continuous 
synthesis of heat-shock transcription factor 32 (99). The heat-shock transcription factor 
32 controls the induction of some 20 heat-shock genes. The requirement of sequential 
interaction of nascent proteins with several chaperone proteins is reported by Gragerov et 
al. 1992, observing extensive aggregation in heat-shock transcription factor  deficient 
mutants, and reporting the effects of four heat-shock proteins on the deficient mutant 
(100).  
 
Where the growth rate of the culture prior to induction is not prohibitively negatively 
impacted by the addition of ethanol it may be advantageous to include ethanol in the 
growth media as early as possible, and also at concentrations greater than 1%. Since the 
addition of 1% (v/v) ethanol at 30 minutes prior to induction produced adequate yield of 
the soluble protein, the alternatives of introducing ethanol prior to inoculation, and higher 
concentrations of ethanol were not evaluated. However, the synthesis of heat-shock 
proteins accelerates rapidly with temperature shift, and is believed to reach steady state 
within 20 minutes (101). Thus it is possible that introducing ethanol prior to inoculation 
may offer no further improvement in solubility over that observed with the introduction 
of ethanol 30 minutes prior to induction.  
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Increasing the concentration of ethanol could increase the concentration of the soluble 
fusion chimera. However, at some point high concentrations of ethanol will produce 
diminishing returns for example: where the growth of the culture is taxed by toxic effects 
of ethanol, and where translocation of recombinant proteins may be inhibited as observed 
by Chaudhuri et al. 2006 at concentrations of ethanol in excess of 2.5% (102). The 
efficacy of ethanol in enhancing the solubility of any recombinant protein, its point of 
introduction into the expression protocol, and the concentration employed must be all 
determined empirically and specifically for each protein target. 
 
7.6. Osmolytes 
Osmolytes are small chemically diverse organic metabolites that are made and 
accumulate in the intracellular medium of cells in response to osmotic stress (103-105). 
Proteins are purportedly stabilized and protected from denaturants in the intracellular 
milieu by organic osmolytes that force folding, despite harsh conditions, by interaction 
with the protein backbone (103,106). Osmolytic interaction with the protein backbone is 
described as a highly unfavorable “solvophobic” interaction that raises the Gibbs free 
energy of the denatured state substantially more than it raises the Gibbs free energy of the 
native state and in this manner stabilizes the folded form of the protein (103,105). Such 
stabilization of folded proteins is highly desirable for structural study. Moreover, 
osmolytes may prove useful in influencing the proper folding of proteins in vivo as well 
as in vitro, potentially as therapeutics in the treatment of misfolding diseases such as 
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cystic fibrosis (106), or as stabilizers of protein therapeutics which are notoriously 
hindered by difficulties with stability and long-term storage (107).  
 
Naturally occurring osmolytes can be grouped into three categories: polyols, amino acids, 
and the combinations of methylamines, methylsulfonium, and urea (103,108). This 
diverse group of compounds can be employed to improve solubility, and stability at many 
different points throughout expression, purification, concentration, and storage of 
recombinant protein protocols. Here the inclusion of the polyols ethylene glycol during 
cell lysis, and glycerol throughout purification and storage of the fusion chimera 
appeared to improve the yield of soluble recombinant protein. In the absence of these 
compounds low amounts of protein were observed in the soluble extract, and the protein 
tended to be lost to precipitation during IMAC purification, and subsequent 
concentration. 
 
7.7. Additional Solubility Enhancing Compounds 
A number of additional co-solvents are well known to positively influence the solubility 
of proteins in solution; among these salts are highly influential and their effects on 
solubility were well described by Hofmeister as early as 1888. Detergents, while most 
often utilized to improve the solubility of membrane proteins, are not infrequently found 
to improve the solubility of non-membrane proteins as well. While detergents often help 
to prevent protein aggregation, above relatively low threshold concentrations many 
detergents tend to form high molecular weight aggregates that are prohibitively difficult 
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to remove, can absorb at 280 nm, and are often incompatible with downstream 
applications. When possible, it is desirable to avoid the use of detergents. 
 
7.8. Salts 
In general the solubility of a protein is dependent upon dissolved salts, pH, temperature, 
and the polarity of the solvent. When working with recombinant proteins the pH is 
generally kept as close to a biological (pH 7.4) as possible, the buffer is polar, and the 
temperature is commonly kept low to prevent degradation. The salt concentration of the 
solution, however, can be modulated to increase the solubility of the protein consistent 
with the phenomenon known as “salting in” in which the solubility of a protein increases 
as salt is added to the solution. In salting in the addition of salt ions shield the ionic 
charges of the protein preventing the aggregation and precipitation of the protein 
molecules. Increasing the salt concentration past the optimal solubility range however, 
will produce the opposite “salting out” effect whereby the solubility of the protein 
decreases as the salt ions and protein molecules compete for molecules of solvent (109) 
(Figure 7-2). 
 
7.9. The Hofmeister Series 
The Hofmeister Series, published in 1888, ranks the effect of ions on protein stability. 
Kosmotropes are anions of high charge density and have a favorable effect on protein 
stability. Chaotropes are cations of low charge density and also tend to stabilize protein 
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structure (Figure 7-3). Though these observations generally hold to be true independent 
of the protein being studied the underlying basis for this is not well understood, and 
despite extensive study of this perplexing phenomenon the mechanisms of stabilization 
remains elusive. So elusive is this mechanism, in fact, that researcher Barry W. Ninham, 
professor emeritus of the Australian National University who has spent much of his 
career studying the phenomenon described it as an area of research that is “rediscovered 
every 10 years” only to be abandoned when it is discovered to be a “Sisyphean task” that 
he maintains is daunting in its complexity (110). 
 
7.10. Timasheff and Thermodynamics in Protein Stability 
Some light was shed on the subject however, nearly one hundred years after the 
introduction of the Hofmeiser Series when Timasheff and colleagues demonstrated that 
osmolytes, several other compounds, and ions are preferentially excluded from the 
immediately surrounding environment of the protein. This exclusion effectively produces 
a “preferential” hydration zone surrounding and stabilizing the folded state of the protein 
(105,111-118). The work of Timasheff provided the thermodynamic basis for the ranking 
of the effect of inorganic salts on solubility by Hofmeiser, and suggested that the 
solubility enhancing effects of these inorganic salts were dependent upon solute-
dependent differences in the preferential interaction of proteins with solvent and co-
solvents in solution (119).  
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The predictable effect of the Hofmeiser Series of ions on the thermodynamic stability of 
the native state can be used to influence solubility, crystallization, aggregation, and the 
stability of proteins. Clearly, a better understanding of stabilization mechanisms has 
tremendous potential for the advancement of protein therapeutics where preventing 
aggregation and maintaining stability are constant challenges, and in structural study 
where the formation of crystals for x-ray crystallography is so notoriously difficult. 
While elucidating the intricacies of the mechanism behind the observed effect of the ions 
in the Hofmeiser series is beyond the scope of this text, the properties and trends of the 
co-solvents aforementioned and their effects on solubility have been considered and 
employed throughout the expression, purification, and storage protocols of the fusion 
chimera in order to achieve adequate yield for structural work. 
 
The challenges and complexities of elucidating the mechanisms of protein solubility and 
stability notwithstanding, the author looks forward to progress in this regard. Advances in 
proteomics, data generated from high-throughput empirical methods of determining 
solubility and stability, and bioinformatics might be used to compile databases which aid 
in the determination of these mechanisms.  
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Figure 7-1 Expression of HisMBP Tat Chimera in LB media.  
Analysis by SDS PAGE of small scale (25 ml) expression of the pDEST HisMBP 
hCycT1-Tat in LB media. Induced with 1 mM IPTG at OD600 0.7 expressed at 28 ºC for 7 
hours. s:  
1 – Ladder 2 – Uninduced 1% EtOH 3 – Uninduced no EtOH 
4 – Induced 1% EtOH   5 – Induced no EtOH 6 – Soluble 1% EtOH 
7 – Soluble no EtOH    8 – Insoluble 1% EtOH 9 – Insoluble no EtOH 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
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Figure 7-2 The effects of increasing salt concentration on protein solubility. 
Salt concentration can be modulated to increase the solubility of protein consistent with 
the phenomenon known as “salting in” in which the solubility of a protein increases as 
salt is added to the solution. In salting in the addition of salt ions shield the ionic charges 
of the protein preventing the aggregation and precipitation of the protein molecules. 
Increasing the salt concentration past the optimal solubility range however, will produce 
the opposite “salting out” effect whereby the solubility of the protein decreases as the salt 
ions and protein molecules compete for molecules of solvent (109). Reprinted from Color 
atlas of biochemistry Koolman, J. and R.H. Rohm Copyright (2005) (120) with 
permission from Jan Koolman. 
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Figure 7-3 The Hofmeister Series of Ions 
 
Reprinted from “Experimental System II: Concentrated Aqueous Solutions & The 
Hofmeister Series” with permission from Darryl Eggers. Accessed online at: 
http://www.chemistry.sjsu.edu/deggers/new_page_3.htm 
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Chapter 8 Protein Extraction  
 
Structural determination of a protein of interest requires highly concentrated and purified 
protein, in native conformation. After expression the target protein must be selectively 
isolated from other cellular proteins, as well as from the cell membrane, and other 
cellular debris. Throughout this process, and from lysis to storage, the factors affecting 
solubility discussed previously must be consistently considered in order to maintain the 
stability of the protein in solution. With each process added to the protocol in an effort to 
improve purity, some of the yield is inevitably sacrificed. Optimization of each process in 
the purification, and the minimization of the number of steps overall, will produce the 
most efficient and reproducible protocol for high yield recombinant protein production. 
After many attempts an efficient and reproducible protocol was developed for the 
expression the HisMBP Tat chimera (Appendix 11). 
 
8.1. Cell Lysis 
The cell culture of the fusion chimera in Turbo media was induced with 1 mM IPTG at 
OD600= 0.7, expressed overnight at 28ºC in 1% ethanol, and then harvested by 
centrifugation. The pellets were washed in ice cold PBS, and then resuspended in 4 ml of 
ice cold lysis buffer (pH 7.4) per gram of wet cell pellet weight. The lysis buffer 
consisted of Tris 20 mM, NaCl 0.5 M, ZnCl2 10 uM, imidazole 20 mM, BME 5 mM, 
ethylene glycol 20% (v/v), HALT protease inhibitor cocktail EDTA Free (Pierce 
Rockford, IL) 10 ul/ml, arginine 50 mM, and lysozyme 10 mg/ml.  
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8.2. Lysis Buffer Design 
Many different formulations of the lysis buffer were evaluated. The original protocol 
received from Koh Fujinaga for the GST tagged chimera specified PBS, but after several 
trials with PBS, HEPES, and Tris, Tris proved to be the most effective buffer for the 
HisMBP fusion chimera. Since phosphate ions are known to chelate metal ions; in the 
interest of maintaining the integrity of the two zinc fingers in the HisMBP fusion 
chimera, PBS was replaced. Trials with HEPES buffer failed to maintain protein stability 
during FPLC purification. This is likely due to difficulties related to the use of secondary 
amines in buffers and the reduction of nickel ions during IMAC purification. 
 
With respect to the use of reducing agents, in initial trials with the HisMBP fusion 
chimera TCEP was used in the hopes of providing more stable and complete reduction, 
and less interference with protein quantitation measurements at 280 nm. However, TCEP 
is inactivated by PBS buffers, and in addition, Bigalke et al 2011 observed that Tat 
protein precipitates slowly in the presence of TCEP. Replacing TCEP with BME 
provided improved solubility of the chimera during cell lysis and purification, as well as 
during concentration, and storage. Improved solubility was apparent from consistent and 
increasing concentration measurement by Nanodrop, when using BME as opposed to 
decreasing concentration observed in samples during processing when TCEP was used 
instead.  
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After several trials of varying salt concentration, the relatively high 0.5 M concentration 
of NaCl proved to be both recommended (GE Life Sciences) and necessary to maintain 
the stability of the protein during FPLC purification. Since the yield and purity achieved 
with sodium chloride was sufficient for downstream applications, other salts were not 
evaluated. However, based on the Hofmeister series and the work of Wei et al. 1998, and 
Frankel et al. 1988 the use of potassium chloride in lieu of sodium chloride could provide 
additional stability and might make a worthwhile substitution where additional stability is 
required (17,43).  
 
A low 10 µM concentration of ZnCl2 was maintained throughout purification and storage 
as a precautionary measure to preserve the integrity of the two zinc fingers. Imidazole is 
present in the lysis buffer at a relatively low 20 mM concentration for the purpose of 
preventing nonspecific binding to the nickel column during IMAC FPLC purification 
later in the protocol. The inclusion of ethylene glycol in lysis buffers is generally present 
as a cryoprotectant, while here it may have the added benefit of being an osmolyte that 
tends to improve both the solubility and the stability of the target. The HALT protease 
inhibitor cocktail (Pierce Rockland, IL) provides seven different protease inhibitors, and 
effectively inhibited protease related degradation. The EDTA free formula of HALT was 
necessary to prevent EDTA chelation of the zinc ions from the fusion chimera.  
8.3. Arginine 
Arginine is a potent aggregation suppressor that purportedly prevents aggregation by 
masking the hydrophobic surface of the protein and prohibiting protein-protein 
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interaction, specifically such aggregation as can occur due to heating, dilution, and partial 
unfolding (121,122). Arginine has been shown to have a solubilizing effect on proteins 
within insoluble inclusion bodies (123). Protein aggregation in low concentration 
environments, while somewhat less intuitive, is frequently a concern during the early 
stages of purification. Arginine is present in the lysis buffer at a concentration of 50 mM. 
However, evaluating the effect of arginine on solubility was difficult due to its removal 
during FPLC purification to prevent interference with downstream applications. 
 
It should be noted that many other co-solvents were explored, and were not found to be 
particularly helpful to any substantial degree. The high number of potentially useful co-
solvents, and the length of time required to complete each expression do not lend 
themselves readily to comparison. In the interest of time several factors were often 
changed between trials and comparison of the effects of any one component was often 
impractical. The appropriate combination of co-solvents determined to achieve adequate 
yield may differ markedly from those required to achieve optimal yield, and it is possible 
that some of the buffer components were redundant in nature, or even antagonistic rather 
than complimentary. Notably however, the addition of osmolytes did appear to have the 
most profound effect on enhancing solubility of the fusion chimera when expression 
levels were compared in SDS PAGE analysis (Figure 7-1). 
8.4. Cell Wall Disruption 
A variety of lysis techniques such as sonication, freeze-thaw, liquid homogenization, and 
mechanical methods are all commonly used methods of rupturing the cell wall of E. coli. 
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While all but mechanical means were tried in the lysis of the chimera, sonication 
provided the most consistent and high yield of soluble fusion protein. Sonication breaks 
down the cell wall by delivering pulses of sonic waves. The sonication process does 
cause the temperature of the cell solution to become elevated, so several short pulses are 
typically alternated with equally short intervals at reduced temperature to maintain the 
low temperature of the solution.  
 
After collecting the cells by centrifugation at 2,500 rpm for 25 minutes at 4°C, the cell 
pellet was held on ice in 4 ml of lysis buffer per liter for 15 to 20 minutes to begin 
degradation of the cell wall. The protein extraction reagent B-PER (4 ml/L of culture) 
(Thermo Fisher Scientific, Inc. Rockford, IL), a non-ionic detergent solution, was added 
for the final 10 minutes on ice. The cells were then lysed by sonication for several 25 
second bursts alternated with 25 seconds on ice until the solution color changed slightly 
becoming somewhat darker and semitransparent. It is important to avoid overheating the 
solution thereby degrading the target protein, and also to avoid producing foam during 
sonication which exposes the protein to air and can lead to aggregation and the formation 
of inclusion bodies. 
 
8.5. Nucleic Acid Precipitation  
Nucleic acids were precipitated with 4% (v/v) polyethyleneimine (PEI) by vortexing 
lightly followed by a brief hold. In addition to removing nucleic acids, PEI may also 
improve solubility. The cationic polymer PEI prevents the aggregation, and oxidation, of 
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proteins, and chelates the metal ions required by proteases to degrade proteins. The 
solution was then centrifuged at 21,000 rpm for 30 minutes at 4°C to separate the soluble 
proteins from the cellular debris. The soluble protein was decanted from the insoluble 
pellet, and the solution was syringe filtered with a 0.2 uM GD/X filter (Whatman 
Piscataway, NJ) prior to Immobilized Metal ion Affinity Chromatography (IMAC) 
purification. 
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Chapter 9 FPLC Purification of the Tat Chimera 
 
The term chromatography, from the Greek for “color-writing”, refers to a group of 
techniques used to separate mixtures. Separation by chromatography was first described 
by Friedlieb Ferdinand Runge in his 1855 work “Der Bildungstrieb der Stoffe, 
veranschaulicht in selbstständig gewachsenen Bildern” on early paper chromatography. 
Runge’s work is often considered the precursor to the invention of chromatography 
(124). The invention of column chromatography is most often credited to M.S. Tswett in 
1903 (published in 1905), but unfortunately due to the political climate in Russia, and the 
criticism of other researchers who were unable to reproduce his results, Tswett’s work 
went largely unrecognized for many years after his report (125,126). In 1952 Martin and 
Synge received the Nobel Prize jointly for their invention of partition chromatography.  
 
9.1. Column Chromatography 
In column chromatography solutions are partitioned into mobile and stationary phases, 
and particles are separated on the basis of retardation from the mixture based on their 
relative affinity for each of these phases. A hollow cylindrical column is packed with 
absorbent material that constitutes the stationary phase, and in biochemical applications is 
usually a solid or a gel material. The column material is then wetted with the solution that 
will serve as the mobile phase for the separation. The mixture being separated, the 
analyte, is applied to the top of the wet column, and travels through the column propelled 
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by gravity, and is then separated by exploitation of the differences in the particles being 
separated, and their relative affinities for of the column material, or stationary phase. 
 
9.2. Liquid/Column Chromatography 
Liquid/column chromatography refers to all forms of chromatography in which the 
mobile phase, the analyte, is a liquid, and in which the stationary phase is linked to an 
inert matrix. Proteins are most often separated and purified with liquid/column 
chromatography by exploiting particle differences such as size, hydrophobicity, charge, 
and by the presence or absence of metal binding residues.  
 
9.3. Fast Performance Liquid Chromatography (FPLC) 
Prior to the 1970s protein separations by liquid/column chromatography were propelled 
through columns by gravity in lengthy procedures that frequently produced poor 
separation. In the late 1970s the addition of pressure during separation, provided by 
nearly pulse-free pumping systems, led to the development of high performance liquid 
chromatography. The improved separation was achieved by greatly decreasing particle 
size, dramatically increasing the surface area of the solid phase. Thus, solutes equilibrate 
more rapidly between the solid and mobile phases effecting higher resolution of solutes 
having similar interactions with the solid phase. Higher pressures are required to maintain 
reasonable flow rates for the mobile phase through the small particles. Fast performance 
liquid chromatography (FPLC) is similar to high performance liquid chromatography 
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except that the wetted surfaces of the column, detectors, and tubing are made from glass 
or fluoropolymers to avoid denaturing proteins on the metal surfaces common in HPLC. 
This requires lower pressures for FPLC, and particle sizes that are larger than for HPLC 
to accommodate reasonable flow rates.   
 
During FPLC the solvent velocity is controlled by pumps that control the flow rate of the 
mobile phase of proteins through one of four types of columns: size-exclusion, ion-
exchange, reverse-phase, and affinity. As the name implies, size-exclusion 
chromatography separates proteins from solutions on the basis of the size of the protein 
and its speed of migration through porous silica beads of variable size. Ion-exchange 
column chromatography separates proteins by differences in the net charge of the protein 
and its affinity for charged column material in high and low salt mobile phases. Reverse-
phase chromatography separates proteins based on differences in their hydrophobicity, 
and therefore by the protein’s affinity for the stationary phase. Finally, affinity 
chromatography exploits the affinity of specific residues of the target protein for a 
specific ligand or column material that is affixed to the matrix of the stationary phase. 
 
In the experiments that follow the ÄKTA FPLC explorer system and the Unicorn 4.11 
system control software (Amersham Pharmacia Biosciences, Uppsala Sweden) were used 
for all protein purifications of the Tat fusion protein chimera. After many trials an 
efficient and reproducible protocol was developed for the purification of the HisMBP Tat 
Chimera (Appendix 12). 
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9.4. Purification of the GST Chimera by Column Chromatography 
Affinity chromatography was used to purify the original GST tagged construct by 
exploiting the affinity of the fusion tag for the GSTrap FF 5 ml column (GE Healthcare 
Biosciences Pittsburg, PA). The low expression level and poor solubility of this original 
construct produced a predictably low yield of the full length protein in the initial 
purification round. Additional issues arising from removal of the GST tag with thrombin 
protease compounded the problem and reduced the yield still further. Much of the full 
length target remained uncleaved after incubation with thrombin at temperatures ranging 
from 7-15°C and over periods of 2 to 24 hours (data not shown) Poor cleavage was 
observed in both on column trials and in solution. The low efficiency of thrombin 
cleavage was likely due, in part, to the fact that the optimal temperature for thrombin 
cleavage is 22°C (127). However, since high temperatures can adversely affect the native 
conformation of the target protein, and appeared to be causing precipitation (as evidenced 
by decreasing concentration measurements of absorbance at 280 nM over time by 
Nanodrop) higher temperatures were avoided.  
 
Predictably, on column cleavage trials were less effective at removing the GST tag from 
the full chimera than were the trials in solution (data not shown). In this case the low 
expression level of the full chimera makes it unlikely that cleavage was hindered by high 
concentrations of the substrate, as is frequently the problem in on column cleavage 
protocols. Steric occlusion, concentration issues, and the restricted movement of proteins 
affixed to the stationary phase are issues known to hinder on column cleavage attempts. 
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For this reason cleavage of solubility enhancing tags with both the target protein and the 
protease free in solution is the generally preferred method. 
 
In addition to the problem of incomplete cleavage, was the problem of non-specific 
cleavage for both the on-column and in-solution trials. Size-exclusion chromatography 
with the Superdex 75 100/300 (GE Healthcare Biosciences Pittsburg, PA) column failed 
to adequately separate the tag-free chimera from the GST tag, the uncleaved full chimera, 
and the non-specifically cleaved fragments despite what should have been sufficient 
differences in molecular weight for adequate separation. Attempts to separate the proteins 
by charge with ion-exchange chromatography were also poorly resolved, and several 
proteins co-purified. When affinity chromatography was used to remove the GST tag, 
yield of the final target was very low and the solution was also contaminated with several 
co-purified proteins. Ultimately, the cleaved chimera was inseparable from the full length 
GST fusion construct, and from a number of non-specifically cleaved fragments, even 
after the addition of a several polishing steps. 
 
9.5. Affinity Chromatography with the HisMBP Tagged Chimera 
Re-engineering the chimera not only improved the overall expression yield and solubility 
dramatically, but the HisMBP tagged chimera proved considerably more tractable 
throughout purification (Figure 9-1). The full chimera was purified by affinity 
chromatography utilizing the affinity of the His6 tag for the nickel residues of the HisTrap 
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HP column (GE Healthcare Biosciences Pittsburg, PA). An adequate yield and purity was 
readily achieved and reproducible.  
 
9.6. Buffer Selection 
Selecting appropriate buffers for all aspects of the purification proved challenging. 
Phosphate buffered saline (PBS) was the initial buffer used for the GST tagged chimera 
in the inherited protocol (Appendix 10). However, concerns over the chelating of metal 
ions by PBS with specific regard to the maintenance of the zinc molecules within the two 
zinc fingers of the chimera, and also concerns over the incompatibility of PBS with the 
reducing agent tris(2-carboxyethyl)phosphine) (TCEP) led to a change in the buffering 
component. 
 
Trials with the buffer HEPES at 20 mM were unsuccessful as the full chimera 
prematurely eluted from the HisTrap HP column. This premature elution could be related 
to the fact that as a Qiagen technical article reports “Buffers with secondary or tertiary 
amines may reduce nickel ions” (128). While Qiagen recommends that such buffers as 
Tris, HEPES, and MOPS can be used with nickel columns at concentrations below 100 
mM, trials with a 20 mM concentration of HEPES were unsuccessful. Ultimately, a Tris 
buffer of 20 mM and pH 7.4 produced the adequate and reproducible yield required.  
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9.7. Reducing Agents 
The reducing agent dithiothreitol (DTT) is known to remove metal ions, as are most 
chelating agents including: ethylenediaminetetraacetic acid (EDTA), and sodium citrate. 
As much as possible, all agents known to remove metal ions were avoided in order to 
preserve the integrity of the two zinc fingers of the Tat chimera. Many trials were 
conducted with the reducing agent TCEP because it is often suggested that it does not 
interfere with concentration measurements made at 280 nM, and because, while more 
expensive, it is known to be a strong and reasonably stable reducing agent. Interestingly 
however, Bigalke et al. 2011 observed the slow precipitation of Tat in the presence of 
TCEP. When TCEP 0.3 mM was replaced by 5 mM BME, the stability of the chimera 
was noticeably improved in the form of higher and more stable final concentrations of 
both the full and the cleaved chimera (52).  
 
The importance of the electrochemical environment in the successful expression and 
purification should not be underestimated as, in general, with the purification of Tat most 
of the concern has been over keeping the chimera reduced (43). Observations suggest that 
there may be a point of diminishing returns at which high concentrations of reducing 
agent may denature the chimera perhaps by disturbing the zinc fingers, or by altering 
some other as yet unknown feature. The use of reducing and/or chelating agents such as 
EDTA and DTT may be the cause of at least some of the dimerization and aggregation 
reported in other work on Tat. Moreover, in vivo the actual conformation of proteins in 
general may be somewhat more dynamic than currently contemplated (129).  
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9.8. Salt 
The FPLC purification of the Tat chimera was successful when using a 0.5 M sodium 
chloride concentration in both the binding and elution buffers, and since this was 
consistent with GE Healthcare Biosciences recommendations for the HisTrap HP column 
higher concentrations were not explored. It is worth noting, however, that Frankel, Bredt 
et al. 1988 found an even higher 0.7 M potassium chloride concentration was needed to 
maintain the solubility of Tat alone (86 amino acid construct), and so such higher 
concentrations during purification might be worth investigating (43). It was necessary to 
lower the salt concentration considerably later on while cleaving the tag from the chimera 
with TEV protease, and during binding assays. Thus, the improved solubility provided by 
increasing the salt concentration may prove unsustainable for downstream applications. It 
may be useful, however, to employ higher salt concentrations when attempting to use 
spin columns to concentrate the Tat chimera which has proved to be somewhat 
problematic. 
 
9.9. Glycerol 
The osmolyte glycerol was present in all FPLC buffers during purification in order to 
enhance the solubility of the chimera. A concentration of 5% glycerol was sufficient to 
maintain solubility of the chimera throughout the FPLC purification, including after 
removal of the solubility enhancing tag and did not appear to hinder TEV cleavage. The 
concentration of glycerol was increased to as much as 20% when storing the purified 
protein long term, as at this point glycerol also serves as a cryoprotectant. When 
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conducting binding assays the glycerol was removed from the solution by dialysis or by 
buffer exchange using Vivaspin® 20 20 ml 5,000 MWCO centrifugal concentrator 
columns (GE Healthcare Bio-Sciences AB Uppsala, Sweden) to prevent any potential 
interference by glycerol in the binding interaction. 
 
9.10. Imidazole 
A low concentration of 20 mM imidazole was present in both the lysis and the binding 
buffer in order to maintain consistency between the two buffers while loading the crude 
protein extract onto the column, and during the column wash. This low concentration of 
imidazole serves to prevent non-specific binding of proteins to the column. A wash buffer 
of 60 mM was employed in several trials to remove any low affinity binding proteins, but 
no further improvement in purification was observed with this increased concentration. 
Subsequent washes were performed with the 20 mM imidazole binding buffer. An elution 
gradient of up to 500 mM imidazole was used to elute the full His6 tagged chimera from 
the HisTrap HP column. The full chimera typically eluted from the column when 66% of 
the 500 mM imidazole elution buffer, and 33% of the 20 mM imidazole binding buffer 
was reached. Alternatively, the full chimera can be successfully eluted with 100% 500 
mM imidazole with acceptable purity. 
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9.11. Sodium Azide 
The anti-microbial agent sodium azide was added to the binding and elution buffers at 
0.02% to prevent degradation of the protein by contaminating microorganisms during the 
several days from cell lysis through purification, dialysis, and downstream assays when 
the protein could not be frozen. 
 
9.12. Protocol 
Following the protocol outlined in Figure 9-2, the syringe filtered cell lysate was applied 
to the HisTrap HP column using a 50 ml Superloop at a flow rate of 0.2-0.4 ml/min. or 
slower. The column was then washed with binding buffer for five column volumes (50 
ml) at a flow rate of 0.4-0.6 ml/min. or until a stable baseline was achieved. After 
allowing ample time to wash at the stable baseline the full length chimera was eluted by 
setting a gradient exchanging the 20 mM binding buffer on pump A for the 500 mM 
elution buffer on pump B over 30 minutes at a flow rate of 2 ml/min (Figure 9-3).  
 
9.13. Results 
With this protocol 40 mg of the 60 kDa full chimera were purified from 17 grams of wet 
cell pellet harvested from one liter of Turbo media which was induced at OD600 = 0.7 
with 1.0 mM IPTG and expressed overnight at 30°C. Figure 9-4 shows the uninduced, 
induced, soluble, and insoluble fractions of the expression prior to FPLC purification, as 
well as the purified fractions, and the loading and elution flow through waste solutions. 
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Lanes 10 through 14 are purified fractions A1 though A5 of the full chimera and 
correspond to the fractions indicated in the chromatogram in Figure 9-3. Lanes 11 and 12 
of Figure 9-4 show the highly concentrated fractions of the 60.8 kDa full chimera. 
Additional bands between 100 and 150 kDa may be dimers of the full chimera and seem 
to be more prevalent in concentrated fractions. 
 
Lanes 6, 7, and 8 (Figure 9-4) are samples of the loading flow through materials that did 
not bind to the column. The highly concentrated ~60 kDa band here appears to indicate 
that the column was overwhelmed by the highly concentrated recombinant chimera.  
Lane 9 is a sample of materials eluted from the column prior to the peak (X1) and 
indicates that a fair amount of protein was eluted prior to the observance of the peak. This 
is likely to be an artifact of the AKTA system and indicates that wherever possible 
fraction collection should begin slightly in advance of the appearance of the peak. The 
highly concentrated fractions A1 though A5 were pooled and then dialyzed into a low 
imidazole buffer for cleavage of the HisMBP tag, and its subsequent removal by 
reapplication to the HisTrap HP column. 
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Figure 9-16 The HisMBP Tat chimera expressed in the Rosetta Gami B 
The HisMBP Tat chimera expressed in the Rosetta Gami B strain in LB media and FPLC 
purified. Induction at 0.7 OD with 0.8 mM IPTG. Incubation at 30°C post induction for 7 
hours before harvest. From left to right:  
 1 – ladder  2 – uninduced  3 – induced 
 4 – soluble  5 – insoluble  6 – full chimera 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
His6-MBP Tat Chimera Expression
1   2   3   4   5   6
1 – Ladder
2 – Uninduced
3 – Induced
4 – Soluble
5 – Insoluble
6 – Full Length MBP
10 
15 
20 
25 
37 
50 
75 
100 
150 
250 
kDa 
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Figure 9-2 Recombinant protein purification flow chart.  
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Figure 9-3 FPLC Chromatograph of the elution of the full chimera. 
The sharp peak starting in fraction A2 eluted approximately one column volume after reaching the full 
500 mM imidazole concentration. The SDS Page analysis of fractions X1 through A5 can be seen in 
Figure 9-4. The UV remains elevated after the peak due to 280 nm absorbance by the 500 mM imidazole 
elution buffer. 
 
  
FPLC Chromatogram
Elution of Full Length Chimera
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Figure 9-4 SDS PAGE of the Tat Chimera Expression and Purification 
The SDS PAGE analysis of the overnight expression and purification of the full chimera 
in Turbo media. The expression and FPLC purification fractions of the full chimera (60.8 
kDa), s from left to right:  
1 – ladder 2 – uninduced 3 – induced   
4 - soluble 5 – insoluble,   6 – loading flow thorough  
7 – loading flow through  8 – loading flow through  9 – elution flow through X1 
10 – full chimera A1 11 – full chimera A2 12 – full chimera A3  
13 – full chimera A4 14 – full chimera A5 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
Full Tris Trial BME 6/8/12
O/N expression in Turbo
1 – Ladder
2 – Uninduced
3 – Induced
4 – Soluble
5 – Insoluble
6 – Flow Thru X1
7 – Flow Thru X2
8 – Flow Thru X3
9 – Elution Flow Thru X1
10 – Full Length A1
11 – Full Length A2
12 – Full Length A3
13 – Full Length A4
14 – Full Length A5
1  2  3 4 5 6  7 8  9  10 11 12 13 14 
kDa 
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Chapter 10 Removal of the Fusion Tag 
 
While fusion tags are often necessary to facilitate expression of recombinant proteins at 
high yield, they also may confound downstream applications, particularly applications 
that explore binding interactions, biological activity, and structural detail. Removal of the 
solubility enhancing tag can introduce an entirely new set of challenges, not the least of 
which is maintaining the solubility of the recombinant protein after this important 
solubility enhancing component has been removed.  
 
Choosing a protease enzyme that is highly specific and cleaves only at a rare series of 
amino acids is a helpful means of preventing non-specific cleavage of the target. Some 
proteases such as thrombin are notorious for cleaving non-specifically (74,130). 
Moreover, non-specific cleavage can be exacerbated by long incubation periods, high 
temperatures, excessive concentrations of proteolytic enzyme, and a variety of other 
factors specific to the chosen enzyme.  
 
In some cases non-specific cleavage by thrombin can be mitigated by the prompt removal 
of the enzyme with affinity purification using benzamidine columns, and perhaps more so 
by removal with heparin sepharose columns (130). However, in the case of the GST-
hCycT1-Tat chimera, non-specific cleavage was still observed even with prompt removal 
of thrombin by benzamidine, and in an unfortunate coincidence the Tat chimera also 
bound to heparin rendering this manner of protease removal useless (131,132).  
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When developing a new recombinant protein expression and purification protocol one 
should carefully consider the available protease enzymes and choose an enzyme that is 
specific, efficient, cost effective, and compatible with downstream applications whenever 
possible. The efficiency of the cleavage can be an extremely important, albeit somewhat 
less obvious, consideration in achieving a high yield of recombinant protein after 
purification.  
 
10.1. Cleavage of HisMBP Tag with TEV 
Having inherited the pGEX 2TK chimera plasmid with a thrombin protease site for the 
purpose of cleavage of the original GST tag, and after many disappointing attempts to 
isolate the tag-free chimera, the highly specific protease TEV was chosen to be the 
protease enzyme for cleavage of the HisMBP tag from the re-engineered chimera. The 
protease sequence ENLYFQ/G was introduced into the chimera sequence between the 
MBP tag and the hCycT1 portion of the chimera in order to facilitate tag removal (Figure 
4-6). This peptide sequence is readily cleaved by the highly active and highly specific 
cysteine protease TEV from the tobacco etch virus.  
 
Unfortunately, wild type TEV is auto-inactivated rapidly in vivo and catalytic activity is 
diminished markedly and in direct proportion to the concentration of the enzyme 
(74,133). Self-cleavage of the enzyme and the multiple fragments that result complicate 
purification, as well as the removal of the enzyme from the cleavage reaction. Further, 
the activity of the enzyme continues to diminish during storage (74). Autoproteolysis 
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takes place between Met218 and Ser219 of the TEV enzyme and may be an 
intramolecular event (74).  Kapust et al. 2001 mutated the TEV enzyme with the 
substitution S219V, and found that self-cleavage was eliminated and the mutated enzyme 
was some 100 fold more stable (74).  
 
10.2. Results: Cleavage of the MBP Tag with GST Tagged TEV 
The initial attempts to remove the MBP tag from the fusion chimera employed a GST-
His6 tagged TEV protease (~ 50 kDa), which was generously donated by Michael 
Cosgrove, Upstate Medical University, NY. However, incubation of 1 mg of the enzyme 
per 20 mg of the fusion chimera produced precipitation with nutation during incubation, 
and appeared to produce incomplete cleavage after 24, and 48 hours at room temperature 
even without nutation (Figure 10-1). Predictably, at 14°C the reaction was even less 
efficient leaving considerably more of the full fusion chimera uncleaved after 24, 48, and 
even 72 hours (Figure 10-2). 
 
In order to optimize the yield of CycT1m-Tat, a TEV protease that was more efficient, 
especially at lower temperatures, was required.  Kapust et al. 1999 compared the 
solubilizing effects of three fusion tags: maltose-binding protein (MBP), glutathione S-
transferase (GST), and thioredoxin (TRX), and found MBP to be, by far, the more 
effective solubilizing fusion partner (68). Further, Kapust et al. 1999 compared the 
solubility of GST tagged TEV to that of MBP tagged TEV, and found that less than 20% 
of the GST-TEV was soluble as opposed to greater than 60% of the MBP-TEV (68).  
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Having observed such poor solubility in the recombinant expression of TEV, Kapust et 
al. 2001 constructed a plasmid for the recombinant expression of MBP-His6-
TEV(S219V)-Arg  in an effort to simultaneously improve both the stability of the enzyme 
and the solubility (74). Fortunately, the pRK793 plasmid was deposited with Addgene 
(Cambridge, MA) from which it was purchased for a nominal fee. In this interesting 
construct the MBP tag is self-cleaved from the recombinant enzyme after expression, and 
the protease can then be purified by affinity for either its remaining N-terminus His6 or 
by the C-terminus Arg tag (74). 
 
10.3. Expression of His6-TEV(S219V)-Arg Protease in E. coli 
Following the work of Tropea, Cherry et al. 2009 the pRK793 plasmid was expressed 
consistent with the published protocol with an exception (Appendix 13). The expression 
strain used by Tropea et al. 2009 is the BL21 (DE3) CodonPlus-RIL(134). Though it is 
not uncommon to recommend the use of a DE3 expression strain with a plasmid 
containing a tac promoter (135), the DE3 strain is designed for the T7 promoter system 
and expresses T7 RNA polymerase. When working with the tac promoter the native E. 
coli RNA polymerase is used, and so production of T7 RNA polymerase places an 
entirely unnecessary stress on the cell (Novagen personal conversation). Since so much 
conflicting information on this exists the two cell lines were compared in the recombinant 
expression of the TEV enzyme from the pRK793 plasmid with a tac promoter (Figure 10-
3). Here the expression is compared in the Rosetta Gami B cell line for both the DE3 
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Rosetta Gami B cells and the non-DE3 Rosetta Gami B cells. Comparison of lanes four 
and five clearly indicates that the non-DE3 cell line produces a substantially higher 
concentration of the TEV protein in the crude induced cell extract, as well as a slight 
increase in basal expression levels. 
 
When performing a large scale expression of TEV the Rosetta 2 expression strain 
(Novagen, Madison, WI) was used. This strain of E. coli is similar to the Rosetta Gami B 
strain but does not provide the folding accommodation for disulfide bond formation in 
the cytoplasm, which was not required here. Three liters of LB media containing 100 
ug/ml ampicillin, 30 ug/ml chloramphenicol, and 0.2% glucose were inoculated with 25 
ml of an overnight culture of Rosetta 2 (non-DE3) cells containing the pRK793 plasmid. 
The culture was grown at 37°C until OD600 ~0.5 when the temperature was reduced to 
30°C and the culture was induced with 1 mM IPTG. The TEV protein was expressed for 
6 hours post induction. On harvesting the 3 liter culture yielded 23.4 g of wet cell pellet 
weight which was slightly above the range of 30-40 g per 6 L reported by Tropea, Cherry 
et al. 2009 (134). 
 
The MBP-His6-TEV(S219V)-Arg5 was purified by affinity chromatography with a 
HisTrap HP nickel column. The Tropea et al. 2009 protocol contains an additional gel 
filtration polishing step at this point. Since the appropriate column was not available the 
gel filtration step was omitted. From the 23.4 g of wet cell pellet weight the 41 mg of 
purified MBP-His6-TEV(S219V)-Arg5 recovered were of sufficient concentration and 
purity for downstream applications (Figure 10-4). The FPLC fractions were pooled, and 
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concentrated with Vivaspin® 20 20 ml MWCO 5,000 columns (GE Healthcare Bio-
Sciences AB Uppsala, Sweden). 
 
10.4. Determination of Optimal Cleavage Conditions 
In order to determine the optimal concentration of the His6-TEV protease for cleavage of 
the HisMBP Tat chimera six different concentrations of the protease were incubated 
overnight at either room temperature or 4°C (Figure 10-5). Ratios of milligrams to 
milligrams 100:1, 50:1, 25:1, 12.5:1, 6:1, and 1:1 are compared with full cleavage in all 
room temperature samples, and nearly complete cleavage in only the 1:1 sample at 4°C. 
  
In Figure 10-5 the lowest concentration ratio of the His6-TEV(S219V)-Arg5 to target to 
achieve efficient cleavage of the HisMBP chimera appeared to be between 50:1 and 25:1 
in the room temperature trials. Using the midpoint concentration of 37.5:1, cleavage 
reactions were compared at room temperature, and at 15°C at intervals of one hour for 
between 1 to 5 hours (Figure 10-6). Here the goal was to achieve the greatest amount of 
cleavage in the shortest amount of time, with the least amount of enzyme, and at the 
lowest incubation temperature possible. All cleavage reactions in this comparison 
achieved efficient cleavage, and so the ratio of 37.5:1 mg/mg, the temperature of 15°C, 
and the incubation time of at least one hour were set as the cleavage conditions for the 
remaining experiments. 
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Figure 10-1 Cleavage of the fusion chimera with GST-His6-TEV protease 
The cleavage of the full fusion chimera with GST-His6-TEV protease at a ratio of 1:20 
milligrams of protease to substrate at room temperature (RT). Cleavage reactions from 
left to right:  
1 – GST-His6-TEV control 2 – Full fusion chimera control  
3 – Cleavage reaction 48 hours 4 – Cleavage reaction 24 hours 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
 
 
 
  
MBP 42 kDa 
Cleaved chimera 17.5 kDa 
Full length fusion chimera 60.8 kDa 
GST-His6 TEV ~50 kDa 
KKdAK~VTEVTE TE 
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Figure 10-2 Cleavage of the full fusion chimera with GST-His6-TEV 
The cleavage of the full fusion chimera with GST-His6-TEV protease at a ratio of 1:20 
milligrams of protease to substrate with incubation at 14°C. Cleavage reactions from left 
to right:  
1 – cleavage reaction 28 hours 2 – cleavage reaction 48 hours  
3 – cleavage reaction 72 hours 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
 
 
 
Cleaved chimera 17.5 kDa 
MBP 40 kDa 
Full length fusion chimera 60.8 kDa 
GST-His6 TEV ~ 50 kDa 
kkkkkkkkkttttttttttttTETEVTTEVTEV 
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Figure 10-3 Comparison of expression conditions for the pRK793 plasmid 
A comparison of the expression conditions for the pRK793 plasmid for the recombinant 
expression of His6-TEV(S219V)-Arg5 in E. coli DE3 vs. non-DE3 cell lines. Expression 
samples from left to right:  
1 – ladder 2 – uninduced Rosetta Gami B DE3  
3 – uninduced Rosetta Gami B non-DE3 4 – induced Rosetta Gami B DE3 
5 – induced Rosetta Gami B non-DE3 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
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Figure 10-4 PAGE analysis of FPLC fractions for His6-TEV(S219V)-Arg5. 
The FPLC purification fractions of His6-TEV(S219V)-Arg5, lanes from left to right:  
1 – ladder 2 - empty 3 – A1 4 – A2   
5 – A3 6 – A4 7 – A5 8 – A6  
9 – A7 10 – A8 11 – A9 12 - concentrated TEV 1   
13 – concentrated TEV 2  14 – concentrated TEV 3 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
  
 
His-MBP TEV Expression
1 – Empty
2 – Ladder
3 – FPLC Fraction A1
4 – FPLC Fraction A2
5 – FPLC Fraction A3
6 – FPLC Fraction A4
7 – FPLC Fraction A5
8 – FPLC Fraction A6
9 – FPLC Fraction A7
10 – FPLC Fraction A8
11 – FPLC Fraction A9
12 – Concentrated TEV 1
13 – Concentrated TEV 2
14 – Concentrated TEV 3
1   2    3    4    5    6   7   8     9   10   11  12  13  14  
20 
25 
37 
50 
75 
100 
150 
250 
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Figure 10-5 Conditions comparison for His6-TEV(S219V)-Arg5 
Comparison of cleavage with increasing concentrations of the His6-TEV(S219V)-Arg5 
protease at room temperature (RT) and 4°C incubated overnight with the HisMBP Tat 
chimera from left to right:   
1 – ladder  2 – full MBP chimera   3 – His6-TEV(S219V)-Arg5    4 – 100:1 RT   
5 – 100:1 4°C 6 – 50:1 RT 7 – 50:1 4°C 8 – 25:1 RT   
9 – 25:1 4°C 10 – 12.5:1 RT 11 – 12.5:1 4°C 12 – 6:1 RT   
13 – 6:1 4°C 14 – 1:1 RT 15 – 1:1 4°C 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
His-TEV Cleavage
Concentration & Temperature O/N
1 – Ladder
2 – Full Length MBP tagged chimera
3 – His-TEV
4 – Cleavage 100/1 RT
5 – Cleavage 100/1 4ºC
6 – Cleavage 50/1 RT
7 – Cleavage 50/1 4ºC
8 – Cleavage 25/1 RT
9 – Cleavage 25/1 4ºC
10 – Cleavage 12.5/1 RT
11 – Cleavage 12.5/1 4ºC
12 – Cleavage 6/1 RT
13 – Cleavage 6/1 4ºC
14 – Cleavage 1/1 RT
15 – Cleavage 1/1 4ºC
1  2  3  4   5  6   7  8  9  10 1112131415
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15 
20 
25 
37 
50 
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Figure 10-6 Comparison of cleavage ratio of 37.5:1 for His6-TEV(S219V)-Arg5 
Cleavage reactions at a concentration ratio of 37.5:1 mg/mg for both room temperature 
(RT) and 15°C at intervals of 1 hour from 1 to 5 hours from left to right:   
1 – ladder                 2 – full MBP tagged chimera                3 – His6-TEV(S219V)-Arg5    
4 –FPLC purified His6-TEV(S219V)-Arg5 (control)  
5 – cleavage reaction RT (1 hour) 6 – cleavage reaction 15°C (1 hour)   
7 - cleavage reaction RT (2 hours) 8 – cleavage reaction 15°C (2 hours)   
9 – cleavage reaction RT (3 hours) 10 – cleavage reaction 15°C (3 hours)   
11 – cleavage reaction RT (4 hours) 12 – cleavage reaction 15°C (4 hours)   
13 – cleavage reaction RT (5 hours) 14 – cleavage reaction 15°C (5 hours)  
15 –FPLC purified His6-TEV(S219V)-Arg5 (control) with additional purification by 
10,000 MWCO spin column. 
His-TEV Cleavage
Temperature & Time
1 – Ladder
2 – Full Length MBP tagged chimera
3 – His-TEV
4 – His-TEV after MWCO 10,000 
5 – Cleavage 37/1 RT 1 hour
6 – Cleavage 37/1 15ºC 1 hour
7 – Cleavage 37/1 RT 2 hours
8 - Cleavage 37/1 15ºC 2 hours
9 – Cleavage 37/1 RT 3 hours
10 - Cleavage 37/1 15ºC 3 hours
11 – Cleavage 37/1 RT 4 hours
12 – Cleavage 37/1 15ºC 4 hours
13 – Cleavage 37/1 RT 5 hours
14 – Cleavage 37/1 15ºC 5 hours
15 – His-TEV after MWCO 10,000
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Chapter 11 FPLC Purification of CycT1m-Tat 
 
Once the HisMBP tag has been sufficiently cleaved from the full chimera the tag and the 
His6-TEV protease can be removed from the solution by affinity chromatography with 
the HisTrap HP column. In contrast to the first round of purification, in this step the His6 
tagged proteins that bind to the column will be the unwanted cleaved tag and protease; 
the desired target (cleaved chimera, CycT1m-Tat) will be captured in the flow through. 
Since a reasonable degree of purity is achieved in the first purification step of the full 
chimera, and the concentration of His6-TEV is low relative to the chimera, the bulk of 
material bound to the column will be the cleaved HisMBP tag. 
 
Isolating the chimera in this manner can be challenging. Purifications with a Tris based 
buffer and using the reducing agent BME tended to produce a more focused UV peak in 
the chromatogram (Figure 11-1) with the concentrated cleaved protein visible by SDS 
PAGE (Figure 11-2). In earlier trials with a PBS based buffer and the reducing agent 
TCEP the peak was either absent or less focused (data not shown), yet the fairly pure and 
concentrated cleaved target was present and was observed by SDS PAGE. Since the 
cleaved target is present in solution and does not bind to the column theoretically a peak 
should not necessarily be anticipated as the target simply passes through and is not 
focused in any manner. 
 
 In general, when performing FPLC purification one should collect as many fractions 
throughout the process as possible regardless of the visible absorption recorded by the 
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chromatogram. Each fraction should be analyzed by SDS PAGE before assessing the 
purification or attempting to concentrate the target protein. Proper selection of the 
fractions will help to reduce dilution of the final sample, and prevent contamination by 
any undesirable co-purified proteins. 
 
11.1. Results 
Figure 11-1 is the FPLC chromatogram for the purification of the cleavage reaction 
solution with a HisTrap HP column. The peak at 15 ml was collected in fractions A2 and 
A3 and contained the concentrated CycT1m-Tat. An SDS PAGE analysis (Figure 11-2) 
of the cleavage reaction demonstrates nearly complete cleavage of the chimera in lane 2 
of the gel. The A2 and A3 FPLC fractions corresponding to the UV peak in the 
chromatogram in Figure 11-1 appear to be highly concentrated and of greater than ~80% 
purity. In the final yield approximately 6.5 mg of CycT1m-Tat were recovered in 8 ml 
after purification from a 1 liter culture, 17 g of wet cell pellet weight, and 40 mg of the 
full chimera. The chromatogram peak at 35 ml corresponds to the elution of the HisMBP 
tag and the His6-TEV protease from the HisTrap HP column in the full strength 500 mM 
imidazole elution buffer. 
 
Notably, CycT1m-Tat migrates at nearly 25 kDa despite a true molecular weight of 17.5 
kDa, and a doublet of CycT1m-Tat was often apparent. Proteins frequently do not 
migrate to their calculated positions due to preferential SDS loading at hydrophobic 
regions. It has also been suggested that the SDS loading capacity of a protein may be 
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related to the protein structure, secondary or tertiary, and here the protein may not have 
been completely denatured by the presence of SDS (136). Finally, observations of 
similarly anomalous migratory behavior are well documented in proteins with a high 
number of basic residues, such as are present in the Tat chimera (137,138).  
 
 The appearance of the doublet of CycT1m-Tat could indicate the presence of two species 
of the target in different oxidation states, as while it might be reasonable to suspect a 
truncated form of the target as the source of the doublet, a single molecular weight 
species at 17.5 kDa was later confirmed by matrix-assisted laser desorption-
ionization/time-of-flight (MALDI-TOF) experiments on the same sample (data not 
shown).  
 
All fractions from the final purification of CycT1m-Tat were analyzed by SDS-PAGE to 
ensure that some fraction of the target was not lost in the waste material nor was it 
binding to the column. Fractions from the cleaning of the column at the end of the 
procedure were also analyzed, and no proteins were observed in the gel for these washes 
(Figure 11-2). Finally, a control containing the His6-TEV in a concentration equivalent to 
that of the cleavage solution was run on the gel (Figure 11-2 lane 13) to assess whether 
this low concentration of the enzyme would be visible, and the enzyme is not apparent in 
the gel at this concentration. 
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11.2. Buffer Exchange and Concentration 
At the end of the purification procedure the buffer must be exchanged based on either 
downstream applications, or storage requirements. Removing the imidazole is necessary 
for accurate measurement of protein concentrations since imidazole absorbs at 280 nM. 
Downstream binding assays are confounded by the presence of high salt concentrations 
such as the 0.5 M NaCl in the FPLC binding buffer, and so the buffer was exchanged for 
a lower salt concentration solution free from the presence of imidazole. If storage is the 
next step the glycerol concentration will likely be increased, but for binding and other 
assays glycerol and perhaps BME may need to be removed.  
 
Buffer exchange worked well with the use of a dialysis membrane and where little 
change the in concentration took place, but was considerably more complicated when 
both concentration and buffer exchange were attempted simultaneously.  When the salt 
concentration was lowered and the glycerol was removed during concentration with 
Vivaspin® 5,000 MWCO columns (GE Healthcare Bio-Sciences AB Uppsala, Sweden) 
the protein appeared to aggregate. Though the precipitation was not visibly apparent, the 
concentration of the retentate decreased, when measuring absorbance at 280 nm by 
Nanodrop, rather than increased with each successive spin even when using a refrigerated 
centrifuge. Measurements of washes from pipetting up and down on the membrane 
indicated that at least some of the protein had precipitated onto the membrane. The 
addition of arginine may be helpful toward mitigating this aggregation, but could also 
interfere with downstream applications such as NMR. The empirical determination of 
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appropriate conditions for highly concentrated solutions of CycT1m-Tat could prove 
daunting, and here also high throughput methods would definitely be desirable.  
 
11.3. Storage of CycT1m-Tat 
When storing proteins a number of factors can affect the stability and biological activity 
of the protein and must be considered. Degradation of stored proteins can result from 
changes in temperature, protease activity, and the presence of some heavy metals. 
Another frequent concern is damage caused by oxidation. Aggregation and precipitation 
can result from changes in concentration, pH, ionic composition, and changes in 
temperature. Freeze thaw damage caused by extremes of temperature can also degrade 
proteins. During storage important cofactors of the protein can also be lost that can 
compromise the integrity of the protein such as the zinc atom from each of the zinc 
fingers. In general, the chimera was stored in 20% glycerol in 20 mM Tris, 0.2 M NaCl, 
10 uM ZnCl2, 5 mM BME, and pH 7.4 at -80°C in the interest of circumventing as much 
of the damage from storage as possible. Samples of the chimera stored in these conditions 
for several months and then run in SDS PAGE analysis appeared as a single band at the 
same molecular weight as when freshly purified. 
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Figure 11-1 FPLC chromatogram of CycT1m-Tat 
The FPLC chromatogram of the elution of CycT1m-Tat. The chimera with HisMBP tag 
removed flows through the HisTrap HP column without binding to it and is collected in 
the flow through solution. A peak at 15 ml was collected in fractions A2 and A3 and 
contained the concentrated (from the first round of purification) and purified CycT1m-
Tat. 
FPLC Chromatogram
Cleaved Tat and Final Elution 
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Figure 11-2 SDS PAGE of cleavage reaction and FPLC fractions and washes. 
The SDS PAGE analysis of the cleavage reaction solution and the FPLC fractions and 
wash solutions from left to right:   
1- ladder 2 – cleavage reaction        3 – CycT1m-Tat A2           4 – CycT1m-Tat A3  
5 – waste 1 6 – waste 2 (MBP, His6-TEV)      7 – NaCl wash         8 – water wash 
9 – NaOH wash                      10 – isopropanol wash                  11 – binding buffer wash    
12 – second NaOH wash        13 – His6-TEV 37.5:1 dilution control.  
Note: His6-TEV at 25 kDa in 6 runs at a molecular weight that is nearly indistinguishable 
here from that of CycT1m-Tat. Distinguishing the protease from the chimera is addressed 
by western blot in the following chapter. 
Cleaved Full Tris BME Trial
1 – Empty 
2 - Ladder 
3 – Cleavage Reaction 6/7/12
4 – Cleaved Tat A2 (0.6 mg/ml)
5 – Cleaved Tat A3 (1 mg/ml)
6 – Waste Elution 1 Cleaved Full Length
7 – Waste Elution 2 Cleaved Full Length
8 – NaCl wash
9 – H2O wash after NaCl
10 – NaOH wash
11 – Isopropanol wash
12 – Binding buffer wash
13 – NaOH wash after final elution
14 – TEV 1/37.5 Control
1   2  3   4   5   6    7  8  9  10 1112 13 14
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Chapter 12 Non-Quantitative Binding Assays 
 
Once the recombinant protein purification was complete two experimental techniques 
were used to confirm the correct Tat-chimera sequence. First the presence of the target 
protein was confirmed by the binding of primary and secondary antibodies in a Western 
blot, and second the correct molecular weight, corresponding to the appropriate target 
sequence, was confirmed by matrix-assisted laser desorption-ionization/time-of-flight 
(MALDI-TOF). With the use of both techniques it was possible to confirm the identity of 
the chimera with a reasonable degree of certainty before moving on to additional assays. 
 
12.1. Western Blot  
Western blotting was developed by W. Neal Burnette who submitted the idea in 1981 in 
an article to the journal of Analytical Chemistry (139). Ironically, the article was initially 
rejected. The original technique involves the electrophoretic transfer of proteins from 
SDS-PAGE (during which the proteins are initially separated vertically on the basis of 
molecular weight) to nitrocellulose filters from which a specific protein can then be 
detected by the binding of radioactive iodine-labeled antibodies or “probes” for the 
protein of interest. Today the technique is still widely used for the detection of proteins, 
and is available commercially with both radioactive and non-radioactive visualization 
alternatives including fluorescently and chromogenically labeled antibodies.  
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Since the chimera contains a myc antibody binding sequence between the hCycT1 and 
Tat portions of the protein (Figures 3-1 and 4-11) the presence of the Tat chimera was 
confirmed by first binding a primary anti-myc antibody to the sequence, and 
subsequently binding a secondary chromogenic antibody to the primary antibody for 
visualization by Western blot. The Novex® WesternBreeze™ Chromogenic Anti-mouse 
Kit (Life Technologies Grand Island, NY) detects picogram levels of protein, and was 
used with the iBlot® western blotting system (Life Technologies Grand Island, NY).  
 
12.2. Western Blot Results 
In an unfortunate coincidence the chimera and the His6-TEV protease were found to run 
at nearly the same molecular weight (~25 kDa) in SDS-PAGE. However, while the His6-
TEV runs true to size the actual molecular weight of the chimera is ~17.5 kDa. Thus an 
alternative method of distinguishing between the two proteins is essential. A Western blot 
of the Positope™ positive control, full purified chimera, the cleavage reaction, and the 
His6-TEV protease confirmed that the band appearing in (Figure 12-2 SDS PAGE)  5 is 
His6-TEV which is not myc tagged and is therefore not present in the Western blot 
(Figure 12-1 Western  5). Comparing the two bands in s four and five of Figure 12-2 SDS 
PAGE it is clear that the two proteins migrate with remarkable similarity in SDS PAGE.  
 
A second Western blot of several samples of the full chimera and CycT1m-Tat in a 
variety of buffers (Tris based storage buffer, fluorescence titration buffer, and Octet 
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buffer) confirms the presence and integrity of the full chimera and CycT1m-Tat samples 
that were used in downstream assays (Figure 12-3 Western) (Figure 12-4 SDS-PAGE). 
 
12.3. MALDI-TOF 
The basic principle of mass spectrometry (MS) is that a moving charged particle is 
accelerated in a magnetic field which causes the deflection of the particle. The degree of 
deflection of the charged particles is dependent upon the mass/charge ratio. A detector 
receives the deflected particle, the signal is amplified, and the mass to charge ratio is 
recorded and plotted on the x axis, while the intensity of the signal is plotted on the y axis 
in what is called a mass spectrum.  
 
Developed in 1988 by Franz Hillenkamp at University of Műnster in Germany, matrix-
assisted laser desorption-ionization/time-of-flight (MALDI-TOF) is a highly sensitive 
soft ionization technique that is able to accurately analyze intact biomolecules (Figure 12-
5). In MALDI-TOF the sample is mixed with excess matrix and is then dried to the 
MALDI plate. A laser is directed at the sample on the plate surface and ionizes the 
sample by proton transfer to the sample from the matrix which absorbs the laser light. 
The time that the ionized particle takes to reach the detector is known as “ion drift” and is 
inversely proportional to the square root of the mass to charge ratio of the particle. When 
the particle reaches the detector the signal is amplified and then recorded (140). 
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This technique is particularly useful in the analysis of biomolecules because MALDI-
TOF is a soft ionization technique that produces less fragmentation and is therefore 
useful in the study of larger intact biomolecules. Other soft ionization techniques include:  
chemical ionization, fast atom bombardment, and liquid secondary ionization,  
Over the past 25 years use of MALDI-TOF has grown with the field of proteomics as the 
technique is highly sensitive and accurate and provides reasonable resolution for 
biomolecules up to several hundred kilodaltons (141). 
 
12.4. Results: MALDI-TOF of CycT1m-Tat  
Subsequent to confirming the presence of the chimera with Western blot, the appropriate 
molecular weight of the protein was confirmed by matrix-assisted laser desorption-
ionization/time-of-flight (MALDI-TOF). The Bruker AutoFlex III MALDI TOF/TOF 
Mass spectrometer in the Jahn Lab at the State University of New York College of 
Environmental Science and Forestry (SUNY-ESF) was used to confirm the molecular 
weight of a 20 uM sample of CycT1m-Tat in a 3,5-dimethoxy-4-hydroxycinnamic acid 
(sinapinic acid) matrix. 
 
The base peaks of the two spectra produced from two samples of CycT1m-Tat (Figure 
12-4 MALDI-TOF) indicate molecular weights of 17,485.1 and 17,485.9 daltons 
respectively and are within 4.4 daltons of the 17481.5 daltons predicted by the Protein 
Calculator version 3.3 provided online by The Scripps Research Institute (Appendix 3). 
This relatively small experimental error may be attributable to: protonation, differences in 
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isotopic abundance calculations of the calculator, and/or to calibration error for the 
Bruker AutoFlex III. 
 
12.5. Electrophoretic Mobility Shift Assay  
An electrophoretic mobility-shift assay (EMSA), formerly known as a gel-retardation 
assay and also known as a gel shift or band shift assay is sensitive and inexpensive 
technique that was originally described by both Fried and Crothers, and by Garner and 
Revzin, in 1981 (142,143). This non-denaturing electrophoresis technique permits both 
the qualitative and quantitative characterization of protein-nucleic acid complexes (144). 
In EMSA molecules are separated at near neutral pH on the basis of shape, size, and 
charge since SDS is omitted and no negative charge is artificially imparted as it would be 
in denaturing electrophoresis (145). 
 
12.6. Characterization of the Protein-Nucleic Acid Complex 
In EMSA the formation of complexes between nucleic acid and protein is evidenced by a 
reduction in the distance traveled by the higher molecular weight bound complex through 
the polyacrylamide gel when compared to the distance traveled by the free nucleic acid. 
This so called “retardation” of the distance traveled by the nucleic acid is referred to as 
“shifting” or “super-shifting” and is rendered visible by staining. The band produced by 
the complex appears vertically higher or closer to the well than that of the lighter 
unbound nucleic acid. 
 - 144 - 
 
The binding affinity of the protein-nucleic acid complex can be characterized, to a limited 
degree, by the length of time that the complex travels through the gel before separating 
into its primary components. In some cases the relative intensity of the bands produced 
by the complexed nucleic acid versus those produced by the free nucleic acid can be 
measured and used for a more quantitative analysis. However, both the formation and 
stability of the complex are affected by numerous factors including: binding buffer, and 
running buffer components, gel concentration, temperature, and competitor molecules. 
For any particular protein-nucleic acid interaction EMSA conditions must be determined 
empirically (146). 
 
 The EMSA technique is useful for nucleic acids ranging in size from short 
oligonucleotides to longer and more complicated nucleic acid structures including small 
circular DNA, but is limited to approximately 5,000 base pairs or less (144). Assays with 
shorter oligonucleotide segments tend to be hindered by difficulties related to binding 
sites positioned close to the end of the molecules, while longer nucleic acids tend to 
exhibit more non-specific binding (144). With respect to protein, the EMSA technique is 
effective for proteins ranging from small oligopeptides to molecular weights greater than 
1,000 kDa and is useful for both crude and purified solutions (144).  
 
12.7. Visualizing Proteins and Nucleic Acids in the EMSA 
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In a traditional EMSA the protein-nucleic acid interaction is visualized by 32P labeling of 
the nucleic acid, and provides a high degree of sensitivity detecting 0.1 nM or less of the 
nucleic acid (144). However, new and highly sensitive staining techniques have been 
developed that permit the circumvention of radioactive techniques. Chemiluminescent, 
fluorescent, and immunohistochemical detection methods are commercially available, 
reasonably sensitive, and stain either nucleic acids or proteins, or both. 
 
For use in protein staining SYPRO Ruby Protein Gel Stain (Molecular Probes, Inc. 
Eugene, OR) is a highly sensitive luminescent stain with two excitation maxima at 
approximately 280 nM, and 450 nM, and with an emission maximum of approximately 
610 nM (147). This stain can be visualized at 300 nM with a UV transilluminator. The 
sensitivity of this stain is comparable to that of silver staining with a lower detection limit 
between 0.25 ng and 1 ng of protein. This highly sensitive protein stain does not stain 
nucleic acids, and binds to basic amino acids and the peptide backbone of the protein 
(147). 
 
The nucleic acid stain SYBR Gold (Molecular Probes, Inc. Eugene, OR) has excitation 
maxima for the dye-nucleic acid complexes at approximately 495 nM, and 300 nM and 
an emission maximum at approximately 537 nM. This proprietary unsymmetrical cyanine 
dye exhibits a greater than 1000-fold fluorescence enhancement when bound to nucleic 
acids and has a high quantum yield (~0.6) upon binding to double- or single-stranded 
nucleic acid (148). While this stain is highly sensitive and useful for EMSA, it is 
important to note that in general unsymmetrical cyan dyes bind the minor groove of 
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nucleic acids (149) and could potentially interfere with the binding interaction of a 
protein ligand.  
 
12.8. Limitations of Electrophoretic Mobility Shift Assays 
In addition to the complications already presented regarding the use of dyes that have the 
potential to alter or inhibit binding interactions there are other limitations to EMSA. 
Specifically, little can be gained from the assay regarding the molecular weight of the 
complex, or of the location of the binding interaction. Moreover, during electrophoresis 
samples are not at equilibrium, and both the ionic strength of the buffer and the so called 
“caging effects” of the gel may cause certain interactions to be stabilized, while the rapid 
dissociation of other interactions may prevent their detection entirely (144).  
 
Glycerol, often added to the sample buffer for the purposes of increasing the density of 
the sample for loading, often has a stabilizing effect both on the unbound protein, and on 
the protein-nucleic acid complex (144,150,151) and can confound attempts at more 
quantitative analysis. Because of these issues, the aforementioned complications 
experienced with the positioning of small oligonucleotide binding sites, and the potential 
effects of the temperature of the gel on the affinity of the complex EMSA may be more 
useful in a semi-quantitative role. Here EMSA was used in the preliminary confirmation 
of binding interactions between recombinant purified proteins and their native nucleic 
acid binding partners prior to moving on to the more quantitative methods of surface 
plasmon resonance, and biolayer interferometry. 
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An additional complication in this non-denaturing assay is the issue of protein charge. 
While nucleic acid is always negatively charged and migrates from the negative to the 
positive electrode, proteins can be positively charged, negatively charged, or can have no 
net charge at their respective isoelectric points complicating migration in non-denaturing 
gel electrophoresis. In the case of positively charged proteins in non-denaturing gels the 
positively charged proteins will migrate in the opposite direction from the nucleic acid 
toward the negative electrode and in some cases can migrate up out of the wells of the gel 
and be dispersed into the running buffer.  
 
12.9. Method 
In order to qualitatively characterize the interaction between the recombinant Tat chimera 
and the TAR RNA an EMSA was performed in which both the full Tat chimera, and 
CycT1m-Tat (from which the tag had been removed) were bound to a 27 nucleotide 
stem-loop portion of the wild type TAR RNA (Figure 13-1). Two additional proteins 
were included in the assay: the MBP tag alone in order to determine whether the tag itself 
bound the RNA, and a 13 amino acid arginine rich peptide which is the minimal portion 
of the Tat protein found by Weeks et al. 1990 to bind the TAR RNA, and which also 
contains the nuclear localization signal (NLS) of the Tat protein.  
 
The concentration of the polyacrylamide gel used for EMSA was determined empirically 
to suit the 27-nt nucleic acid, and the various proteins ranging in molecular weight from 
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1.7 kDa for the Tat minimal peptide to 60.8 kDa for the full tagged Tat chimera. A 12% 
acrylamide non-denaturing gel was pre-run for one hour at ~8°C and 100 Volts in 1 X 
TBE buffer at pH 8.0. Nucleic acid was heated for three minutes at 90°C vortexed lightly 
and briefly and then cooled on ice briefly before being added to samples.  Protein 
samples in 20 mM Tris, 0.2 M NaCl, 10 uM ZnCl2, 5 mM BME, and pH 7.4 were 
incubated with the wild type TAR RNA stem loop to a final concentration of 500 nM of 
the RNA, and 5 and 10 uM of each of three experimental proteins assayed. Glycerol was 
added to each of the samples to a final concentration of 5% in order to facilitate loading 
on the gel. Once the samples were mixed they were equilibrated at 4°C for 15 min. 
Positive and negative control samples of known binding partners HIV-1 SL3 RNA 33-nt 
with and without HIV-1 Ncp7 (7 kDa), respectively, were loaded in the first and second s 
of each gel. Negative control samples of the wild type TAR RNA alone were loaded in 
the third, and negative control samples of each of the proteins in the absence of RNA 
were loaded in the final three s (Appendix 16). 
 
The EMSA gel was run for 90 minutes at ~8 °C and 100 Volts, removed from the 
apparatus, incubated in Millipore Milli-Q Biocel ultrapure water (Millipore, Billerica, MA) 
for 15 minutes, and then stained with SYBR® Gold nucleic acid stain (Molecular Probes, 
Inc. Eugene, OR) for one hour. After rinsing the gel with water the RNA was visualized 
and photographed with the Kodak Gel Imager equipped with UV transilluminator. The 
gel was then incubated in 100 ml of fixing solution comprised of 50% methanol and 7% 
acetic acid for 30 minutes two times. The gel was then incubated in 60 ml of SYPRO® 
Ruby gel stain solution (Molecular Probes, Inc. Eugene, OR) overnight, and then 
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visualized and photographed again with the Kodak Gel Imager. The two images were 
then superimposed over one another in order to facilitate the interpretation of the pattern 
of protein and nucleic acid migration. 
 
12.10. Results: Electrophoretic Mobility Shift Assay 
In Figure 13-2 (EMSA) the negative control in  one demonstrates the migration of the 
free HIV-1 SL3 RNA at 500 nM, and with the addition of 10 uM of Ncp7 the positive 
control in  two demonstrates the super-shifting of the SL3 RNA as predicted for this well 
characterized interaction. The negative control free wild type TAR RNA in three 
migrates slightly less than the SL3 as predicted based on the two nucleotide difference 
between the two oligonucleotides. In the experimental four the addition of Tat minimal 
peptide at 10 uM binds to TAR 500 nM and produces a small shift consistent with 
expectations for the low molecular weight (1.7 kDa) peptide. In experimental five a 
super-shift appears where the 10 uM recombinant CycT1m-Tat (17.5 kDa) binds the 500 
nM TAR RNA. In this interaction the RNA appears to have been completely prevented 
from migration into the gel. In six a super-shift appears where 10 uM recombinant full 
MBP tagged chimera (60.8 kDa) binds the 500 nM TAR RNA and is indistinguishable 
from the shift produced by CycT1m-Tat in the prior. In  seven no shift is observed where 
10 uM of the MBP tag has been incubated with the 500 nM TAR RNA indicating that the 
MBP tag alone does not bind TAR. In s eight, nine, ten, and eleven the previous four s 
are repeated albeit with 5 uM of each of the proteins and the same 500 nM TAR RNA 
with similar results except for the binding of the minimal peptide where slightly less 
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shifting is observed. In the same figure lanes twelve, thirteen, fourteen, and fifteen 
contain the proteins alone at 10 uM and demonstrate that none of the recombinant 
proteins contains any observable nucleic acid contamination. 
 
12.11. Discussion 
The results of the EMSA were as predicted for both positive and negative controls, and 
for the experimental samples. Shifting of the TAR RNA was minor for the low molecular 
weight Tat minimal peptide, and was absent for MBP which is not known to bind TAR. 
Super-shifting of the TAR RNA for both the full Tat chimera, and CycT1m-Tat is readily 
apparent. The binding affinity of the two samples was almost indistinguishable from the 
EMSA experiment alone. However, CycT1m-Tat did appear to bind with slightly higher 
affinity than its tagged counterpart. 
 
In Figure 13-2 s 5 and 6, and 9 and 10 for CycT1m-Tat and the full chimera, at 10 uM 
and at 5 uM respectively, the nucleic acid is not visible. The large, high molecular 
weight, and high affinity complexes formed in these s appear to have super-shifted the 
nucleic acid preventing its migration into the gel. In general, conditions known to prevent 
visualization of nucleic acid in EMSA are where the nucleic acid has been degraded, 
where protein-nucleic acid complexes are too large for the gel system, where protein 
aggregation occurs, or where the ratio of nucleic acid to protein is higher than the gel 
system can accommodate (144). The appearance of the nucleic acid in both the positive 
and negative controls indicates that degradation was unlikely. Lower concentration of 
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polyacrylamide in other trials failed to improve resolution (data not shown). Reducing the 
ratio of nucleic acid to protein, and the addition of non-ionic detergents or higher 
concentrations of glycerol might improve the visualization of the nucleic acid (144). 
However, since MBP (43.4 kDa) at identical concentrations did not prevent the migration 
of the TAR RNA it could reasonably be concluded that neither the ratio of nucleic acid to 
protein nor the concentration of the gel were particularly unsuitable. While aggregation 
of the recombinant full chimera and CycT1m-Tat could not be ruled out, the EMSA did 
prove to be a successful screening tool for the Tat-TAR interaction as specific binding 
was readily apparent (Figure 13-2).  
 
With regard to the free protein samples, at the pH 8.0 of the 1 X TBE buffer the charges 
of the Tat minimal peptide, CycT1m-Tat, full MBP tagged chimera, and the MBP tag 
alone are +7.5, -0.5, -5.9 and -5.9, and their respective isoelectric points are 12.7, 7.9, 6.6, 
and 5.71 (Appendices 2,3,4, and 5). These characteristics along with the fact that in this 
non-denaturing system protein migrates based on a combination of size, shape, and 
charge and are influenced by a multitude of additional factors including pH, and ionic 
conditions could be responsible for the modest migration of the free protein through the 
gel.  
 
Although not quantitative, EMSA did prove to be a suitable initial method for screening 
binding interactions between the recombinant chimeric proteins and the TAR stem-loop 
nucleic acid.  
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Figure 12-1 Western blot of the Tat chimera and His6-TEV protease. 
A Western blot of the Tat chimera and His6-TEV protease from left to right:  
 1 – ladder  2 – Positope™ control  
 3 – full chimera control  4 – cleavage reaction  
 5 – His6-TEV control 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine buffer. 
Run condition: 200V, 50 minutes. 
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Figure 12-2 SDS-PAGE of the Tat chimera and His6-TEV protease. 
The SDS-PAGE analysis of the Tat chimera and His6-TEV protease samples from left to 
right:  
 1 – ladder  2 – Positope™ control,  
 3 – full chimera control  4 – cleavage reaction,  
 5 – His6-TEV protease control. 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. The same gel is used in Figure 12-1 Western blot. 
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Figure 12-3 Western blot of full chimera and CycT1m-Tat. 
A Western blot of the full chimera and CycT1m-Tat samples in various concentrations 
and buffers from left to right:  
 1 – ladder  2 – Positope™ 
 3 – CycT1m-Tat 0.5 mg/ml  4 – CycT1m-Tat 1.0 mg/ml  
 5 – full chimera  6 – full chimera concentrated  
 7 – CycT1m-Tat (fluor buffer)  8 – full chimera (Octet buffer) 
 9 – CycT1m-Tat (Octet buffer) 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. 
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Figure 12-4 SDS-PAGE of full and CycT1m-Tat. 
SDS-PAGE analysis of the full chimera and CycT1m-Tat samples from left to right:   
1 – ladder                         2 – Positope™               3 – CycT1m-Tat 0.5 mg/ml 
4 – CycT1m-Tat 1.0 mg/ml                         5 – full chimera,  
6 – full chimera (fluor buffer)                               7 – CycT1m-Tat (fluor buffer)   
8 – full chimera concentrated (Octet buffer)         9 – CycT1m-Tat (Octet buffer) 
Precast Gradient Gel 4-20% (Bio-Rad, Hercules, CA), running buffer: 1X Tris-Glycine 
buffer. Run condition: 200V, 50 minutes. The same gel is used in Figure 12-3. 
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Figure 12-5 Diagram of the MALDI-TOF Method of Mass Spectrometry. 
In MALDI-TOF a pulsed laser beam ionizes proteins affixed to the surface of the target 
plate (bottom right). The mass to charge ratio of the ionized proteins causes the particle to 
be deflected. A detector receives the deflected particle, the signal is amplified, and the 
mass to charge ratio is recorded and plotted on the x axis, while the intensity of the signal 
is plotted on the y axis in what is called a mass spectrum. Reprinted from: “The Next 
Generation Technology for Microbial Identification: MALDI-TOF”, Copyright 2011 
Accugenix, Inc. with permission from Accugenix, Inc. Accessed online at: 
http://www.accugenix.com/microbial-identification-bacteria-fungus-knowledge-
center/micro-id-basics/maldi-tof-method/ 
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Figure 12-6 Bruker Daltonics flexAnalysis of CycT1m-Tat 
The Bruker AutoFlex III MALDI TOF/TOF Mass spectrometer in the Jahn Lab at the 
State University of New York College of Environmental Science and Forestry (SUNY-
ESF) was set for the range of 8000 to 50000 Daltons. The molecular weight determined 
by two trials is in close agreement with the theoretically calculated molecular weight of 
17,481.5 Daltons. 
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Figure 12-7 Wild type HIV-1 TAR (27-nt) stem loop structure for EMSA 
The wild type HIV-1 TAR (27-nt) stem-loop nucleotide sequence and structure used in 
the electrophoretic mobility shift assay (EMSA) for the characterization of the binding 
complexes formed with the full MBP tagged Tat chimera, cleaved tag free Tat chimera, 
and the Tat minimal peptide.  
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Figure 12-8 Electrophoretic mobility shift assay (EMSA) 
EMSA of wild type HIV-1 TAR (27-nt) RNA complexed with full-length MBP tagged 
Tat chimera, CycT1m-Tat, and the Tat minimal peptide (see also, Appendix 16). An 
image of gel stained with SYBR Gold (RNA) was superimposed with an image from the 
same gel stained with SYPRO Ruby (protein). [SL3] = [TAR] = 500 nM when present. 
Lanes are color-coded for the most important analytes, numbered left to right:  
1 – SL3 RNA   2 – SL3 + NCp7 protein 10 uM  
3 – TAR RNA  4 – TAR + Tat minimal peptide 10 uM 
5 – TAR + CycT1m-Tat 10 uM 6 – TAR + MBP tagged chimera 10 uM  
7 - TAR + MBP 10 uM   8 - TAR + Tat minimal peptide 5 uM 
9 - TAR + CycT1m-Tat 5 uM  10 - TAR + MBP tagged chimera 5 uM  
11 - TAR + MBP 5 uM  12 – Tat minimal peptide 10 uM  
13 – CycT1m-Tat 10 uM  14 – MBP tagged chimera 10 uM 
15 – MBP 10 uM  
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Chapter 13 Label-Free Binding Analysis  
 
From its introduction in the 1960’s (152-154), biosensor technology has developed into a 
multibillion dollar market utilized by a large and diverse group of industries as well as by 
the general public (152). Though many different definitions exist, in general a biosensor 
is a device that is used to detect a signal that is produced when a target molecule interacts 
with a biological component in close proximity to a transducer (152,155). This label-free 
technology is now widely employed, and is the basis of several home diagnostic devices 
available to the general public such as: the ClearBlue pregnancy test, and the electronic 
blood glucose monitors commonly used by diabetics (152).  
 
For biochemists, biosensors permit the detection and quantitation of interactions between 
unlabeled biological components, and facilitate a wide variety of experiments by 
obviating the tedious and problematic process of labeling the biological components 
under investigation. In addition to the difficulties encountered during labeling, the study 
of labeled components is frequently hindered by inefficient labeling, as well as by 
interference, or the necessity to rule out interference, caused by the label itself. A wide 
array of enzymes, antibodies, and nucleic acids are now assayed by label-free methods 
using biosensors that employ electrode, thermistor, or optical transducers to convert the 
interaction between biomolecules into a quantifiable signal (152,156). 
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13.1. Optical Biosensors 
Among optical biosensors surface plasmon resonance (SPR) is at present the most 
commonly used affinity-based biosensor technique. Several different manufacturers have 
developed equipment that varies widely in price, ease of use, and popularity among 
researchers. BIAcore® is currently the market leader, and most of the published research 
protocols detail techniques applicable to the BIAcore system (GE Healthcare 
Biosciences, Piscataway, NJ). The system in our lab is a GWC Technologies 
SPRimager®II (Madison, WI) that, while less popular among researchers, is a more 
moderately priced model that is capable of a comparable range of assays. Another 
important variant is biolayer interferometry, discussed below in Section 16.6.  As of this 
writing the bulk of published SPR research still tends to pertain to the investigation of 
protein-protein interaction, and a good deal less published work is to be found regarding 
the interaction between a protein and a nucleic acid binding partner such as is the subject 
of this research. 
 
13.2. Surface Plasmon Resonance 
The technology behind SPR affinity-based biosensors is based on the detection of 
changes in the refractive index of a solution with a positive real part of the dielectric 
constant Re () flowing over an oscillating electromagnetic wave parallel to a metal (Au, 
Ag, Cu, Ti, Cr) sensor surface with a negative  (157). Surface plasmons at the metal 
surface produce a self-propagating electromagnetic wave called surface plasmon 
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polaritons (SPP) when infrared polarized light couples (through a prism-coupling 
arrangement) with free oscillating electrons in the metal (156-159).   
 
Coupling must occur at a specific angle known as the angle of incidence. When 
biomolecules bind within the sensitive region of 300 nm from the metal surface, incident 
light is lost to the metal at the surface and the reduction in light is detected as the angle of 
reflection is shifted by the binding event (Figure 14-1) (159). The difference between the 
angle of reflection prior to adsorption of the analyte and after binding has occurred is 
plotted as response versus time and is displayed in real time on the system’s computer 
monitor (Figure 14-2) (156,158,159). 
 
In the typical SPR assay a “bait” ligand, either a protein or nucleic acid, is affixed to a 
gold surface over which a solution containing the analyte binding partner is passed. The 
interaction between the analyte and the ligand is recorded as intensity of response versus 
time in a real-time curve generated by the system software (Figure 14-3). The kinetics of 
the reaction, in terms of the on-rate, off-rate, and dissociation constant of the interaction, 
are then calculated by fitting the curves of the association and dissociation phases of the 
response. The height of the SPR response is related to the mass of material bound to the 
sensor surface. 
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13.3. Surface Plasmon Resonance Surface Chemistry 
When performing binding assays with the GWC SPRimager®II a self-assembled 
monolayer (SAM) must be created on the gold spots on the surface of a glass chip prior 
to beginning the experiment. The SAM provides the surface chemistry for the attachment 
of the ligand to the metal on the chip surface. Several different types of surface chemistry 
are available including: amine, streptavidin, or polyethylene glycol (PEG). Deciding 
which surface chemistry to use for a specific interaction is most frequently an empirical 
process. The preparation of the SAM is performed over the course of two days. Preparing 
the chip fresh prior to each experiment is advisable, although regeneration is theoretically 
possible results are frequently not reproducible.  
 
13.4. Limitations of Surface Plasmon Resonance 
Set-up and execution of the SPR experiment with the GWC SPRimager®II is a relatively 
long procedure that is complicated to assemble, and it is generally not possible to recover 
sample after the experiment. Accurate determination of the ligand concentration on the 
surface is not possible due to the potential for artifacts related to the application of the 
surface chemistry to the chip. Ligand may or may not have successfully bound to the 
surface chemistry in some regions of the chip surface producing inter-spot or intra-spot 
binding heterogeneity (160). Consequently, the concentration of bound analyte cannot be 
accurately known if the concentration of bound ligand is unknown. 
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13.5. Mass Transport Limitation 
In addition to the SPR limitations related to the efficiency of the surface chemistry, are 
limitations related to analyte delivery. When attempting to measure the binding affinity 
of an interaction with a fast on-rate it is common for the measured rate to be slower than 
the true rate according to chemical kinetics. This can occur when the density of the 
affixed ligand is so great as to sterically hinder the delivery of the analyte to the binding 
site, and also when the on-rate of the interaction is faster than the rate of analyte delivery 
that the system can accommodate (160). Further, where the on-rate of the interaction is 
fast a local depletion of analyte concentration can occur preventing an accurate 
determination of on-rate (160).  
 
Interference with dissociation can occur when the density of the ligand prevents the free 
dissociation and diffusion of the analyte. The size and concentration of the analyte must 
also be considered, as large proteins can hinder binding at other sites. Thus the potential 
effects of mass transport limitation on the determination of binding kinetics in SPR are 
not trivial. However, in the evolution of SPR protocols researchers have found that 
determining and employing a minimal working ligand concentration, and keeping the 
concentration of the analyte well below that of the ligand are prudent approaches to 
minimizing the potential for mass transport limitation problems (personal conversation 
with Dr. Thomas Duncan, Upstate Medical University, Syracuse NY) (160). 
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13.6. Biolayer Interferometry 
Improving upon SPR biosensor technology, biolayer interferometry (BLI) is another 
label-free optical biosensor detection platform used to study the interaction of 
biomolecules. In BLI (Figure 14-4 and 14-5) the interaction of light waves in constructive 
and destructive interference produces a wave pattern that is the basis of optical 
interferometry technology. Glass fiber-based biosensors, with a variety of available 
surface chemistries, bind the ligand and are then dipped into 96 well plates containing the 
analyte in solution.  
 
White light travels down the sensor and is reflected back to the detector from two 
surfaces within the tip: a reference layer surface, and the interface surface where the 
ligand meets the analyte solution (Figure 14-6) (161). At the spectrometer individual 
reflected wavelengths that are either in phase or out of phase combine to form an 
interference pattern. When binding occurs at the second interface surface of the tip, the 
change in the interference pattern of the reflected wavelengths is detected as the intensity 
variation by wavelength. The change in intensity is then plotted as response (in 
nanometers) versus time (161). The kinetics of the reaction can then be calculated from 
the association and dissociation phases of the resulting response versus time curve, as in 
SPR. 
 
However, unlike SPR where microfluidics govern the delivery of the analyte through a 
flow cell, BLI systems such as the ForteBio’s Octet optical biosensor provide 
“microfluidic-free” delivery of the analyte by dipping the fiber optic sensor tip loaded 
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with the affixed ligand into an open shaking 96 well microplate rather than flowing the 
analyte solution over the chip as in SPR (161). In this manner many of the complications 
of microfluidics and analyte delivery are avoided. The ForteBio Dip and Read™ 
Biosensors are available in a wide variety of surface chemistries and can also be 
customized for a specific application. Assays can be performed in crude or purified 
analyte solutions, and in many cases it is possible to recover the sample after the 
experiment. 
 
13.7. Biolayer Interferometry ForteBio Octet Method 
Many attempts to obtain kinetic data for the interaction between the recombinant Tat 
chimera and the TAR stem-loop using the GWC SPRimager®II failed to produce 
consistent and reproducible results. At the time of the experiments manufacturer 
suggestions for ligand density of 1 to 2 mM on the chip surface proved to be too dense 
and appeared to contribute to steric hindrance. Results were somewhat more reproducible 
when ligand concentrations were reduced, however the three dimensional nature of the 
surface chemistry on the chip was also a likely contributor to steric hindrance (personal 
conversation with Dr. Thomas Duncan, Upstate Medical University). Hence, BLI was an 
attractive alternative for acquiring these data. The Octet Red 96 (Pall FortéBio Corp, 
Menlo Park, CA) provides real time data for protein kinetics and quantitation and was 
generously made available by Dr. Thomas Duncan of Upstate Medical University in 
Syracuse, New York. The streptavidin biosensor tips used with the Octet system affix the 
ligand with a surface chemistry that is more two dimensional in nature and less likely to 
 - 167 - 
contribute to steric hindrance (personal conversation with Dr. Thomas Duncan, Upstate 
Medical University). 
 
To begin each experiment the instrument was set at 22°C so that it could be heated to the 
experimental temperature of 25°C rather than cooled as this requires more time. 
Streptavidin-coated fiber optic tips were incubated in buffer at pH 7.4, containing 20 mM 
Tris, 0.2 M NaCl, 10 µM ZnCl2, 0.02% Sodium Azide, 5 mM BME, and 0.5 mg/ml fat 
free bovine serum albumin (BSA) for a minimum of 10 minutes prior to beginning the 
assay.  
 
The first trial compared the response for ligand concentrations of TAR RNA-27 nt at 0.3 
µM, 0.6 µM, 1.25 µM, 2.5 µM, and 5.0 µM in a BLI binding assay with a static CycT1m-
Tat analyte concentration of 1.5 µM (data not shown). From the results of this assay a 0.5 
µM ligand concentration was chosen as the working concentration for subsequent trials. 
The 0.5 µM ligand concentration was low enough to minimize mass transport limitations, 
while high enough to produce the appropriate and characteristic response curve for BLI. 
 
13.8. Non-specific Binding 
The second experiment was designed to assess the level of nonspecific binding of the 
protein to the streptavidin tips utilizing negative controls. Raw aligned data in figures 14-
7 and 14-8 demonstrates very low level response for the non-specific binding of the 
CycT1m-Tat (17.5 kDa) to the streptavidin sensor tips in the absence of 5’ biotinylated 
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TAR RNA ligand at analyte concentrations of 1.5, 0.5, and 0.2 µM. This response was 
similar even at concentration of up to 4.0 µM of CycT1m-Tat (data not shown). The 
nonspecific response is approximately 0.05 nm above the background response for the 
negative control sensor in the absence of both the RNA ligand and CycT1m-Tat analyte, 
and well below the positive control response of 0.5 nm for 1.5 µM CycT1m-Tat bound to 
the 0.5 µM 5’ biotinylated TAR stem-loop.  
 
13.9. Tat-TAR Binding Interaction 
Eight disposable fiber-optic sensors were used in the third experimental assay. The single 
use Dip and Read™ Streptavidin (ForteBio Menlo Park, CA) sensors were incubated in a 
solution of 0.5 µM 5’ biotinylated TAR 27-nt stem-loop RNA ligand (10.6 kDa) 
purchased from Integrated DNA Technologies, Coralville, IA. Protein analyte solutions 
used for the assay were: full Tat chimera (60.8 kDa) 4 µM, CycT1m-Tat (17.5 kDa) 4 
µM, 2 µM, 1 µM, 0.5 µM, 0.25 µM, and MBP (42.0 kDa) 4 µM (MBP purchased from 
GenWay Biotech, Inc. San Diego, CA.). All samples were prepared in the same buffer 
solution containing 0.5 mg/ml fat free bovine serum albumin (ffBSA) to inhibit 
nonspecific binding. 
 
A 96 well plate was prepared with buffer solution in rows 1, 3, and 5 (Figure 14-9) 
(Table 14-1). The 5’ biotinylated TAR RNA 0.5 µM ligand (in buffer solution) was 
loaded in 2. In 4 various analyte solutions (in the same buffer solution) were loaded as 
listed in Table 14-1. For the first 300 seconds (step 1) (Figure 14-10) of the experiment 
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the streptavidin biosensor tips were incubated in 1 (buffer 1), followed by a 400 second 
incubation (step 2) in 2 with 0.5 µM 5’ biotinylated TAR RNA 27-nt affixing the ligand 
to the tip. At 700 seconds the tips were incubated in 3 (a fresh buffer solution of the same 
composition) (step 3) for 600 seconds to remove unbound ligand. In step 4 the tips were 
incubated for 60 seconds in a fresh buffer solution in 5 in order to achieve a stable 
baseline in fresh buffer unadulterated by the presence of unbound RNA. In step 5 the 
biosensor tips were incubated in the various concentrations of analyte solutions for 900 
seconds which was sufficient to achieve saturation. In step 6 the tips were returned to the 
unadulterated buffer in 5 for 1800 seconds for the dissociation step. Data were displayed 
in real time using the ForteBio Data Acquisition 6.4 software program (ForteBio Menlo 
Park, CA) (Figure 14.9). 
 
13.10. Determining the Dissociation Constant of the Tat-TAR Interaction 
In the formation of the bound Tat-TAR complex the binding event can be represented as 
a two-state process by: 
Tat + TAR       Tat-TAR           
 
 
Thus the corresponding equilibrium dissociation constant Kd is defined as: 
Kd = [Tat]·[TAR] 
         [Tat-TAR] 
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where [Tat], [TAR] and [Tat-TAR] represent molar concentrations of the Tat protein, the 
TAR RNA ligand and the bound [Tat-TAR] complex, respectively. 
The equilibrium of this reaction will be reached when  
[Tat]·[TAR] kon = [Tat-TAR] koff 
where kon and koff are the on and off rates of the reaction in M
-1 s-1, and s-1 respectively. 
The equation can then be rearranged 
Kd  =  koff  = [Tat]·[TAR] 
          kon           [Tat-TAR] 
  
The actual concentrations of Tat, TAR, and the Tat-TAR complex cannot be known 
during BLI as discussed previously. Therefore the equilibrium constant Kd must be 
calculated from the ratio of the off rate to the on rate for the Tat-TAR interaction.  
The data calculated by the ForteBio Data Analysis 6.4 reports a response of kobs for the 
binding event. The equation for a trend line of the linear regression of kobs versus 
concentration is: 
kobs = ka[L] + kd 
where ka is equal to the on rate of the interaction, L is the ligand concentration, and kd is 
the off rate of the interaction in units of per nanomolar per second when reported by Data 
Analysis 6.4. 
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13.11. Biolayer Interferometry ForteBio Octet Results: Fitting the Data 
The measured response was minimal and consistent with expectations for the negative 
control MBP protein (the solubility enhancing tag alone) (Figure 14-10, B7). A larger 
response, with a rapid onset and early approach to saturation was observed for the full 
MBP-Tat chimera (Figure 14-10 A7). The samples of CycT1m-Tat demonstrated the 
largest response that increased in proportion to concentration, saturating at about 2-4 uM 
for the present conditions. CycT1m-Tat comprises only 29% of the full chimera, so each 
binding event for the full protein should carry 3.4 times more mass than for CycT1m-Tat 
(60/17.5 = 3.4) if both proteins had the same binding constant and an equivalent number 
of binding sites. Figure 14-10 portrays the opposite situation, where the final A7-signal is 
less than half of that for C7. While it is possible that the MBP portion of the full chimera 
renders its CycT1m-Tat domain less effective in binding TAR, the most likely 
explanation is that the MBP portion of the full chimera occludes some of the TAR RNA 
sites on the Octet tip. The data are consistent with a high-affinity interaction between 
CycT1m-Tat and surface-immobilized TAR RNA. 
 
13.12. Association 1:1 Model Fit 
The association and dissociation phases of the binding response versus time curves 
(Figure 14-10 steps 5 and 6) were displayed in real time during the experiment. 
Excluding the MBP protein and full Tat chimera, the association phase (step 5) for the 
five remaining samples of CycT1m-Tat chimera (4.0 µM, 2.0 µM, 1.0 µM, 0.5 µM, and 
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0.25 µM) were fit to a 1:1 model. Using ForteBio Data Analysis 6.4 software program 
the 1:1 model was selected with settings for global fit and Rmax unlinked by sensor. As 
seen visually in Figure 14-11, the data did not fit perfectly to the 1:1 model (the fit is 
improved by invoking a second binding class – see next paragraph). The regression 
analysis of the 1:1 model to the data in Figure 14-12 for the five concentrations of 
CycT1m-Tat gave an R2 value of 0.98 (Figure 14-12). 
 
13.13. Association 2:1 Model Fit 
The same data for the association phase of CycT1m-Tat samples fit well to a 2:1 model 
(Figure 14-13). A linear regression analysis for the response kobs1 was plotted for all data 
points with an R2 value of 0.99 (Figure 14-14). The slope of the trend line for 
concentration (nM) versus response is equal to ka, the on rate for the primary binding 
event, which accounted for approximately 88% of the response. For the predominant high 
affinity species the on rate ka is equal to 2.0 x 10
-5 nM-1 s-1 or 2.0 x 104 M-1 s-1. 
 
In the linear regression analysis kobs2 for the second binding event, a minor fraction of the 
response, a single data point was removed as an artifact of the software calculations 
(Figure 14-15). From the remaining data points the R2 value was 0.92 and from the slope 
of the trend line ka is equal to 1.0 x 10
-6 nM-1 s-1 or 1.0 x 103 M-1 s-1. 
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13.14. Dissociation Fit 1:1 Model 
The majority of data for the dissociation step (step 6) fit well to a 1:1 model. The first 
200 seconds indicate the presence of a second species which is fast dissociating and did 
not fit well to the 1:1 model. These first 200 seconds were excluded from the 1:1 model 
fit. The predominant species, however, was slow to dissociate. Only approximately 0.1 
nm of the approximately 0.8 nm total response or 12% was attributable to a fast 
dissociation by the presence of a second species (Figure 14-16). The average off rate, kd, 
for the five cleaved Tat samples was 8.8±0.6 x 10-4 s-1 with a R2 > 0.99.  
 
13.15. Equilibrium Dissociation Constant 
The equilibrium dissociation constant KD is a measure of the strength of the binding 
interaction between two molecules and is defined as the ratio of the off rate to the on rate 
of the interaction: 
 
 
 
where kd is the off rate of the interaction in units of s
-1, and ka is the on rate of the 
interaction in units M-1 s-1.  
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Using the ka = 2.0x10
4 M-1 s-1 for the 2:1 model predominant interaction, and kd = 
8.8x10-4 s-1, the KD for the interaction between CycT1m-Tat and the TAR 27-nt stem-
loop is 44 x 10-9 M (44 nM) indicating a high affinity for the protein-RNA interaction. 
 
For these studies, the CycT1m-Tat protein was not purified to absolute homogeneity and 
it takes time to concentrate the protein with appropriate buffer exchanges, during which 
time one might expect a small amount of degradation. There could also be a small 
amount of the full-length chimera present. Thus, a leading explanation for the Octet 
results is that 85-90% of the CycT1m-Tat fusion binds TAR RNA with low nanomolar 
affinity, exhibiting fast association and slow dissociation (ka ~ 210
4 M-1 s-1 and kd ~ 9 
10-4 s-1), while related impurities having reduced affinity for TAR RNA exhibit slower 
association and faster dissociation (ka ~ 110
4 M-1 s-1 and a larger kd [value not 
determined] and accounting for ~12% of the Octet response). 
 
13.16. Biolayer Interferometry Discussion: Non-Ideal Behavior 
For the sake of completion, it is useful to formally consider the effects that may occur in 
Biolayer interferometry due to imperfect samples. Non-ideal behavior is typically 
observed under three circumstances: (1) heterogeneity of the ligand (2) heterogeneity of 
the analyte (3) mass transport limitation (4) interactions more complicated than a simple 
1:1 binding ratio (ForteBio Product Literature). 
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13.17.  Heterogeneity of the Ligand or Analyte 
From Figure 14-10 step 5 the five Tat samples appear to reach equilibrium in the 
association phase, but fail to reach a complete dissociation in step 6. Fitting the data to a 
1:1 model demonstrates that a small portion of the dissociation is fast in nature and 
deviates substantially from the predominant interaction that dissociates slowly. This may 
indicate heterogeneity of the ligand, the analyte, or possibly both.  
 
Heterogeneity of the RNA ligand can result from a variety of causes, among them: 
artifacts related to the surface chemistry, dimerization, contamination, and degradation. 
Similarly, heterogeneity of the analyte can be caused by a multitude of factors such as: 
impurities in the sample, incomplete or improper folding of some portion of the analyte, 
contamination, the absence of cofactors, “bridging” (binding more than one ligand 
molecule), and degradation. Determining the factors or combination of factors 
responsible for the observed heterogeneity could require many additional assays, and 
unless the non-ideal behavior is resolved it is possible that the source of the heterogeneity 
may remain obscure.  
 
13.18. Non-ideal Behavior and Mass Transport Limitation 
Non-ideal behavior in the association phase is often associated with a mass transport 
limitation. Since the association phase of the experiment did reach equilibrium a mass 
transport limitation is unlikely to be the cause of the observed deviation from ideal 
behavior.  
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13.19. Non-ideal Behavior with Multiple Binding Sites 
Non-ideal behavior is frequently observed when binding events have a stoichiometry 
more complicated than a simple one to one ratio. Since the Tat chimera has two zinc 
fingers which purportedly bind at two separate regions of the TAR stem-loop (the apical 
loop and the tri-nucleotide bulge) it is possible that the binding of the two zinc fingers 
may contribute in some manner, as yet unanticipated, to the observed analyte 
heterogeneity although in theory, binding of either zinc finger individually should 
produce a similar response (personal conversation with Dr. Thomas Duncan). Moreover, 
partially or incorrectly folded proteins may be present, and the zinc co-factor may or may 
not be present in all zinc finger sites. Either of these conditions present in some fraction 
of the analyte solution has the potential to inhibit, mitigate, or even to enhance binding of 
the protein resulting in the observance of heterogeneous behavior. Finally, several of 
these conditions could be contributing simultaneously to the observed non-ideal behavior.  
 
13.20. Reversibility of the Binding Interaction 
Since the dissociation step of the experiment did not continue longer than 1800 seconds, 
and complete dissociation was not observed it is not possible to confirm that the 
interaction is reversible. Additional experiments with such additives as EDTA (to remove 
the zinc ions from the zinc fingers), or mutation experiments could be employed to 
disrupt the binding interaction and demonstrate reversibility in future work. 
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Figure 13-1 Surface plasmon resonance Kretchmann configuration 
The surface plasmon resonance (SPR) Kretchmann configuration is the standard design 
for most SPR instruments. A soluble analyte solution is delivered to the chip surface 
through a flow cell. The interaction between the ligand affixed to the chip surface and the 
analyte in solution is detected by an increase in mass at the surface that corresponds to a 
shift in the angle of the reflected light. This shift is detected and displayed in real time on 
the system’s computer monitor. Reprinted from: Methods in Enzymology, vol. 399 
Hartmann-Petersen, R., and Gordon, C., Pages 164-177, Copyright 2005 (158) with 
permission from R. Hartmann-Petersen. 
 - 178 - 
 
 
Figure 13-2 Adsorption profile for SPR 
A diagram of the adsorption profile for the surface plasmon resonance (SPR) assay. A 
shift in the angle of reflection is produced when an analyte in solution binds to a ligand 
affixed to the chip surface. The shift in the angle of reflection is detected and plotted as 
response versus time in a real time display on the system monitor. Reprinted from: 
Methods in Enzymology, vol. 399 Hartmann-Petersen, R., and Gordon, C., Pages 164-
177, Copyright 2005 (158) with permission from R. Hartmann-Petersen. 
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Figure 13-3 A surface plasmon resonance sensorgram. 
A surface plasmon resonance sensorgram in which real time data is plotted as response 
versus time and displayed on the system monitor. Reprinted from: Methods in 
Enzymology, vol. 399 Hartmann-Petersen, R., and Gordon, C., Pages 164-177, Copyright 
2005 (158) with permission from R. Hartmann-Petersen. 
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Figure 13-4 Biolayer interferometry sensor tip 
A diagram of a biolayer interferometry glass fiber-based sensor tip. White light traveling 
down the tip is reflected from two points at the tip surface. Changes in the wave patterns 
of the reflected light are used to detect binding at the tip surface. Reprinted with 
permission from ForteBio. 
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Figure 13-5 Constructive, partially constructive and destructive interference  
Constructive, partially constructive and destructive interference patterns of white light. 
Reprinted with permission from ForteBio. 
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Figure 13-6 Interference captured by the spectrometer 
Interference captured by the spectrometer reported as relative intensity in nanometers. 
Reflected wavelengths are altered by binding at the surface and the thickness of the 
optical layer. Reprinted with permission from ForteBio. 
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Figure 13-7 Nonspecific binding to Octet biosensor tips 
Assessment of the nonspecific binding of CycT1m-Tat to the streptavidin biosensor tips. 
Raw aligned data demonstrates a low level of Tat chimera nonspecifically bound to the 
streptavidin biosensor tips in the absence of TAR RNA. From left to right:  
A (dark blue) – Positive control - 5 uM TAR RNA with 1.5 M cleaved Tat,  
E (yellow) – No RNA bound to sensor with 1.5 uM CycT1m-Tat,   
F (violet) – No RNA bound to sensor with 0.5 uM CycT1m-Tat,  
G (turquoise) – No RNA bound to sensor with 0.2 uM cleaved Tat,  
H (red-orange) – Negative control - No RNA bound to sensor and buffer only (No 
Protein) analyte solution
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Figure 13-8 Raw aligned nonspecific protein response 
Raw aligned nonspecific protein response for streptavidin biosensor tips in the absence of 
the RNA ligand:  
E (yellow) – No RNA 1.5 uM Cleaved Tat,  
H (red-orange) – No protein No RNA. 
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Figure 13-9 The experimental set-up of Octet Red 96 well plate 
A diagram of the experimental set-up of Octet Red 96 well plate arrangement for the 
loading of samples in Table 14-1.  
 
 
 
 
 
 
 
  
 - 186 - 
 
 
 
 
Table 3 The experimental set up for Octet 96 well plate 
The experimental set up for Octet 96 well plate from left to right:  1 - buffer at pH 7.4 
containing 20 mM Tris, 0.2 M NaCl, 10 uM ZnCl2, 0.02% Sodium Azide, 5 mM BME, 
and 0.5 mg/ml fat free bovine serum albumin (BSA),  2 – wild type TAR 27-nt RNA at 
0.5 µM in same buffer as  1,  3 – buffer as in  1,  4 – various concentrations of 
recombinant proteins,  5 – buffer as in  1, and 3. 
 
 
 
 
  
Experiement Set Up
1 2 3 4 5
A Buffer RNA 0.5 uM Buffer FL Chimera 4 uM Buffer
B Buffer RNA 0.5 uM Buffer MBP 4uM Buffer
C Buffer RNA 0.5 uM Buffer Cleaved Tat 4 uM Buffer
D Buffer RNA 0.5 uM Buffer Cleaved Tat 2 uM Buffer
E Buffer RNA 0.5 uM Buffer Cleaved Tat 1 uM Buffer
F Buffer RNA 0.5 uM Buffer Cleaved Tat 0.5 uM Buffer
G Buffer RNA 0.5 uM Buffer Cleaved Tat 0.25 uM Buffer
H Buffer RNA 0.5 uM Buffer NO PROTEIN Control Buffer
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Figure 13-10 ForteBio Octet Sensogram for TAR stem-loop bound to Tat chimera. 
A ForteBio Octet Sensogram for the TAR RNA stem-loop bound to the full Tat chimera, 
CycT1m-Tat, and MBP. Steps 1 through 6 are delineated by dashed red lines. Samples 
from left to right:  
A7 (green) – full chimera 4 µM,  B7 (pink) – MBP 4 µM,  
C7 (yellow) – CycT1m-Tat 4 µM,  D7 (purple) – CycT1m-Tat 2 µM,  
E7 (dingy green) - CycT1m-Tat 1 µM,  F7 (black) – CycT1m-Tat 0.5 µM,  
G7 (red) – CycT1m-Tat 0.25 µM,  H7 (blue) – negative control (no protein) 
  
1 2 3 4 5 6 
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Figure 13-11 Association phase 1:1 data fit 
The association phase data for TAR [0.5 µM] RNA bound to CycT1m-Tat at 4, 2, 1, 0.5, 
and 0.25 µM fit to a 1:1 model. The blue line is the actual binding data and indicates a 
response in proportion to concentration. The red line is the curve fitting model. The 
actual data deviated from the 1:1 model considerably indicating a multiphasic response 
and the possibility of analyte heterogeneity.  
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Figure 13-12 Association phase 1:1 data fit regression analysis. 
The association phase 1:1 data fit regression analysis for the TAR-Tat interaction in 
Figure 14-11. The slope of the trend line for concentration versus kobs is ka = 1.0 x 10
-5 
nM-1 s-1 the on rate of the reaction. 
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Figure 13-13 Association phase 2:1 data fit. 
The association phase data for TAR [0.5 µM] RNA bound to CycT1m-Tat at 4, 2, 1, 0.5, 
and 0.25 µM fit to a 2:1 model. The blue line is the actual binding data and indicates a 
response in proportion to concentration. The red line is the curve fitting model. The 
actual data fit well to a 2:1 model consistent with predictions for the multiphasic response 
and analyte heterogeneity.  
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Figure 13-14 – Association phase 2:1 data fit regression analysis 
The Association phase 2:1 data fit regression analysis for the predominant binding event 
kobs1. The slope of the trend line for concentration versus k observed (1/s) is ka = 2.0 x 10
-
5 nM-1 s-1 the on rate of the primary reaction. 
 
 
 
y = 2E-05x - 0.001
R2 = 0.9915
0.00E+00
1.00E-02
2.00E-02
3.00E-02
4.00E-02
5.00E-02
6.00E-02
7.00E-02
8.00E-02
0 1000 2000 3000 4000 5000
Concentration (nM)
k
 o
b
s
e
rv
e
d
 (
1
/s
)
K observed 1
Linear (K observed 1)
 - 192 - 
 
 
Figure 13-15 Association phase 2:1 data fit regression analysis 
The Association phase 2:1 data fit regression analysis for the minor binding event kobs2. 
The slope of the trend line for concentration versus k observed (1/s) is ka = 1.0 x 10
-6 nM-
1 s-1 the on rate of the reaction. 
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Figure 13-16 Dissociation 1:1 fit minus 
The dissociation phase for TAR [0.5 µM] RNA bound to CycT1m-Tat at 4, 2, 1, 0.5, and 
0.25 µM fit to a 1:1 model. The first 200 seconds have been omitted from the curve 
fitting to remove the data for the fast dissociating species. Less than 15% of the response 
appears to be attributable to the low affinity fast dissociating species. 
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Table 4 Dissociation phase responses 
A table of Octet dissociation data indicating the off rates kd for the dissociation step of 
TAR RNA [0.5 µM] bound to five concentrations of CycT1m-Tat (4.0 µM, 2.0 µM, 1.0 
µM, 0.5 µM, and 0.25 µM). The average kd was 8.8 ±0.6 x 10
-4 s-1. 
 
 
Sensor  Sensor Type 
Sample 
ID 
Conc. 
(nM) Response kdis(1/s) 
kdis 
Error 
Dissoc 
X^2 
Dissoc 
R^2 
C7 
SA 
(Streptavidin) 
Cleaved 
TAT 4000 3.838 8.58E-04 
3.62E-
06 0.026 0.999 
D7 
SA 
(Streptavidin) 
Cleaved 
TAT 2000 3.988 9.43E-04 
4.28E-
06 0.045 0.999 
E7 
SA 
(Streptavidin) 
Cleaved 
TAT 1000 3.851 9.64E-04 
4.29E-
06 0.046 0.999 
F7 
SA 
(Streptavidin) 
Cleaved 
TAT 500 3.273 8.37E-04 
4.09E-
06 0.031 0.999 
G7 
SA 
(Streptavidin) 
Cleaved 
TAT 250 2.193 7.98E-04 
3.59E-
06 0.014 0.999 
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Chapter 14 Labeling the Tat Chimera with Stable Isotopes for 
NMR  
 
As discussed in Chapter 3, the first NMR structures of a TAR-arginine complex were 
reported by Puglisi, Tan et al. 1992. The structure of TAR alone was reported by Aboul-
ela, Karn et al. in 1995, and a 24 residue Tat peptide bound to TAR was reported by Long 
and Crothers in 1999 (21,22,40,162). However, these structures did not consider or 
contain any portion of the human Cyclin T1 protein, the essential TAR interacting 
component of PTEF-b. At present there is still no structural NMR data of the purportedly 
essential 261 Cys residue of Cyclin T1 that is believed to complete zinc finger 2 in 
concert with three additional cysteine residues Cys22, Cys25, and Cys27 of Tat (Figure 
1-5) (15) , and the active domain of Tat remains obscure. 
 
14.1. Structural Detail of the Tat-TAR Interaction 
Initially, the Tat-TAR interaction was predicted to occur at the bulge region of the TAR 
stem-loop where an arginine rich region of Tat has been shown to interact (21). However, 
Garber et al. 1998, and Wei et al. 1998 found, by Western blot, that an additional binding 
interaction between zinc finger 2 and the apical stem-loop contributed substantially to the 
high affinity of the interaction (15,17). While the crystal structure solved by Tahirov and 
Babayeva in 2010 of PTEF-b and HIV-1 Tat was groundbreaking the reported structure 
was disordered in this crucial region of hCycT1 and also failed to elucidate the active 
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domain of Tat (7). The opportunity then remains to gain insight into this important region 
from 2D 1H-15N HSQC spectra that could either support or refute the findings of Garber 
and Wei, while providing structural detail to facilitate rational drug design. 
 
Structural information for the folded state of a protein is reported by 2D 1H-15N HSQC 
NMR in the form the dispersion pattern, intensity, and number of cross peaks observed, 
with most of the cross peaks corresponding to the amide 1H-15N nuclei of individual 
residues in the backbone of the protein. The pattern of cross peaks then provides a 
diagnostic fingerprint specific to the protein of interest (163). These peaks can then be 
assigned to begin the process of determining the structure of the protein. 
 
14.2. Determining the Suitability of the Tat-TAR Interaction for NMR 
The results of biophysical techniques discussed previously indicated that recombinant 
CycT1m-Tat was comprised of the appropriate sequence and molecular weight, and that 
the unlabeled protein could be sufficiently purified and concentrated for structural work. 
When expressed in Turbo Broth™ a concentration approaching the requisite 0.6 ml of 0.2 
mM protein for 2D 1H-15N HSQC NMR was obtained. However, it is still possible that 
heterogeneity of the sample could prove problematic in structural experiments, for 
example: by the presence of more cross peaks than residues in the HSQC NMR spectrum. 
In addition, the presence of multiple domains, as is the case with Tat, has been cited as a 
potential impediment to NMR structural determination (93,164).  
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Most of the structures solved by 2D 1H-15N HSQC NMR are less than 30 kDa (164). 
Proteins larger than 30 kDa may be candidates for the more recently developed TROSY 
technique (165). In general, proteins with multiple domains tend to be more troublesome 
subjects for structural study due to difficulties with expression in E. coli, conformational 
heterogeneity, and the frequently large size of these proteins (93). Initially however, the 
wild type TAR RNA at 10.2 kDa, and CycT1m-Tat 17.5 kDa appear to be within the 
acceptable range of size necessary for structural study. Although the CycT1m-Tat 
chimera does exceed, by four residues, the approximate 150 residue recommended limit 
cited by Edwards, Arrowsmith et al. 2000. It is most likely that fully 15N,13C-labeled 
protein and RNA will be used to determine the structure by combination of 2D, 3D, and 
4D NMR experiments as was done for determining the structure of the complex between 
the HIV-1 nucleocapsid protein and the SL3 RNA stem-loop (166).  
 
14.3. The Expression of 15N Labeled Proteins for NMR 
The first step toward obtaining 2D 1H-15N HSQC NMR structural data for CycT1m-Tat is 
the production of recombinant protein which is uniformly 15N-labeled. Typically an M9 
minimal media formula (Appendix 19) containing the 15N isotope in the form of 15NH4Cl 
is used to grow the culture and all other sources of nitrogen are removed thereby forcing 
the incorporation of heavy nitrogen. In addition to 15NH4Cl, trace metals, and vitamins 
are added to the media to aid the bacterial growth under the sub-optimal and taxing 
growth conditions afforded by the M9 minimal media. Frequently, the target protein can 
be otherwise expressed with the same protocol as would be used for rich media, but a 
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lower yield of the recombinant protein may be reasonably predicted (rich media contain 
amino acids with 100% 14N, which would dilute 15N-crosspeaks to an extent that makes 
the HSQC spectrum useless). 
 
Since the amount of protein required for NMR experiments is relatively large, 
optimization of the growth conditions, cell density, and protein expression is highly 
recommended. When expressing 15N labeled proteins, optimization of the growth 
conditions is limited considerably by the use of minimal media. High cell density cultures 
can be employed to improve protein yield, but efforts in this regard are often hampered 
by resulting plasmid loss, reduced pH, and low levels of dissolved oxygen in the growth 
medium (165). One attractive approach to increasing the yield of the labeled protein 
without altering the medium, or increasing the culture density is to perform a double 
colony selection of the expression strain (165). The double colony selection method of 
selection can be used for normal or high density cell cultures. 
 
14.4. Double Colony Selection 
It is always advisable when embarking on a recombinant protein expression to begin with 
a fresh transformation of the plasmid of interest into its intended host. Plasmid loss 
occurs over time and during storage due to ampicillin instability and will reduce the 
overall yield of recombinant protein expression. In addition to a fresh transformation, it is 
also advisable to screen the transformed colonies as genetic differences will cause some 
colonies to demonstrate a higher level of target protein production than other colonies. 
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Exploiting this fact, in a double colony selection several colonies are selected from a 
fresh transformation plate and separately screened for the highest level of protein 
expression and, where possible, the lowest level of background expression. The colony 
demonstrating the most efficient expression in this first round is then grown and plated, 
and several colonies are selected from this second plate and separately screened in a 
second round of selection. The colony demonstrating the most efficient expression in the 
second round of selection is then employed in a large scale expression and purification 
(165). In this way it is possible to substantially improve protein expression yield and 
purification without otherwise altering the protocol. 
 
14.5. Method 
Following the work of Sivashanmugam, Murray et al. 2009 with minor modifications, a 
double colony selection was performed in accordance with their published protocol. A 
fresh transformation of the pDEST His-MBP-hCycT1-Tat plasmid into Rosetta Gami B 
(Novagen) was performed (Appendix 18). Four colonies were selected from the 
transformation plate and grown overnight to an OD600 of approximately 2-3 in 2 ml of LB 
media with 100 ug/ml of ampicillin and 35 ug/ml of chloramphenicol at 37 °C. The 
culture was then spun down, the cell pellet was resuspended in 5 ml of M9 minimal 
media (Appendix 19) with 100 µg/ml of ampicillin and 35 µg/ml of chloramphenicol to 
an OD600 = 0.1, and the culture was grown to OD600 = 1.0 at 28 °C. Then the culture was 
induced with a final concentration of 1 mM IPTG, and grown overnight at 28 °C. 
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14.6. Results: Protein Expression in Minimal Media 
Predictably, protein expression in minimal media was reduced when compared with 
expression levels in rich media. Despite the lower overall expression however, the third 
colony from the first round of selection demonstrated the highest level of expression from 
among the four colonies selected (Figure 15-1 lane 3). A 2 ml culture of LB with 100 
ug/ml ampicillin and 35 µg/ml of chloramphenicol was then inoculated with colony three 
and grown overnight. An aliquot of 100 µl of the overnight culture was plated on LB with 
100 µg/ml of ampicillin and 35 µg/ml of chloramphenicol, and four colonies were 
selected from the plate after overnight incubation at 37 °C. The expression protocol was 
repeated as for the first round of selection above and the expression levels of all colonies 
are compared in Figure 15-1. After two rounds of selection the fourth colony (Figure 15-
1 lane 8 - DCS 3.4) from the second round demonstrated the highest level expression of 
the target and the lowest level of background expression of all other cellular proteins. A 
low level of background expression is desirable when attempting to achieve a high degree 
of purity after chromatography. Hence, colony 3.4 was selected for 15N labeled protein 
expression. 
 
To assess the effects of IPTG concentration on protein expression a comparison was 
made of the effects of increasing concentrations of IPTG from 0.2 mM to 1.0 mM on 
both the original glycerol stock Rosetta Gami B strain (RGB), and the DCS 3.4 freshly 
transformed high expression mutant. The culture was incubated for 49 hours at 37°C and 
reached an OD600 of 0.5 for RGB, and 0.3 for DCS. At 20 minutes prior to induction 1% 
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ethanol was added to the minimal media with 100 µg/ml ampicillin and 35 µg/ml of 
chloramphenicol and the culture was grown for 42 hours at 28°C. 
 
Comparing the original glycerol stocks of the pDEST HisMBP-hCycT1-Tat plasmid in 
Rosetta Gami B to the DCS 3.4 mutant the increased expression of the recombinant 
protein by the DCS 3.4 mutant is clear (Figure 15-2). For both the original transformed 
colony and the DCS 3.4 1.0 mM IPTG produced the highest level of recombinant protein 
production (Figure 15-2 lane 8 and lane 15) when compared to IPTG concentrations of 
0.2 mM, 0.4 mM, 0.6 mM, and 0.8 mM. Notably, the DCS mutant produced considerably 
more protein despite a lower OD600 at induction. 
 
Increasing the concentration of IPTG above 1.0 mM did not appear to further enhance 
recombinant protein expression (Figure 15-3), nor did decreasing the temperature post-
induction to 14°C improve yield. In fact, at 14°C the recombinant protein expression was 
decreased markedly. While decreasing the post-induction incubation temperature does 
tend enhance protein solubility, purportedly by allowing increased time to fold, in this 
case the detrimental effects of the lower growth rate at 14°C eclipsed any gain in yield of 
the soluble form.  
 
Attempts to improve the expression level of the recombinant protein further by 
transferring high cell density starter cultures from rich media to minimal media prior to 
induction were also unsuccessful, despite careful attention to the maintenance of a neutral 
pH. The cultures required an extraordinarily lengthy incubation to reach an adequate 
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OD600 for induction yet increasing the incubation time after induction from 42 hours to 88 
hours actually appeared to reduce the level of expressed protein rather than enhance it 
both at 28°C and at 14°C (Figure 15-4). This observation is likely due to degradation, and 
the buildup of toxic waste by-products that accumulated during the lengthy incubation.   
 
14.7. Protein Expression in BioExpress Cell Growth Media 
Since most of the more commonly employed techniques for improving recombinant 
protein expression levels in minimal media had been exhausted it became apparent that a 
nutrient deficiency could possibly be causing the low level of expression observed for the 
recombinant chimera in minimal media. Researchers have observed that some proteins 
are particularly “stubborn” or do not express well in minimal media (University of 
Connecticut Health Center). In these cases The Gregory P. Mullen NMR Structural 
Biology Facility at the University of Connecticut Health Center has succeeded at 
increasing recombinant expression levels of 15N labeled protein with the use of 
BioExpress cell growth media (Cambridge Isotope Laboratories, Inc. Andover, MA). 
However, the downside to the use of BioExpress cell growth media is the high cost of 
this media when compared to traditional formulas. Some researchers have circumvented 
this drawback, and found that at little as 10% BioExpress formula in the cell growth 
media can substantially improve the expression of labeled protein for difficult targets 
(167). 
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Trials with 100% BioExpress cell growth media were conducted by inoculating a 25 ml 
culture of BioExpress cell growth media with lightly spun down cells from 2 ml of an 
overnight culture of either freshly transformed RGB cells or the DCS mutant in LB with 
100 ug/ml ampicillin and 35 ug/ml of chloramphenicol. After 4 ½ hours of growth the 
cultures were induced at OD600 ~0.7 with 1 mM IPTG. Samples of the post-induction 
culture were taken after 4 hours and after 18 hours. The target protein expression levels 
of samples of the DCS mutant in BioExpress cell growth media were compared to the 
target protein expression levels of the RGB strain in LB, Turbo, and BioExpress cell 
growth media (Figure 15-5). 
 
The expression levels of the 15N labeled chimera in the DCS mutant (Figure 15-5 lanes 
12 and 13) were comparable to the expression levels of unlabeled protein expressed by 
the RGB strain in rich media (Figure 15-5 lanes 3,4, 6,7,9 and 10). Of note is the clear 
decrease in target protein expression level observed for the DCS mutant in BioExpress 
cell growth media after the extended post-induction incubation time of 18 hours when 
compared to the expression level after 4 hours (Figure 15-5 lane 13). While a similar 
decrease in target protein expression level is apparent for the RGB strain in LB after 18 
hours when compared to the expression level after 4 hours (Figure 15-5 lanes 3, and 4), 
when expressed in Turbo Media™ the expression level was actually increased after 18 
hours. For the RGB strain in BioExpress cell growth media the difference in expression 
level between the two time intervals is barely detectible (Figure 15-5 lanes 9 and10).  
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Based on these results, and the yield of the cleaved recombinant protein achieved for 
unlabeled cultures, it is reasonable to assume that the 2 mg/ml 15N labeled sample 
concentration required for NMR HSQC would be obtainable by expressing a 1 or 2 liter 
culture of the DCS mutant in BioExpress cell growth media for approximately 4 or 
slightly more hours. While typically protein samples might be concentrated for NMR 
structural study by such methods as the use of concentrating spin columns, CycT1m-Tat 
did not concentrate well by this method and often appeared to either precipitate or bind to 
the column material. This loss of protein was evidenced by a concentration which 
reduced both counter intuitively and unpredictably after multiple rounds of attempted 
concentration. The decrease in concentration was measured by UV detector at 280 nM 
with a NanoDrop spectrophotometer (Thermo Scientific Wilmington, DE).  
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Figure 14-1 Double colony selection and expression in M9 minimal media 
The SDS PAGE comparison of the double colony selection (DCS) and expression in M9 
minimal media for the selection of a colony expressing high levels of the full Tat 
chimera. The four colonies from the first round of selection appear in s 1-4. The third 
colony was selected ( 3) as the highest expressing colony from the first round and then 
employed in a second round of selection with colonies from the second round appearing 
in s 5-8. From left to right:  
Round 1:   
1 – colony 1  2 – colony 2 3 – colony 3   4 – colony 4  
Round 2:    
5 – colony 3.1   6 – colony 3.2   7 – colony 3.3   8 – colony 3.4  
1      2     3      4     5      6      7      8 
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Figure 14-2 Minimal media expression comparison 
The SDS PAGE comparison of minimal media expression of the full Tat chimera in the 
wild type and double colony selection (DCS) mutant (3.4) with variable IPTG 
concentrations after 42 hours of post-induction growth at 28°C. From left to right:   
1 – ladder,              2 – uninduced wild type (wt),                3 – induced wt    0 mM IPTG   
4 – induced wt    0.2 mM IPTG 5 – induced wt    0.4 mM IPTG   
6 – induced wt    0.6 mM IPTG 7 – induced wt    0.8 mM IPTG   
8 – induced wt    1.0 mM IPTG           9 – uninduced DCS colony 3.4   
10 – induced DCS 3.4       0 mM IPTG 11 – induced DCS 3.4    0.2 mM IPTG   
12 - induced DCS         0.4 mM IPTG 13 - induced DCS 3.4     0.6 mM IPTG  
14 - induced DCS 3.4    0.8 mM IPTG  15 – induced DCS 3.4    1.0 mM IPTG 
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Figure 14-3 An IPTG and temperature comparison for the DCS (42 hours) 
An SDS PAGE IPTG induction concentration and post-induction temperature 
comparison for the double colony selection (DCS) mutant expression of the full Tat 
chimera in minimal media with increasing concentration of IPTG 1.0-5.0 mM at both 
28°C and 14°C for 42 hours post-induction. From left to right:   
1 – ladder 2 – uninduced 3 – 1.0 mM IPTG 28°C,   
4 - 2.0 mM IPTG 28°C 5 – 3.0 mM IPTG 28°C 6 - 4.0 mM IPTG 28°C,   
7 – 5.0 mM IPTG 28°C 8 – 1.0 mM IPTG 14°C 9 – 2.0 mM IPTG 14°C,   
10 - 3.0 mM IPTG 14°C 11 - 4.0 mM IPTG 14°C 12 - 5.0 mM IPTG 14°C 
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Figure 14-4 An IPTG and temperature comparison for the DCS (88 hours) 
An SDS PAGE IPTG induction concentration and post-induction temperature 
comparison for the double colony selection (DCS) mutant expression of the full Tat 
chimera in minimal media with increasing concentration of IPTG 1.0-5.0 mM at both 
28°C and 14°C for 88 hours post-induction. From left to right:   
1 – ladder 2 – uninduced 3 – 1.0 mM IPTG 28°C,   
4 - 2.0 mM IPTG 28°C 5 – 3.0 mM IPTG 28°C 6 - 4.0 mM IPTG 28°C,   
7 – 5.0 mM IPTG 28°C 8 – 1.0 mM IPTG 14°C 9 – 2.0 mM IPTG 14°C,   
10 - 3.0 mM IPTG 14°C 11 - 4.0 mM IPTG 14°C 12 - 5.0 mM IPTG 14°C 
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Figure 14-5 Media comparison for expression of the full Tat chimera 
The SDS PAGE media comparison of protein expression of the full Tat chimera from 
Rosetta Gami B (RGB) wild type and double colony selection mutant (DCS) in LB media, Turbo 
Media™, and BioExpress media. All cultures were induced at OD600 = 0.7 with 1 mM IPTG and 
expressed for 4 hours at 28°C. From left to right:   
1 – ladder                         2 – uninduced RGB in LB                  3 – induced RGB in LB, 4 hrs   
4 - induced RGB in LB, 18 hrs 5 – uninduced RGB in Turbo Media   
6 – induced RGB in Turbo Media, 4 hrs 7 – induced RGB in Turbo Media, 18 hrs   
8 – uninduced RGB in BioExpress 9 – induced RGB in BioExpress, 4 hrs   
10 - induced RGB in BioExpress, 18 hrs 11 – uninduced DCS in BioExpress   
12 – induced DCS in BioExpress, 4 hrs 13 – induced DCS in BioExpress, 18 hrs 
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Chapter 15 Conclusions and Suggestions for Further Work 
The expression and purification of CycT1m-Tat, at a concentration sufficient for 
structural study, proved to be considerably more challenging than was initially 
anticipated. The sheer number of options available for modification of expression and 
purification protocols requires researchers not working with high throughput screening 
methods to make a series of educated guesses in order to achieve reasonable results in an 
efficient manner. While such “best guess” conditions may prove to be sufficient to 
produce adequate protein concentration and purity for a particular downstream 
application it is unlikely that these will be the optimal conditions for the chosen target. If 
a substantial quantity of the chimera is to be produced frequently the expression and 
purification protocols presented in this work should continue to be tested and optimized 
to the greatest extent necessary for the intended application. 
 
In addition to optimizing expression and purification, the activity of the 257-280 
hCycT1-Tat chimera must be assessed. The high affinity binding observed between the 
re-engineered chimera and TAR is promising, especially with respect to is application 
toward the production of a diagnostic tool for drug discovery. However, assessing the 
ability of this chimera to produce transactivation is essential. Moreover, future mutation 
and deletion experiments modifying key residues of the zinc fingers as well as 
modifications to arginine residues suspected of playing important stabilizing roles should 
lend much to our understanding of the key features necessary for recognition, binding, 
and transactivation 
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In this section suggestions will be made for: future improvement to the expression and 
purification of the chimera, activity assays, confirming the zinc content of the chimera, 
confirming the folded state of the chimera, mutation and deletion experiments, and for 
the future structure elucidation of the Cyclin T1-Tat-TAR interaction by NMR 
 
15.1. Alternative Expression Strains 
 
An educated guess was made when selecting the expression strain Rosetta Gami B for the 
recombinant production of the MBP-His6-CycT1m-Tat chimera. The hope initially was 
not only that the rare codons would be accommodated by Rosetta Gami B but that target 
solubility might be enhanced by the “tunable” feature of the strain which permits the 
modulation of expression levels with induction by IPTG. Since no increase in expression 
level was observed when the concentration of IPTG was varied this feature appears 
unnecessary for expression of the MBP-His6-CycT1m-Tat chimera.  
 
An additional feature of the Rosetta Gami B expression strain is the formation of 
disulfide bonds in the cytoplasm as opposed to in the periplasm of the cell. It is possible 
that the folding of the target protein might in some way be improved by this feature, but 
no information could be found on the effect of this feature on zinc finger proteins. It is 
also conceivable, however, that this feature could have no effect or could even hinder the 
expression of zinc finger proteins which are sensitive to the redox state of the cell (168).  
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The choice of this strain imposed limitations on the expression of the Tat chimera in that 
it is not possible to use the Rosetta Gami B strain with an auto-induction media. A 
comparison could be made between expression and purification in the Rosetta Gami B 
strain and the Rosetta strain without the “Tuner” lacZY mutation. If a similar yield is 
obtained expression in auto-induction media may improve yield and facilitate expression 
by optimizing the induction. Furthermore, it is possible that other strains not considered 
here may prove superior to the Rosetta strains in the expression of the Tat chimera. If 
large scale expression of the Tat chimera is undertaken it would be worthwhile to 
evaluate the performance of several other strains. Ideally, such an evaluation would be 
done in a high-throughput manner. 
 
15.2. Alternate Solubility Enhancing Fusion Tags 
The MBP fusion tag is highly effective at enhancing the solubility of many recombinant 
proteins. However, from the perspective of structural study, MBP is large (43 kDa) and 
likely to interfere with many downstream applications; thus its removal is generally 
required. As has been demonstrated previously in this work, removal of the tag can be 
time consuming and difficult and will inevitably result in a decrease in the final yield. In 
addition, removing the fusion tag from less tractable targets frequently and predictably 
renders the target insoluble once again. For these reasons it might be advantageous to 
explore other smaller but similarly effective fusion tags such as Small Ubiquitin-like 
Modifier (SUMO) (12 kDa) which is available with a His6 modification for affinity 
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purification. With a fusion tag of this size it may be possible to obtain Tat chimera 
structural data by NMR while circumventing removal of the fusion tag entirely. 
 
15.3. Optimizing Reduction of the Tat Chimera 
Reducing agents used in the expression of the Tat chimera have been discussed at length 
previously. However, in the literature reviewed there was a conspicuous absence of 
discussion on the determination of the optimal concentration of reducing agent employed. 
While insufficient reduction may permit aberrant disulfide bond formation, potentially 
leading to aggregation and insolubility, conversely it is also possible that the excessive 
use of reducing agents may alter the secondary structure of the protein and confound 
downstream applications and structural determination. Therefore, it would be worthwhile 
to examine the effects of a series of reducing agents and concentrations on the binding 
affinity of the Tat chimera for the HIV-1 TAR RNA. 
 
15.4. Confirming the Presence of Zinc 
Since the native structure of the Tat chimera is dependent on the presence of the two zinc 
atoms complexed in the zinc fingers of the chimera it is necessary to confirm the 
presence of zinc in the purified recombinant protein. Several attempts were made to 
determine the concentration of zinc in the purified samples by a direct spectrophotometric 
method. Since Zn2+ itself is spectroscopically silent 4-(2-pyridylazo)resorcinol 
(PAR)resorcinol and iodoacetamide were used to measure the presence of Zn2+ (169). In 
this reaction 2-iodoacetamide is used as an alkylating agent to covalently bind to the thiol 
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group of the cysteine residues in the two zinc fingers of the Tat chimera and release Zn2+. 
Free Zn2+ is then complexed to form Zn(PAR)2 (170-172) and the solution changes color 
from yellow to orange. A change in absorbance at 490-500 nm can then be measured 
spectroscopically and used to calculate the approximate concentration of zinc complexed 
in the zinc fingers of the recombinantly  produced Tat chimera (171,172). 
 
Method 
 
First a standard curve was calculated using the absorbance measured at 500 nm of ZnCl2 
and PAR added to a solution to form Zn(PAR)2 for a range of ZnCl2 from 10 uM to 100 
uM. The response for this range was fairly linear (Figure 16-1). Next, following a 
protocol by Pfister et al. 2000, a 48.75 ul sample of 48.6 uM Tat chimera was incubated 
with 1.25 ul of Proteinase K (2.0 ug/ul) and incubated for 30 minutes at 56 °C (172). 
Subsequently, Iodoacetamide (5 mM) and PAR (0.2 mM) were added to a total volume of 
100 ul, and the absorbance of the solution at 500 nM was measured by NanoDrop 
spectrophotometer (Thermo Scientific Waltham, MA).  
 
Results 
 
The absorbance of two redundant samples ranged from .063 to .151 placing the estimated 
concentration of Zn2+ in the Tat chimera samples at between approximately 13 and 30 
uM according to the standard curve (Figure 16-1). Since the final concentration of the Tat 
chimera should theoretically have been approximately 24.3 uM, but two atoms of Zn2+ 
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should be present for each molecule of the chimera the predicted concentration of 
Zn(PAR)2 would be 48.6 uM with, according to the standard curve, a predicted 
absorbance at 500 nm of approximately 0.280. Allowing for approximately 20% 
contamination in the sample the actual absorbance measurements of Zn(PAR)2 still fall 
short of the predicted value. This deviation from prediction may be attributable to a 
variety of factors including: inaccuracies inherent in the nature of the calculation of 
extinction coefficients using NMR data, limitations of the NanoDrop spectrophotometer 
equipment (especially for absorbance values close to background levels), and pipetting 
error. Furthermore, some of this error may be due to misfolded proteins that are missing 
either or both Zn2+ cofactors. 
 
15.5. Inductively Coupled Plasma Mass Spectrometry 
The determination of Zn2+ concentration by spectrophotometric means continued to be 
problematic after many trials. Hence an alternative method of determining the Zn2+ 
concentration of the Tat chimera, such as might be accomplished by inductively coupled 
plasma mass spectrometry (ICP–MS), is desirable in order to confirm the presence of the 
zinc cofactor at the appropriate concentration. A generally quantitative instrument, ICP-
MS has low detection limits in the parts per thousand range and is used for determining 
the concentration of a large group of elements including zinc. Such equipment is readily 
available for use by our lab. Assessment of the Zn2+ content of the Tat chimera should be 
undertaken regularly in this native recombinant expression and purification protocol, and 
may offer valuable insight into the efficacy of any future modifications of same. 
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15.6. Activity Assay 
In order to assess the activity of the recombinant CycT1m-Tat chimera an activity assay 
should be conducted. Such an assay might be similar to that performed by Fujinaga et al. 
2002 which measured the levels of transactivation produced by the Tat chimera from the 
HIV-1 LTR in NIH 3T3 cells (28). However, this assay requires working with 
mammalian cells, and as our laboratory is not currently equipped to handle this work 
collaboration with another laboratory may be required.  
 
15.7. Confirming the Native Structure and Assessing Folding 
Since the data acquired from biolayer interferometry indicates the presence of a (minor) 
fast dissociating species it is reasonable to suspect the presence of some partially or 
incorrectly folded proteins. One interesting and high-throughput method that has been 
useful in assessing protein folding involves the interaction of the promiscuous and high 
affinity chaperonin protein GroEL with a purified target protein in biolayer 
interferometry experiments (173-176). Here chaperonin is employed as a “kinetic trap” 
which binds promiscuously to hydrophobic regions of partially folded proteins. Due to 
the fairly large size of chaperonin (802 kDa) a large BLI signal is observed when the 
protein binds preferentially to a partially folded target protein (176). Such an assay might 
reasonably be used to determine the degree to which the purified Tat chimera sample may 
be present in a non-native confirmation, as well as to identify optimal conditions for 
target solubility and correct protein folding.  
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15.8. Analytical Ultracentrifugation 
In addition to determining the binding affinity of the interaction between the CycT1m-Tat 
chimera and TAR RNA, accurate quantitative characterization requires a determination 
of the stoichiometry of the unbound recombinant protein as well as the stoichiometry of 
the protein-RNA complex. A number of matrix-based and matrix-free techniques are 
available for the identification of protein aggregates. Among the matrix-based techniques 
SDS-PAGE, and size exclusion chromatography (SEC), and among the matrix-free 
sedimentation velocity (SV), dynamic light scattering (DLS), and field flow fractionation 
(FFF) are most common (177). 
 
Analytical ultracentrifugation (AUC) is one of the most efficacious techniques currently 
available for the quantitative characterization of macromolecular associations in solution 
(178). The Beckman Coulter ProteomLab XL-A AUC, in the laboratory of Dr. Michael 
Cosgrove at Upstate Medical University, is equipped with absorbance optics and 
calculates the sedimentation velocity of macromolecules in solution by measuring the 
absorbance of monochromatic light passed through a sample cell during high speed 
centrifugation (177). Sedimentation velocity data provides information about size 
distribution that can be extracting using SEDFIT computer software developed by Peter 
Schuck (177,179). The SEDFIT software utilizes Lamm equation solutions to describe 
the sedimentation data and from these data oligomeric state can reasonably be determined 
(177,179). 
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The use of the AUC has generously been extended to us by the Cosgrove lab for our 
work on the CycT1m-Tat chimera. A gel filtration polishing step will be added to the 
purification protocol to remove residual contaminants that might confound the data from 
this sensitive technique. In addition to confirming the monomeric state of the 
recombinant chimera, this assay may also yield data about the affinity of the interaction 
between CycT1m-Tat and TAR RNA.  
 
15.9. Structural Study 
The ultimate goal of this work is to produce a sample of Tat chimera protein of sufficient 
concentration and purity to obtain structural NMR data. The yield and purity obtained 
from the small scale minimal media experiments indicated that, theoretically, a large 
scale expression and purification of the Tat chimera protocol herein should yield 
adequate protein for structural work. A few additional trials with fresh solutions, and 
perhaps different formulae, of trace minerals and with minimal solutions of BioExpress 
media would be helpful toward optimizing the protocol and minimizing expenditures.  
 
15.10. Mutation and Deletion Experiments 
 
Toward improving our understanding of the essential features of the hCycT1-Tat 
interaction mutation and deletion experiments substituting or removing key residues are 
likely to yield valuable insight into the nature of interaction with TAR. Specifically, 
mutation or deletion of residues of the two zinc fingers, mutation and deletion of R251 
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and R254 (which have been mentioned as possible stabilizers of this interaction (26)), 
and mutation or deletion of key arginine residues in the arginine-rich region of Tat could 
offer this much needed structural insight. By minimizing the interaction between the 
chimera and TAR to that afforded solely by the two zinc fingers the impact of the zinc 
fingers contribution to binding and transactivation can be more clearly demonstrated. 
15.11. HIV-1 Drug Discovery 
Having produced a high affinity Tat chimera containing the appropriate zinc cofactors, 
and after confirming the appropriate biological activity, the production of a Tat-TAR 
indicator (Figure 2-1) can then commence. Many small molecule inhibitors with potential 
for the treatement of HIV-1 can be simultaneously screened for efficacy by means of 
high-throughput methods that detect the compounds ability to disrupt the interaction 
between the Tat chimera and the HIV-1 TAR RNA. The Tat chimera recombinantly 
produced here offers the great advantage of a secondary structure more closely 
resembling the in vivo structure encountered in the disease process where such mimicry is 
otherwise prevented by the dissordered nature of the Tat protein independent of the 
essential portion of hCycT1. 
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Figure 15-1 Standard curve for the formation of Zn(PAR)2 measured at 500 nm. 
A standard curve was calculated by measuring the absorbance at 500 nm of ZnCl2 and 
PAR added to a solution to form Zn(PAR)2 for a range of ZnCl2 from 10 uM to 100 uM. 
The response measured by a Nanodrop spectrophotometer for this range was reasonably 
linear. 
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Appendix 
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Appendix 1 - Full length GST-hCycT1-Tat Chimera Sequence Details 
 
MEGAVLDIRY GVSRIAYSKD FETLKVDFLS KLPEMLKMFE DRLCHKTYLN GDHVTHPDFM  60   
LYDALDVVLY MDPMCLDAFP KLVCFKKRIE AIPQIDKYLK SSKYIAWPLQ GWQATFGGGD  120  
HPPKSDLVPR GSPNRLKRIW NWRACEAAKK TKADDRGTDE KTSEQTMPEQ KLISEEDLAM  180  
EFLEIDPVDM EPVDPNLEPW KHPGSQPRTA CNNCYCKKCC FHCYACFTRK GLGISYGRKK  240  
RRQRRRAPQD SQTHQASLSK QPASQSRGDP TGPTESKKKV ERETETDPFD L           291  
 
 
Isotopically Averaged Molecular Weight = 33491.1992 
 
Estimated pI = 8.10 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
 
Estimated charge at pH 7.00 = 5.3 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Estimated charge over pH range 
pH Charge 
4.00 41.8 
4.50 30.0 
5.00 19.4 
5.50 13.5 
6.00 10.3 
6.50 7.7 
7.00 5.3 
7.50 3.3 
8.00 0.7 
8.50 -3.4 
9.00 -8.7 
9.50 -16.2 
10.00 -26.8 
 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Appendix 2 - Full length MBP-hCycT1-Tat Chimera Sequence Details 
 
MKIKTGARIL ALSALTTMMF SASALAKIEE GKLVIWINGD KGYNGLAEVG KKFEKDTGIK     
VTVEHPDKLE EKFPQVAATG DGPDIIFWAH DRFGGYAQSG LLAEITPDKA FQDKLYPFTW   
DAVRYNGKLI AYPIAVEALS LIYNKDLLPN PPKTWEEIPA LDKELKAKGK SALMFNLQEP   
YFTWPLIAAD GGYAFKYENG KYDIKDVGVD NAGAKAGLTF LVDLIKNKHM NADTDYSIAE   
AAFNKGETAM TINGPWAWSN IDTSKVNYGV TVLPTFKGQP SKPFVGVLSA GINAASPNKE   
LAKEFLENYL LTDEGLEAVN KDKPLGAVAL KSYEEELAKD PRIAATMENA QKGEIMPNIP   
QMSAFWYAVR TAVINAASGR QTVDEALKDA QTRITKGANW RACEAAKKTK ADDRGTDEKT   
SEQTMPEQKL ISEEDLAMEF LEIDPVDMEP VDPNLEPWKH PGSQPRTACN NCYCKKCCFH   
CYACFTRKGL GISYGRKKRR QRRRAPQDSQ THQASLSKQP ASQSRGDPTG PTESKKKVER   
ETETDPFDLS                                                          
 
Isotopically Averaged Molecular Weight = 60850.9727 
 
Estimated pI = 6.60 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
 
Estimated charge at pH 7.00 = -1.8 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Estimated charge over pH range 
pH Charge 
4.00 57.5 
4.50 36.6 
5.00 18.1 
5.50 8.0 
6.00 3.4 
6.50 0.5 
7.00 -1.8 
7.50 -3.6 
8.00 -5.9 
8.50 -9.9 
9.00 -16.5 
9.50 -28.6 
10.00 -47.9 
 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Appendix 3 - Cleaved hCycT1-Tat Chimera Sequence Details 
 
GANWRACEAA KKTKADDRGT DEKTSEQTMP EQKLISEEDL AMEFLEIDPV DMEPVDPNLE  60   
PWKHPGSQPR TACNNCYCKK CCFHCYACFT RKGLGISYGR KKRRQRRRAP QDSQTHQASL  120  
SKQPASQSRG DPTGPTESKK KVERETETDP FDLS                              154  
 
Isotopically Averaged Molecular Weight = 17481.4746 
 
Estimated pI = 7.89 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition. 
 
Estimated charge at pH 7.00 = 2.4 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Estimated charge over pH range 
pH Charge 
4.00 23.0 
4.50 16.1 
5.00 9.9 
5.50 6.6 
6.00 4.9 
6.50 3.6 
7.00 2.4 
7.50 1.3 
8.00 -0.5 
8.50 -3.3 
9.00 -6.6 
9.50 -10.6 
10.00 -15.9 
 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition. 
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Appendix 4 – Tat Minimal Peptide Sequence Details 
 
RKKRRQRRRP PQG                                                     13   
 
 
Isotopically Averaged Molecular Weight = 1719.0298 
 
Estimated pI = 12.72 
 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
 
Estimated charge at pH 7.00 = 7.9 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Estimated charge over pH range 
pH Charge 
4.00 8.1 
4.50 8.0 
5.00 8.0 
5.50 8.0 
6.00 8.0 
6.50 8.0 
7.00 7.9 
7.50 7.8 
8.00 7.5 
8.50 7.2 
9.00 6.9 
9.50 6.5 
10.00 6.0 
 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Appendix 5 - MBP (Maltose Binding Protein) Sequence 
 
MKIKTGARIL ALSALTTMMF SASALAKIEE GKLVIWINGD KGYNGLAEVG KKFEKDTGIK    
VTVEHPDKLE EKFPQVAATG DGPDIIFWAH DRFGGYAQSG LLAEITPDKA FQDKLYPFTW   
DAVRYNGKLI AYPIAVEALS LIYNKDLLPN PPKTWEEIPA LDKELKAKGK SALMFNLQEP   
YFTWPLIAAD GGYAFKYENG KYDIKDVGVD NAGAKAGLTF LVDLIKNKHM NADTDYSIAE    
AAFNKGETAM TINGPWAWSN IDTSKVNYGV TVLPTFKGQP SKPFVGVLSA GINAASPNKE   
LAKEFLENYL LTDEGLEAVN KDKPLGAVAL KSYEEELAKD PRIAATMENA QKGEIMPNIP   
QMSAFWYAVR TAVINAASGR QTVDEALKDA QTRITK                             
 
Isotopically Averaged Molecular Weight = 43387.5195 
 
Estimated pI = 5.71 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
 
Estimated charge at pH 7.00 = -4.3 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Estimated charge over pH range 
pH Charge 
4.00 34.6 
4.50 20.6 
5.00 8.2 
5.50 1.5 
6.00 -1.5 
6.50 -3.1 
7.00 -4.3 
7.50 -5.1 
8.00 -5.9 
8.50 -7.4 
9.00 -10.8 
9.50 -19.0 
10.00 -33.1 
 
WARNING: pI estimate assumes all residues have pKa values that are equivalent to the 
isolated residues. For a folded protein this is not valid. However, this rough value can be 
useful for planning protein purifications. pKa values for the individual amino acids from 
Stryer Biochemistry, 3rd edition.  
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Appendix 6 - hCycT1-Tat Site-Directed Mutagenesis Protocol 
 
1. Get template (plasmid with hCycT1-Tat from isolated from XL1) 
Start 5 ml LB/Amp liquid culture of XL1-Blue cells containing the plasmids 
Do plasmid miniprep using QIAprep Spin Miniprep kit. Elute plasmid with 50ul of H2O. 
A 16-hr 5-ml XL1-Blue culture typically gives a plasmid yield of 7.5ug (~150ng/ul). 
2. Site-directed mutagenesis (Day 1) 
 Material:  
 Stratagene QuikChangeII Site-Directed Mutagenesis Kit (Stored @ -20°C) 
 Template: dilute to 10ng/μl 
 Primers: dilute to 10μM (100~150ng/μl) 
Primer design: Use QuikChange Primer Design Tool: 
https://www.genomics.agilent.com/CollectionSubpage.aspx?PageType=Tool&SubPageT
ype=ToolQCPD&PageID=15 
PCR Mix: 
5 μl of 10× reaction buffer  
10 μl of dsDNA template (1 ng/ul) 
1.25 μl of forward primer (100 ng/ul) 
1.25 μl of reverse primer (100 ng/ul) 
1.0 μl of 10mM dNTP mix  
1.0 μl of PfuUltra polymerase (2.5 U/μl) 
30.5 μl of nuclease free H2O 
final volume: 50 μl  
PCR Cycle: 
1) 95°C 30s 
2) 95°C 30s 
3) 55°C 1min 
4) 68°C 5 min 
5) go to 2) for a total of 18 cycles 
6) hold at 4°C 
 
Note: Make a negative control with no template (add 0.5 μl of nuclease free H2O instead 
of template). 
3. DpnI digestion (Day 1) 
Add DpnI 1.0 μl into each PCR reaction 
Incubate @ 37°C for 1hr 
4. Check product size on agarose gel (Day 1) 
1% gel, 160V, 40min.  
Use 5 μl of each sample/control per well, 2.5 μl of 1kb DNA ladder (Promega 
Cat# G5711).  
Note: Do not proceed to next step until you see successful amplification (single band of 
size ~ 5kb). 
5. Transform into XL-1 Blue Competent Cells (Day 1) 
Material:  
 XL-1 Blue competent cells(Stratagene), stored @ -80°C 
 Digested PCR mix 
 LB+0.4% glucose 
 LB/AMP plates 
Procedure: 
1) Estimate concentration of PCR product based on the agarose gel. (UV absorption 
won’t be accurate because of dNTPs and free primers.) If you loaded 2.5 μl of 1kb 
DNA ladder onto your gel earlier, the four brighter bands are 30ng each, other 
bands are 10ng each.  Compare your sample band to the ladder and make your best 
guess. 
2) Use ~5ng of DNA (DNA volume should not exceed 10% of reaction volume, in 
this case, 2μl) for each transformation. Add the DNA into a 200μl PCR tube, let it 
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chill on ice. Use 1 μl of pUC18 control DNA (0.1ng/μl, included in the kit) as 
positive control. 1 μl of nuclease free H2O as negative control.  
3) Thaw a tube of XL-1 Blue competent cells on ice. Add 20 μl of competent cells 
into each tube. If you have competent cells left, make 20 μl aliquots of them and 
freeze them on dry ice immediately. These aliquots should be good to use for next 
time, but their transformation efficiency will be lower. 
4) Incubate the mixture on ice for 30min. In the meantime, warm up a tube of 
LB+0.4% glucose @ 42°C. 
5) Put the tubes into a thermal cycler. Heat shock @ 42°C for 45s. 
6) Immediately put tubes back on ice, incubate for 2min. 
7) Add 100 μl of pre-warmed LB+0.4% glucose (42°C), gently mix. 
8) Pool the tubes in a falcon tube, shake @ 250rpm in a 37°C incubator for 1hr. Warm 
up a few LB/AMP plates during this time. 
9) Spread 50 μl of the recovered cells onto each LB/AMP plate. Grow @ 37°C 
overnight. 
6. Pick single colony from plate (Day 2) 
Pick single colony from plate, inoculate a 5ml LB/AMP liquid culture, grow @ 37°C 
overnight, shaking @ 220~250rpm. 
7. Make glycerol frozen stock and Miniprep (Day 3) 
Make permanent glycerol storage culture by adding 350 μl of overnight LB/AMP culture 
into 150 μl of 50% glycerol (final glycerol concentration 15%). Freeze immediately on dry 
ice. Store @ -80°C. 
Do plasmid miniprep using QIAprep Spin Miniprep kit. Elute plasmid with 50ul of H2O. 
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Measure UV using Nanodrop, calculate concentration. 
Take 200~800ng of each plasmid miniprep as sequencing sample. Store the rest @ -20°C 
or -80°C. 
8. Sanger Sequencing 
Sequencing facility at Upstate Medical University. University Hospital Room 4840 
Contact: Vicki Lyle lylev@upstate.edu  
Sequencing primers for pGEX-2TK plasmid) 
Sample dropped off every day by 11AM will be sequenced on the same day. Results usually 
get sent via email the second day. 
9. Check sequence for mutation (Day 4) 
Use BLAST or ClustalW to check mutated sequence against wildtype. 
BLAST: http://blast.ncbi.nlm.nih.gov/ (use bl2seq) 
ClustalW: http://www.ebi.ac.uk/Tools/clustalw2/index.html 
Note: Do not proceed to next step until you confirm the plasmid has the right mutation 
and nothing else. 
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Appendix 7 - Invitrogen Protocol for Gateway® Reactions 
 BP Reaction 
Creating a Gateway® entry clone from an attB-flanked PCR product is an easy 1 
hour reaction. See below for an overview of the set-up. For more detailed 
information, refer to the manual. 
1. Add the following components to a 1.5 ml tube at room temperature and 
mix: 
attB-PCR product (=10 ng/µl; final amount ~15-150 ng) 1-7 µl 
Donor vector (150 ng/µl) 1 µl 
TE buffer, pH 8.0 to 8 µl 
2. Thaw on ice the BP Clonase™ II enzyme mix for about 2 minutes. Vortex 
the BP Clonase™ II enzyme mix briefly twice (2 seconds each time). 
3. To each sample (Step 1, above), add 2 µl of BP Clonase™ II enzyme mix 
to the reaction and mix well by vortexing briefly twice. Microcentrifuge 
briefly. 
4. Return BP Clonase™ II enzyme mix to -20°C or -80°C storage. 
5. Incubate reactions at 25°C for 1 hour. 
6. Add 1 µl of the Proteinase K solution to each sample to terminate the 
reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes. 
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Transformation 
7. Transform 1 µl of each BP reaction into 50 µl of One Shot ® OmniMAX 
™ 2 T1 Phage-Resistant Cells (Catalog no. C8540-03). Incubate on ice for 
30 minutes. Heat-shock cells by incubating at 42°C for 30 seconds. Add 
250 µl of S.O.C. Medium and incubate at 37°C for 1 hour with shaking. 
Plate 20 µl and 100 µl of each transformation onto selective plates. Note: 
Any competent cells with a transformation efficiency of >1.0 × 10 8 
transformants/µg may be used. 
8. Transform 1 µl of pUC19 DNA (10 ng/ml) into 50 µl of One Shot ® 
OmniMAX ™ 2 T1 Phage-Resistant Cells as described above. Plate 20 µl 
and 100 µl on LB plates containing 100 µg/ml kanamycin, or the 
appropriate selection marker for your donor vector. 
Expected Results 
An efficient BP recombination reaction will produce >1500 colonies if the entire 
BP reaction is transformed and plated.   
 
 LR Reaction 
Transferring your gene from a Gateway® entry clone to destination vector is an 
easy 1 hour reaction. See below for an overview of the set-up. For more detailed 
information, refer to the manual. 
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1. Add the following components to a 1.5 ml tube at room temperature and 
mix: 
Entry clone (50-150 ng) 1-7 µl 
Destination vector (150 ng/µl) 1 µl 
TE buffer, pH 8.0 to 8 µl 
2. Thaw on ice the LR Clonase ™ II enzyme mix for about 2 minutes. 
Vortex the LR Clonase ™ II enzyme mix briefly twice (2 seconds each 
time). 
3. To each sample (Step 1, above), add 2 µl of LR Clonase ™II enzyme mix 
to the reaction and mix well by vortexing briefly twice. Microcentrifuge 
briefly. 
4. Return LR Clonase ™ II enzyme mix to -20°C or -80°C storage. 
5. Incubate reactions at 25°C for 1 hour. 
6. Add 1 µl of the Proteinase K solution to each sample to terminate the 
reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes. 
 
Transformation 
Follow the protocol as indicated for the BP reaction, except use the appropriate 
selection marker for the LB plates suited to your destination vector (typically 100 
µg/ml ampicillin). 
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Expected Results 
An efficient LR recombination reaction will produce >5000 colonies if the entire 
LR reaction is transformed and plated.   
 
One Tube Format 
If you want to transfer your attB-flanked PCR product directly into an expression clone, 
you can easily combine the BP and LR reactions using the following protocol. This will 
potentially eliminate the transformation and DNA isolation of the Gateway® entry clone. 
1. In a 1.5 ml microcentrifuge tube, prepare the following 15 µl BP reaction: 
attB DNA (50-100 ng) 1.0-5.0 µl 
attP DNA (pDONR™ vector, 150 ng/µl) 1.3 µl 
BP Clonase™ II enzyme mix 3.0 µl 
TE Buffer, pH 8.0 add to a final volume of 15 µl 
2. Mix well by vortexing briefly and incubate at 25°C for 4 hours. 
Note: Depending on your needs, the length of the recombination reaction can be 
extended up to 20 hours. An overnight incubation typically yields 5 times more 
colonies than a 1 hour incubation. Longer incubation times are recommended for 
large plasmids (=10 kb) and PCR products (=5 kb). 
3. Remove 5 µl of the reaction to a separate tube and use this aliquot to assess the 
efficiency of the BP reaction (see below). 
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4. To the remaining 10 µl reaction, add: 
Destination vector (150 ng/µl) 2.0 µl 
LR Clonase™ II enzyme mix 3.0 µl 
Final volume 15 µl 
5. Mix well by vortexing briefly and incubate at 25°C for 2 hours. 
Note: Depending on your needs, the length of the recombination reaction can be 
extended up to 18 hours. 
6. Add 2 µl of proteinase K solution. Incubate at 37°C for 10 minutes. 
7. Transform 50 µl of the appropriate competent E. coli with 1 µl of the reaction. 
8. Plate on LB plates containing the appropriate antibiotic to select for expression 
clones.  
 
Assessing the Efficiency of the BP Reaction 
1. To the 5µl aliquot obtained from “One-Tube” Protocol, Step 3, above, add 0.5 µl 
of proteinase K solution. Incubate at 37°C for 10 minutes. 
2. Transform 50 µl of the appropriate competent E. coli with 1 µl of the reaction. 
Plate on LB plates containing the appropriate antibiotic to select for entry clones.  
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Appendix 8 - pRK793 Plasmid Map for TEV Protease S219V Mutant 
 
Map of the pRK793 plasmid for recombinant expression of the Tobacco Etch Virus 
(TEV) protease S219V mutant, Addgene #8827, deposited by Principal Investigator 
David Waugh, National Cancer Institute, Frederick, MD. 
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Appendix 9 - M9 Minimal Media Recipe 
M9 Minimal Media 1L 
Na2HPO4·7H2O  12.8g 
Or 
Na2HPO4 (anhydrous) 6 g 
KH2PO4   3 g 
NaCl    0.5 g 
NH4Cl    1 g 
Carbon Source  0.2% (v/v) 
(glucose, sodium gluconate, or glycerol) 
Adjust pH to 7.4 with NaOH 
Autoclave prior to adding sterile micronutrients: 
Stock [C]     Micronutrient                         [C] Final      
1 M  MgSO4   1 mM 
1 M  CaCl2    100 M 
3 mM  (NH4)6Mo7O24·4H2O   3x10
-9
  M 
400 mM H3BO3    4x10
-7 M 
30 mM CoCl2 ·6H2O   3x10
-8 M  
10 mM CuSO4 ·5H2O   1x10
-8 M 
80 mM MnCl2 ·4H2O   8x10
-8 M 
10 mM ZnSO4 ·7H2O   1x10
-8 M 
5 mM  FeSO4 ·7H2O§  1x10
-6 M 
Filter sterilize all micronutrients. Make FeSO4 fresh immediately prior to use 
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Appendix 10 - Protocol for Expression of the GST Tat Chimera K. Fujinaga. 
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 Bio 
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Appendix 11 -  Tat Chimera Expression Protocol  
HISMBP-TEV hCycT1/Tat Chimera in Rosetta Gami B Cells  
non-DE3 non-p(lysS) strain  
TRIS Buffer 
 
1. Inoculate a 250 ml starter culture of LB media with RGB Mut 5 with 100 ug/ml 
ampicillin and 35 ug/ml chloramphenicol and grow overnight at 37°C 
2. Autoclave 1 L baffle bottom flasks of Turbo media  
3. Inoculate 150 ml of overnight culture into 1 L flask of Turbo media with 1.0 ml of 
[100mg/ml] ampicillin.  
4. Grow at  37°C until A600 = 0.6-0.7 (~3 hours) 
5. At 20 min prior to induction add ethanol to Turbo media to final concentration of 
1% for expression of heat shock and chaperone proteins. Add 10 ml of EtOH per 
L culture. 
6. Take 1 mL uninduced sample (for running gel later) spin down and freeze. 
Resuspend in 200 ul 1 X SDS loading buffer  
7. Induce culture with 1.0 ml 1M IPTG per 1 L to final concentration of 1.0 mM. 
8. Incubate overnight shaking at 200-240 rpm at room temp - 28°C.  
9. Take 1 mL induced sample (for running gel later); spin down and freeze. 
Resuspend in 100 ul 1 x SDS 
10. Collect cells by centrifugation at 2,500 rpm for 25 min. 
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11.  Weight pellets determine weight of cell paste. 
12. Pellet can be frozen at this point. 
13. Resuspend the cells (in lysis buffer) completely with no clumps by pipetting in 
~46 ml per L cell culture. 
14. Incubate on ice for 15-20 min. 
15. Optional: Add 4 ml BPER per L and incubate additional 10 min on ice 
16.  Sonicate (without inducing foaming) at moderate level in burst of 25 sec followed 
by 25 sec on ice four times or until solution changes color and transparency. 
17. Precipitate nucleic acids with 2 ml 4% PEI /L (polyethyleneimine) (per Liter of 
culture). Add and mix well by shaking or vortexing lightly. This will produce a 
visible white precipitate. (Additional guideline is 20-80 ul of 5% per ml crude). 
18. Spin in pre-cooled ultracentrifuge tubes (Vti 50.2) at 21,000 rpm  for 30 min at 
4ºC  
19. Remove supernatant and keep supernatant.  
20. Syringe filter supernatant. 
21. Take a 20 uL sample, add 20 uL 5x SDS sample buffer, and 60 ul dH20; vortex 
heat at 90℃ for 10 min. vortex and reserve. As soluble extract sample.  
22. Resuspend pellet in 5 ml Insoluble Extraction Solution for Insoluble and prepare 
sample as per supernatant above. This is insoluble extract gel sample.   
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Lysis Buffer pH 7.4 (s/b 7.5) 100 ml 
Tris 20 mM (MW 121.14)              0.242 g 
NaCl (MW 58.44) 0.500 M              2.92 g 
ZnCl2 (MW 136.31) 10 uM              0.2 ml of 5 mM 
Imidazole 20 mM (68.077 g/mol)    .136 g 
BME 5 mM     
Ethylene Glycol 20 %                         20.0 ml 
HALT protease inhibitor (EDTA free) (10 ul/ml)    1.0 ml 
Arginine (MW 174.2) 50 mM             0.87 g 
Lysozyme ( Cf ~150 ug/ml in H20) 
   
Insoluble Extract Solution (pH 8.0) 20 ml 
Urea (mw 60.06) 8 M                                        9.61 grams 
Na2HPO4 (mw 141.96) 100 mM                       283.9 mg 
Tris-Cl (121.14) 10 mM                                    24.2 mg 
DTT  10 mM 
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Appendix 12 – Tat Chimera FPLC Purificiation Protocol with TEV Cleavage 
Full Length MBP Tagged Protein Recovery 
 Turn on UV and warm up 15 min 
 Pump wash A and B with dH2O 
 Attach 2 - 5 ml HisTrap column columns in series. 
 Wash with dH2O 1 ml/min. 
 Equilibrate column with Tris binding buffer 
 Clean superloop by removing it from the system and disassembling it. Be sure 
to refill the loop and push plunger to top before re-assembling. 
 Apply Sample: Load supernatant in lysis buffer into superloop and then inject 
at 0.2 ml/min (2x5 ml column) during sample application switch to binding 
buffer. (Make sure to stop the flow after injecting and returning to load) 
 Wash with 5 column volumes of binding buffer to remove unbound proteins 
until no material appears in the effluent at flow rate of 0.4-0.6 ml/min (2x5 
ml column) 
 Gradient elution with elution buffer (IMAC-B) for 30 min to 100% elution 
buffer 
 Analyze fractions by SDS PAGE and/or Nanodrop and combine purest 
fractions for cleavage. 
 Perform a buffer exchange on the full chimera back into binding buffer 
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Pro-TEV Cleavage of HIS MBP Tag 
1. Use a ratio of 1/50 grams of TEV per gram of protein to be cleaved. 
2. Incubate the cleavage reaction overnight at ~14 ºC 
 
CLEAN THE COLUMN AS PER DIRECTIONS BELOW BEFORE APPLYING 
CLEAVAGE REACTION BACK ONTO COLUMN 
 
Re-Application of Cleaved Protein to HisTrap Column for Removal of TEV and MBP 
Tag 
1. Apply the cleaved supernatant in binding buffer to the superloop and inject onto 
column at a flow rate of 0.2 to 0.4 ml 
2. Collect Fractions after 7 column volumes of buffer have passed. 
3. Determine concentration with Nanodrop 
4. Analyze the fractions by SDS PAGE 
5. Store Fractions in 20% glycerol at -80 ºC 
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Solutions: 
Binding Buffer pH 7.4 1 L (1 X) 
Tris 20 mM (MW 121.14)                             2.42 g 
 NaCl 0.500 M (MW 58.44 g/mol)                 29.22 g    
ZnCl2 (MW 136.31) 10 uM                           2.0 ml of 5 mM        
Imidazole 20 mM (68.077 g/mol)                 1.36 g 
Sodium Azide 0.02%                                     0.20 g 
BME 5 mM    
Glycerol 5%                                                   50 ml 
 
Wash Buffer pH 7.4 1 L (1 X) 
Tris 20 mM (MW 121.14)                              2.42 g 
 NaCl 0.500 M (MW 58.44 g/mol)                29.22 g 
ZnCl2 (MW 136.31) 10 uM                           2.0 ml of 5 mM 
Imidazole 60 mM (68.077 g/mol)                  4.08 g 
Sodium Azide 0.02%                                     0.20 g 
BME 5 mM    
Glycerol 5%                                                   50 ml 
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Elution Buffer pH 7.4 1 L   1 X 
Tris 20 mM (MW 121.14)                              2.42 g 
 NaCl 0.500 M (MW 58.44 g/mol)                  29.22 g    
ZnCl2 (MW 136.31) 1 uM                              2.0 ml of 5 mM        
Imidazole 500 mM (68.077 g/mol)                34.0 g 
Sodium Azide 0.02%                                     0.20 g 
BME 5 mM 
Glycerol 5%                                                  50 ml 
 
Short Term Storage Buffer pH 7.4 1 L (1 X) 
Tris 20 mM (MW 121.14)                               2.42 g 
Glycerol 5%                                                   50 ml 
NaCl 0.200 M (58.44 g/mol)                         11.68 g   
ZnCl2 (MW 136.31) 10 uM                           2.0 ml of 5 mM   
Sodium Azide 0.02%                                     0.20 g 
BME 5 mM 
 
Octet Buffer pH 7.4 1 L (1 X) 
Tris 20 mM (MW 121.14)                               2.42 g 
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NaCl 0.200 M (58.44 g/mol)                         11.68 g   
ZnCl2 (MW 136.31) 10 uM                           2.0 ml of 5 mM   
Sodium Azide 0.02%                                     0.20 g 
BME 5 mM 
 
Column Maintenance: 
 
Stripping and Recharging should be performed after 5 to 7 purifications. It should not be 
necessary to perform this procedure after batch purification of the same protein 
 
Stripping Buffer (GE) pH 7.4 100 ml 
Sodium Phosphate                                             20 mM 
 Monosodium Phosphate, monohydrate             0.0623%            0623 g 
 Disodium Phosphate, heptahydrate                   0.4149%         0.415 g 
NaCl (MW 58.44) 0.5 M                                   2.922 g 
EDTA 50 mM 
 
1. Wash with 5 to 10 volumes of stripping buffer 
2. Wash with 5 to 10 volumes of binding buffer 
3. Wash with 5 to 10 volumes of dH2O 
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4. Recharge column with 0.5 ml or 2.5 ml of 0.1 M NiSO4 in dH2O on on HisTrap HP 1 
ml and 5 ml column respectively (other salts may also be used). 
5. Wash with 5 column volumes of dH2O 
6. Wash with 5 column volumes of binding buffer (to adjust pH before storage) 
Column can be cleaned or stored at this point 
Cleaning 
1. Remove ionically bound proteins by washing the column with several column 
volumes of 1.5 M NaCl; then wash the column with approximately 10 column 
volumes of dH2O. 
2. Remove precipitated proteins, hydrophobically bound proteins, and lipoproteins 
by washing the column with 1M NaOH, contact time usually 1-2 hours (12 hours 
or more for endotoxin removal). Then wash the column with approximately 10 
column volumes of binding buffer, followed by 5-10 column volumes of dH2O. 
3. Remove hydrophobically bound proteins, lipoproteins, and lipids by washing the 
column with 5-10 column volumes 30% isopropanol for about 15-20 minutes. 
Then wash the column with approximately 10 column volumes of dH2O. 
Alternatively, wash the column with 2 column volumes of detergent in a basic or 
acidic solution. Use, for example 0.1-0.5% nonionic detergent in 0.1 M acetic 
acid, contact time 1-2 hours. After treatment, always remove residual detergent by 
washing with at least 5 column volumes of 70% ethanol. Then wash the column 
with approximately 10 column volumes of dH2O. 
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Storage 
Ethanol 20% 
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Appendix 13 - Expression and Purification of MBP-His6-TEV (S219V)-Arg5 
Plasmid: pRK793 
Extinction Coefficient: 32,290  M-1 cm-1 
Adapted from (134): 
 
Expression: 
1. Inoculate 50-150 ml of LB broth containing 100 ug/ml ampicillin and 30 ug/ml 
chloramphenicol in a 500 ml bafflebottom shake flask from a glycerol stock of 
pRK793 transformed E. coli BL21 (DE3) CodonPlus-RIL cells (here I will 
substitute Rosetta 2 (non-DE3 as per Novagen: do not produce T7 polymerase, 
provide more tRNA and possess OmpT and Lon mutations eliminating proteases). 
Place in an incubator and shake overnight at 250 rpm and 37ºC. 
2. Add 25 ml of the saturated overnight culture to each 1 L of fresh LB broth 
containing 100 ug/ml ampicillin, 30 ug/ml chloramphenicol and 0.2% glucose 
(glucose should be added separately and not autoclaved in LB because it will 
caramelize). Glucose (a/k/a dextrose) should be mixed slowly into a water 
solution to prevent clumping. Filter sterilize the glucose solution before adding it 
to LB. To ensure that there will be an adequate yield of pure protein at the end of 
the process, Tropea et al. grow 4-6 L of cells at a time. (Here we attempt 3 
separate 1 L cultures). 
3. Shake the flasks at 250 rpm and 37ºC until the cells reach mid-log phase (OD600nm 
~0.5); approximately 2 h. 
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4. Take a 1 ml uninduced sample, spin down, and resuspend in 100 ul 1 x SDS 
loading buffer. 
Heat sample at 95 ºC for 10 minutes, then spin down at 14,000 rpm for 5 minutes. 
5. Shift the temperature to 30ºC and induce the culture(s) with IPTG at a final 
concentration of 1 mM (5 ml of 200 mM IPTG stock solution per liter of culture). 
Continue shaking at 250 rpm for 4-6 h. Place cultures at 4ºC. 
6. Take a 1 ml induced sample, spin down, and resuspend in 100 ul 1 x SDS loading 
buffer. 
7. Recover the cells by centrifugation at 5,000 x g for 15 min at 4 ºC, and store at 
-80ºC. A 6 L preparation yields 30-40 g of cell paste. 
 
 
Purification: 
 
His6-TEV(S219V)-Arg5 protease can be purified to homogeneity in two steps: 
immobilized metal affinity chromatography (IMAC) using Ni-NTA resin followed by 
size exclusion chromatography.  
 
1. All procedures are performed at 4-8ºC. Thaw the cell paste from 6 L of culture on 
ice and suspend in ice-cold cell lysis/IMAC equilibration buffer (10 ml/g cell 
paste). 
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2 L Cell Lysis/IMAC Equilibration buffer pH 8.0: 
 
Sodium Phosphate Dibasic 50 mM                            14.2 g 
NaCl 200 mM                                                              23.38 g 
Glycerol 10 %                                                             200 ml 
Imidazole 25 mM                                                         3.41 g 
Add H2O to 1980 ml 
Adjust pH with HCl 
Adjust Volume to 2 L with H2O 
Re-check pH 
Filter through 0.22 um polyethersulfone membrane or equivalent 
Store at 4ºC. 
 
2. Lyse the cell suspension and measure the volume using a graduated cylinder. Add 
polyethylenimine (PEI) to a final concentration of 0.1% (a 1:50 dilution of the 5% 
stock solution at pH 8) and mix gently by inversion. Immediately centrifuge at 
15,000 x g for 30 min and filter.  
 
3. Apply the supernatant to two tandem 5 ml HisTrap HP columns equilibrated in 
cell lysis/IMAC equilibration buffer. Wash the columns with equilibration buffer 
until a stabile baseline is reached and then elute the bound His6-TEV(S219V)-
Arg5 with a linear gradient to 100% elution buffer over ten column volumes. 
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Note: It may be helpful to split up the supernatant into several batches to 
accommodate the 10 ml column volume. Also, make sure to sample flow through 
to monitor efficiency, and run flow through over column a second time (after 
eluting from it) if necessary to recover unbound TEV. 
 
1 L IMAC Elution Buffer pH 8.0: 
 
Sodium phosphate dibasic 50 mM                             7.1 g 
NaCl 200 mM                                                           11.69 g 
Glycerol 10%                                                            100 ml 
Imidazole 250 mM                                                    17.02 g 
Adjust volume to 750 ml with H2O 
Adjust pH to 8.0 using HCl. 
Adjust volume to 1 L with H2O 
Let cool to room temperature 
Re-check pH. 
Filter through 0.22 um polyethersulfone membrane or equivalent. 
Store at 4ºC. 
 
4. Pool the peak fractions containing the protease and measure the volume. Add 
EDTA to a final concentration of 2 mM (a 1:250 dilution of the 0.5 M EDTA, pH 
8 stock solution) and mix well. Add DTT to a final concentration of 5 mM (1:200 
dilution of the 1M DTT stock solution) and mix well. 
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5. Concentrate the sample approximately tenfold using an Amicon ultrafiltration 
YM10 membrane. Remove the precipitation by centrifugation at 5,000 x g for 10 
min. Estimate the concentration of the partially pure protein solution 
spectrophotometrically at 280 nm using a molar extinction coefficient of 32,290 
M-1 cm-1. The desired concentration is between 5 and 10 mg/ml. 
6. Filter through a 0.2 uM syringe filter, aliquot and flash freeze with liquid 
nitrogen. Store at -80ºC. 
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Appendix 14 - Mass Spectrometry Sample Preparation Protocol 
 
Solutions required for MALDI-TOF: 
Acetonitrile 
Trifluoroacetic Acid 0.1% 
Sinapinic Acid 10 mg 
TA solution – 1 Part Acetonitrile to 2 parts Trifluoroacetic Acid 0.1% 
 
1. Prepare a 1.5 ml solution of 0.1% aqueous Trifluoroacetic acid from the ampules 
(located in the crisper of the fridge in 215) by adding 1.5 ul of TFA to a total of 
1.5 ml in H2O 
2. Prepare a solution with 10 mg of Sinapinic Acid in 1 ml of TA solution  
3. Allow the solution to dissolve for ~ 30 min then spin down the undissolved SA 
briefly 
4. Dilute the protein samples for your experiment to ~ 20 uM using TFA 0.1% (if 
possible the target sample should be dialyzed into H2O PRIOR to the dilution 
with TFA. However, due to precipitation Tris buffer was used in lieu of H20 
PRIOR to dilution. Do not use PBS with MALDI-TOF.) 
5. Mix the protein sample 1:1 with TA solution (ex.: 10 ul of ~20 uM sample + 10 ul 
TA solution) 
6. Spot 1 ul of each sample on to MALDI Sample Plate 
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Appendix 15 - Western Blot Protocol 
 
For use with the WesternBreeze® Chromogenic Immunodetection Kit 
Anti-myc FITC antibody 
 
1. Run SDS page gel with appropriate concentrations of protein, and 10 ul of the 
Positope Control Protein in a control . 
2. Take gel to iBlot with bottom, top, filter, and sponge. 
3. Set up iBlot and run for 7-8 min. 
4. Remove the gel and discard all but the membrane 
5. Place membrane in a plastic container, cover, and add 10 ml of Invitrogen NC 
Blocking Solution.  
` 
Blocking Solution: 
Ultra filtered Water  14 ml 
Blocker/Diluent (Part A)  4 ml 
Blocker/Diluent (Part B)  2 ml 
Total Volume             20 ml 
 
6. Rock the membrane slowly for 30 min (~1 rev/sec). 
7. Decant Blocking Solution 
8. Rinse membrane with 20 ml dH2O and incubate in dH2O for 5 min; decant and 
repeat. 
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9. Add 10 ml of Primary Antibody Solution with 2 ul of FITC Myc Antibody 
(1:5000 dilution). For nitrocellulose membranes the primary antibody solution is 
the blocking solution above. Use remaining 10 ml. Incubate for one hour. 
10. Wash membrane in 20 ml of Antibody Wash (Anti-Body Wash provided in kit 
is 16 X be sure to dilute before use) for 5 minutes; decant and repeat 3 times. 
11. Add 10 ml of Secondary Antibody Solution incubate for 30 min then decant. 
12. Wash membrane in 20 ml of Antibody Wash for 5 minutes; decant and repeat 3 
times. 
13. Wash the membrane with 20 ml dH2O for 2 minutes, decant and repeat 2 times. 
14. Add 5 ml of Chromogenic Substrate and incubate until purple bands appear on the 
membrane (1-60 minutes). 
15. Wash the membrane with 20 ml dH2O for 2 minutes, decant and repeat 2 times. 
16. Allow the membrane to dry on filter paper in the open air. 
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Appendix 16 – EMSA Sample Preparation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAGE Non-Denaturing Tat minimal: 1.7 kDa
Date: 6/9/2012 hCycT1-Tat: 17.481 kDa
Stain: SYBR Gold RNA SYPRO Ruby Protein Full Length Chimera 60.8 kDa
Pre-Run 100 V > 1 hr  Ncp7 ~7 kDa
Gel %: Native PAGE 12% SNAP COOL RNA
Voltage: 100 V 85 ⁰C 5 min then Ice 5 min
Run Time 90 min C initial
Spin down 2 sec then Incubate Samples   4 ⁰C for 15 V initial
Running Buffer: 1 X TBE
Sample Buffer: Tris 20 mM Binding Buffer 5 mM BME 20 mM Imidazole 10 uM ZnCl2 5% Glycerol
Stock Protein Date: Date of Gel:
Setup: Component Volume (ul)
Lane 1 SL3 Negative Control 500 nM 20
Lane 2 SL3-Ncp7 Positive Control 500 nM/10 uM 20
Lane 3 TAR WT 500 nM 20
Lane 4 TAR WT 500 nM Positive Control Tat Minimal 10 uM 20
Lane 5 TAR WT 500 nM hCyctT1-Tat no tag 10 uM 20
Lane 6 TAR WT 500 nM Full Length MBP tagged chimera 10 uM 20
Lane 7 TAR WT 500 nM MBP 10 uM 20
Lane 8 TAR WT 500 nM Positive Control Tat Minimal 5 uM 20
Lane 9 TAR WT 500 nM hCyctT1-Tat no tag 5 uM 20
Lane 10 TAR WT 500 nM Full Length MBP tagged chimera 5 uM 20
Lane 11 TAR WT 500 nM MBP 5 uM 20
Lane 12 Tat Minimal 10 uM 20
Lane 13 hCycT1 Tat no tag 10 uM 20
Lane 14 Full Length His MBP tagged chimera 10 uM 20
Lane 15 MBP 10 uM 20
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Sample/Lane # 1 SL3 Negative Control 500 nM
ID Initial Conc.(M) Vol (uL) Final Conc.(M) Ck
RNA SL3 4.00E-06 2.5 5.00E-07
Buffer Tris 20 mM + 10 uM ZnCl2 10x 2.0 1x
Glycerol 50% 2.0
dH2O  11.5
Gel Pilot loading dye  1.0
BME 0.1 1.0
Total Volume 20.0
Sample/Lane # 2 SL3-Ncp7 Positive Control 500 nM/10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M) Ck
RNA SL3 4.00E-06 2.5 5.00E-07
Protein Ncp7 5.50E-05 3.6 1.00E-05  
Buffer Tris 20 mM + 10 uM ZnCl2 10x 2.0 1x
Glycerol 50% 2.0
dH2O  8.9
BME 0.1 1.0
  Total Volume 20.0
Sample/Lane # 3 TAR WT 500 nM 
ID Initial Conc.(M) Vol (uL) Final Conc.(M) Ck
RNA TAR WT 4.00E-06 2.5 5.00E-07
     
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0
dH2O  12.5
BME 0.1 1.0
   Total Volume 20.0
Sample/Lane # 4 TAR WT 500 nM Positive Control Tat Minimal 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M) Ck
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein Tat Minimal 3.00E-05 6.7 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0
dH2O  5.8
BME 0.1 1.0
Total Volume 20.0
Sample/Lane # 5 TAR WT 500 nM hCyctT1-Tat no tag 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M) Ck
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein hCycT1-Tat no tag 3.00E-05 6.7 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  5.8  
BME 0.1 1.0
Total Volume 20.0
  
Sample/Lane # 6 TAR WT 500 nM Full Length MBP tagged chimera 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M) Ck
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein Full Length MBP tagged chimera 3.00E-05 6.7 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  5.8  
BME 0.1 1.0
Total Volume 20.0
Sample/Lane # 7 TAR WT 500 nM MBP 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M) Ck
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein MBP 2.38E-05 4.2 5.00E-06
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  8.3  
BME 0.1 1.0
Total Volume 20.0
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Sample/Lane # 8 TAR WT 500 nM Positive Control Tat Minimal 5 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein Tat Minimal 3.00E-05 3.3 5.00E-06
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  9.2  
BME 0.1 1.0
Total Volume 20.0
  
Sample/Lane # 9 TAR WT 500 nM hCyctT1-Tat no tag 5 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein hCycT1-Tat no tag 3.00E-05 3.3 5.00E-06
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  9.2  
BME 0.1 1.0
Total Volume 20.0
  
Sample/Lane # 10 TAR WT 500 nM Full Length MBP tagged chimera 5 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein TAR WT 500 nM Full Length MBP tagged chimera 5 uM3.00E-05 6.7 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  5.8  
BME 0.1 1.0
Total Volume 20.0
  
Sample/Lane # 11 TAR WT 500 nM MBP 5 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
RNA TAR WT 4.00E-06 2.5 5.00E-07
Protein MBP 2.38E-05 8.4 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  4.1  
BME 0.1 1.0
Total Volume 20.0
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Sample/Lane # 12 Tat Minimal 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
    
Protein Tat Minimal 10 uM 3.00E-05 6.7 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  8.3  
BME 0.1 1.0
Total Volume 20.0
Sample/Lane # 13 hCycT1 Tat no tag 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
    
Protein hCycT1-Tat no tag 3.00E-05 6.7 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  8.3  
BME 0.1 1.0
Total Volume 20.0
Sample/Lane # 14 Full Length His MBP tagged chimera 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
    
Protein Full Length MBP 3.00E-05 6.7 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  8.3  
BME 0.1 1.0
Total Volume 20.0
Sample/Lane # 15 MBP 10 uM
ID Initial Conc.(M) Vol (uL) Final Conc.(M)
    
Protein MBP 10 uM 2.38E-05 8.4 1.00E-05
Buffer Tris 20 mM + 10 uM ZnCl2 10X 2.0 1x
Glycerol 50% 2.0  
dH2O  6.6  
BME 0.1 1.0
Total Volume 20.0
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Appendix 17 - EMSA Protocol 
 
Sample Preparation: 
Snap Cool RNA: ~3 min @ 90° C, vortex, incubate on ice. 
Pre-run gel @ 100 V for ~ 30 min to 1 hour 30 min 4 ⁰ C.  
TBE running buffer (1 x) or other 
Run gel @ 100 V  
Actual running time: ~1:30 min @ 4 ⁰ C 
 
12% Acrylamide Native Gel 
30 ml Total Volume (~ 2 gels) 
9 ml Accugel 40% 
3 ml 10X TBE 
18 ml dH2O 
12 µl TEMED 
300 µl APS 20% (.2 g/ml) 
 
10 X  TBE electrophoresis buffer 
Tris Base  108g  [Cf] 890 mM 
Boric Acid 55 g [Cf] 890 mM 
dH2O 960 ml 
EDTA [0.5 M]   40 ml 
pH 8.0 [Cf] 20 mM 
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300 µl APS 20%  (.2 g/ml) 
 
Nucleic Acid Stain: 
Prepare 1X SYBR Gold gel stain:  
5 µl SYBR Gold (50,000X) in 
50 ml TBE buffer 
 
Remove gel from cast and stain with 1 X staining solution, and gentle agitation for 10-40 
min. in a plastic container protected from light. 
Wash gel two times in 150 ml dH2O for 10 sec.  
Visualize nucleic acid by UV transillumination, take a picture. 
 
Protein Stain: 
Quick Protocol    
 Reagent Basic Protocol Rapid Protocol 
Fix 50% Methanol, 
7% Acetic acid 
100 mL 
30 min 
100 mL 
30 min 
100 ml, 15 min 
 
100 ml, 15 min 
Stain SYPRO 
Ruby gel 
Stain 
60 mL 
overnight 
60 ml 
Microwave 30 sec, 
agitate 30 sec, 
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microwave 30 sec, 
agitate 23 min 
Wash 10% Methanol,  
7% Acetic acid 
100 mL 
30 min 
100 mL, 30 min 
Hands-on Time  10 min 15 min 
Total time  ~18 hours 90 minutes 
 
Fix 
After electrophoresis, place the gel into a clean container with 100 mL of fix solution and 
agitate on an orbital shaker for 30 minutes. Repeat once more with fresh fix solution. 
Pour off the used fix solution. 
 
Stain 
Add 60 mL of SYPRO Ruby gel stain. Agitate on an orbital shaker overnight. 
 
Wash 
Transfer the gel to a clean container and wash in 100 mL of wash solution for 30 minutes. 
Transfer step helps minimize background staining irregularities and stain speckles on the 
gel. Before imaging rinse the gel in ultrapure water a minimum of two times for 5 
minutes to prevent possible corrosive damage to the imager. Visualize protein with the 
UV transilluminator; take a picture. 
Overlay nucleic acid and protein images with Photoshop. 
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Appendix 18 -  Novagen Rosetta B Gami Transformation Protocol 
Materials:  
1. Novagen Rosetta B Gami non-DE3 non-pLys competent cells stored at -80°C  
2. Chimera plasmid DNA, dilute to 10ng/μl  
3. LB Media 
4. LB/AMP/Chl plates  
Procedure:  
1. Add 1 μl of plasmid (10 ng) to a 200 μl PCR tube, let it chill on ice. Use 1 μl of 
pUC18 control DNA (0.1 ng/μl) as positive control Use 1 μl of nuclease free H2O 
as negative control 
2. Thaw competent cells on ice. Add 20ul of Rosetta Gami B competent cells to 
each tube 
3. Incubate the mixture on ice for 5 minutes  
4. Heat-shock the cell mixture at 42°C for 30 seconds 
5. Immediately put tubes back on ice, incubate for 2 minutes 
6. Add 80 μl of room temperature SOC, gently mix 
7. Recover for 1 hour with light shaking at 37°C incubator for 1 hour  
8. Spread 50 μl of the recovered cells onto each pre-warmed LB/AMP/Chl plate 
9.  Grow plates at 37°C overnight 
10. Pick a single colony from the plate and inoculate a 5-ml LB/AMP/Chl liquid 
culture 
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11. Grow at 37°C overnight, shaking at 220~250rpm  
12. Add 50 % glycerol to make a permanent glycerol storage culture  
13. Store the frozen culture at -80°C. 
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Appendix 19 - Double Colony Selection Expression Level Analysis 
 
1. Streak fresh LB+Amp+Chl plate with old glycerol stock for control 
2. Select and mark 3 to 4 different freshly transformed colonies from LB plates and 
one colony from glycerol stock plate to inoculate two falcon tubes in 2 ml LB 
(can also try turbo) for each colony making a total of 8 tubes 
3. Incubate tubes at 37°C until OD600 = 2-3 
4. Spin down tubes at 1500 g for 5 min 
5. Resuspend the pellets in 5 mL of minimal M9 medium to OD600 between 0.07 and 
0.1 
6. Save 100 ul from control tube prior to induction 
7. Induce each tube at OD600 = 1.0 Induce one tube for each colony with 1.0 mM 
IPTG 
8. Incubate overnight at 28°C 
9. Take OD600  of final culture 
10. Collect 250 uL from each tube and spin at 3300g for 5-10 minutes 
11. Prepare SDS PAGE sample by resuspending the pellets in 50 ul of 2X SDS 
loading buffer  
12. Incubate samples for 20 minutes at 70°C and spin down at maximum speed for 20 
minutes prior to loading 
13. Analyze gel and choose highest protein yielding colony  
14. Grow high yield colony O/N in LB or Turbo 
15. Plate high yield culture on LB + amp + chl plate 
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16. Repeat steps 1 through 13 
17. Prepare Glycerol Stock for second high yielding double-colony selected culture 
and store at -80°C 
 
Sivashanmugam et al. Optimized high-cell density IPTG-Induction Minimal Medium 1 L 
Na2HPO4·7H2O 50 mM (MW 268.07) 13.4 g 
KH2PO4 (pH 8.0-8.2) 25 mM (MW 136.1 g)   3.4 g 
NaCl 10 mM (MW 58.44)   0.6 g 
NH4Cl 0.1 % (MW 53.49)   1.0 g 
AUTOCLAVE HERE BEFORE ADDITION OF REMAINING REAGENTS 
MgSO4 5 mM (MW 120.36)   0.6 g or 5 ml of 1 M 
CaCl2 0.2 mM (MW 110.98)   0.2 g or 1 ml of 0.2 M 
Glucose 1.0 % 25.0 ml of 40 % 
ZnCl2 0.1 mM   0.5 ml of 0.2 M  
Trace Metals    2.5 ml of 1000x Trace Metals 
Vitamin Mix  10.0 ml of 100x Vitamin Mix 
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Appendix 20 - Expression of Double Colony Selected Mutant 
 
1. Inoculate 1L of turbo media in baffle bottom flask with highest yielding colony  
2. Grow at 37°C at 240 rpm until OD600 ~5  
3. Save 1 ml uninduced sample and prepare with approximately 500 ul 1X SDS 
4. Collect cells by spinning down at 1500 g for 5 min 
5. Resuspend cells in 1L of minimal media prepared as above 
6. Allow cells to recuperate for 1-1.5 hours at 37°C 
7. Add 1% EtOH 20-30 min prior to induction 
8. Induce with 1 mM IPTG 
9. Grow 24-48 hours 
10. Purify as per hCycT1-Tat chimera in rich media 
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